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This thesis describes studies on the expression, genetics and physiological
regulation of the adipokine, visfatin.
The results from reverse transcription-polymerase chain reaction (RT-PCR)
and western blot demonstrated that full-length visfatin, isoform a, and a shorter
visfatin, isoform b, were expressed in several different cell lines. The full-length
visfatin isoform a was also found to be secreted from these cell lines, as well as
human breast fat tissue.
The visfatin gene was screened in 24 Singaporean obese children. Four single
nucleotide polymorphisms (SNPs) were detected in the upstream promoter and coding
regions of the visfatin gene, and were genotyped in a cohort of 243 Singaporean obese
children through direct DNA sequencing. The detected SNPs were shown to be
statistically significantly associated with fasting serum visfatin, and with components
of the metabolic syndrome including serum triglyceride, fasting glucose and
frequency of hypertension. Furthermore, the diplotypes derived from the combination
of genotypes of the detected SNPs were found to be significantly associated with
these metabolic parameters. The interaction between the variant genotypes and
physical activity level also had a significant effect on serum visfatin and metabolic
risk factors including serum triglyceride, percentage of body fat and hypertension.
Fasting serum visfatin in obese children had statistically significant
correlations with several metabolic parameters including BMI, glucose at 60 minutes
during an oral glucose tolerance test (OGTT), as well as serum triglyceride and liver
enzymes. Moreover, obese children with abnormal glucose tolerance or non-alcoholic
fatty liver disease (NAFLD) had higher serum visfatin level than the other obese
children.
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Serum visfatin decreased significantly in obese children during OGTT. Serum
visfatin also decreased significantly during euglycemic-hyperinsulinemic clamp in a
group of 14 adults with type 2 diabetes mellitus. The decrease in visfatin level was
significantly correlated to the increase in insulin level during OGTT and
hyperinsulinemic clamp, indicating that visfatin may be physiologically regulated by
insulin.
The significant associations between visfatin SNPs and several metabolic
parameters in obese children and the significant relationship of the dynamic changes




Table 2 Summary of common upstream SNPs in the visfatin gene..................27
Table 3.1 ATCC cell lines....................................................................................49
Table 3.2 Primers used in RT-PCR......................................................................52
Table 3.3 Primers used in PCR.............................................................................53
Table 3.4 Primers used for cloning.......................................................................54
Table 3.5 Primers used in sequencing..................................................................55
Table 4.1 Clinical characteristics of obese children.............................................99
Table 4.2 Genotype and allele frequencies of upstream SNPs in obese children
and cord blood samples..............................................................................................101
Table 4.3 Genotype and allele frequencies of exon SNPs in obese children and
cord blood samples.....................................................................................................103
Table 4.4 Chi-square values of Hardy-Weinberg equilibrium for SNPs detected
in obese children and cord blood samples..................................................................105
Table 4.5 Association between genotypes of -3187G>A and continuous
metabolic parameters..................................................................................................107
Table 4.6 Association between dominant/recessive model of -3187G>A and
continuous metabolic parameters...............................................................................111
Table 4.7 Associations between genotypes of -3187G>A and categorical
metabolic parameters..................................................................................................113
Table 4.8 Association between dominant/recessive model of -3187G>A and
categorical metabolic parameters...............................................................................115
xviii
Table 4.9 Association between genotypes of +7489T>C and continuous
metabolic parameters..................................................................................................117
Table 4.10 Association between genotypes of +7489T>C and categorical
metabolic parameters..................................................................................................119
Table 4.11 Association between dominant model of +21426G>A and continuous
metabolic parameters..................................................................................................121
Table 4.12 Association between dominant model of +21426G>A and categorical
metabolic parameters..................................................................................................123
Table 4.13 Effect of interaction between genotypes of -3187G>A and physical
activity level on metabolic parameters.......................................................................125
Table 4.14 Diplotypes (comprising of upstream -3187G>A, +7489T>C at exon2,
+21426G>A at exon7) frequencies of obese children................................................129
Table 4.15 Association between visfatin diplotypes and continuous metabolic
parameters..................................................................................................................131
Table 4.16 Association between visfatin diplotypes and categorical metabolic
parameters..................................................................................................................133
Table 4.17 Spearman’s correlation and partial correlation between serum visfatin
and metabolic parameters...........................................................................................137
Table 4.18 Association between genotypes and changes in visfatin/insulin level
during OGTT in obese children..................................................................................149
Table 4.19 Diplotypes (comprising of upstream -3187G>A, +7489T>C at exon2,
+21426G>A at exon7) frequencies of obese children undergoing OGTT.................151
Table 4.20 Association between diplotypes and changes in visfatin/insulin level
during OGTT in obese children..................................................................................153
xix
LIST OF FIGURES
Figure 4.1 mRNA expression of visfatin isoforms in human cell lines.................79
Figure 4.2 Protein expression of visfatin isoform a in human cell lines...............81
Figure 4.3 Over-expression of visfatin isoform b in 293T cells............................83
Figure 4.4 Secretion of full-length visfatin in human cell lines and breast fat
tissue.............................................................................................................................85
Figure 4.6 Chromatogram of upstream -3187G>A SNP in visfatin gene of obese
children.........................................................................................................................91
Figure 4.7 Chromatogram of upstream -1537C>T SNP in visfatin gene of obese
children.........................................................................................................................93
Figure 4.8 Chromatogram of exon 2 +7489T>C SNP in visfatin gene of obese
children.........................................................................................................................95
Figure 4.9 Chromatogram of exon 7 +21426G>A SNP in visfatin gene of obese
children.........................................................................................................................97
Figure 4.10 Serum visfatin of SNP -3187G>A genotype groups..........................109
Figure 4.11 Serum visfatin in obese children with normal or abnormal glucose
 tolerance....................................................................................................................139
Figure 4.12 Serum visfatin in obese children with normal or abnormal liver
function test, NAFLD.................................................................................................141
Figure 4.13 Dynamic changes in visfatin in obese children undergoing OGTT...145




Figure 2.1 The enzymatic role of Nampt in the biosynthesis of NAD..................16
Figure 2.2 The complex of NMN at the dimer interface of visfatin......................19
Figure 2.3 Genomic structure of visfatin gene......................................................21
Figure 3.1 EMW-hINS lenti-viral vector...............................................................57
Figure 4.5 Schematic diagram of SNPs detected in 3.5kbp upstream promoter and
full coding region of the visfatin gene in DNA of obese children...............................89
xxi
LIST OF PRESENTATIONS
1. Gene and protein expressions of visfatin and its isoforms in human cell lines
            S Q OOI, K O LEE, S U GAN (2009)
            Poster presentation at 8th National Healthcare Group (NHG) Annual Scientific
   Congress 2009
2. Serum visfatin of obese children undergoing oral glucose tolerance test
S Q OOI, S U GAN, K O LEE, Y S LEE (2010)
Poster presentation (Selected for audio poster presentation) at 70th American
Diabetes Association (ADA) Scientific Sessions 2010
3. Genetic polymorphisms of the visfatin gene of obese children
S Q OOI, M E CHAN, K S POH, K Y LOKE, S U GAN, K O LEE, Y S LEE
(2011)
Poster presentation at 1st Yong Loo Lin School of Medicine Graduate
Scientific Congress 2011
4. The genetic polymorphisms of the adipokine, visfatin and its correlation with
different metabolic parameters in obese children
S Q OOI, M E CHAN, K S POH, K Y LOKE, S U GAN, Y H CHAN, C K
HENG,  K O LEE, Y S LEE
Poster presentation (Selected for audio poster presentation) at 1st Asia Pacific
Congress on Controversies to Consensus in Diabetes, Obesity and
Hypertension (CODHy) 2011
5. Visfatin and its genetic variants are associated with obesity related morbidities
and cardiometabolic risk factors in severely obese children
S Q OOI, M E CHAN, K S POH, K Y LOKE, C K HENG, Y H CHAN, S U





ALI Acute lung injury
AP Activator protein
APS Ammonium persulfate
ARDS Acute respiratory distress syndrome
AST Aspartate transaminase
ATCC American type culture collection
ATP Adenosine triphosphate
AUC Area under curve
BAT Brown adipose tissue
BIA Bioimpedance analysis
BLAST Basic local alignment search tool
BMI Body mass index
BMI-SDS Body mass index-standard deviation score
CAD Coronary artery disease
CDK Cyclin-dependent kinase
CHD Coronary heart disease
CKD Chronic kidney disease
CLECs Cord lining epithelial cells
CREB cAmp response element binding protein
CRP C-reactive protein
cDNA Complementary deoxyribonucleic acid
cPPT Central polypurine tract
dbSNP Database of single nucleotide polymorphism
DEXA Dual energy X-ray absorptiometry








eGFP Enhanced green fluorescent protein
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-linked immunosorbent assay
eNampt Extracellular nicotinamide phosphoribosyltransferase
FBS Fetal bovine serum
FGF Fibroblast growth factor
GDM Gestational diabetes mellitus
GGT Gamma-glutaryl transferase





HDL High density lipoprotein
hINS Human insulin
HMW-adiponectin High molecular weight-adiponectin
HOMA-IR Homeostasis model assessment-insulin resistance
HRP Horseradish peroxidase
HSV Herpes simplex virus
IL Interleukin
IMT Intimal media thickness
iNampt Intracellular nicotinamide phosphoribosyltransferase
IR Insulin receptor
IRES Internal ribosomal entry site
IRS Insulin receptor substrate
LB Luria broth
LDL Low density lipoprotein
LPS Lipopolysaccharide
LTR Long terminal repeat
MAF Minor allele frequency
MCT Murine cortical tubule
MMP Metalloproteinase
mRNA Messenger ribonucleic acid
xxv
NaCl Sodium chloride
NAD Nicotinamide adenine dinucleotide
NAFLD Non-alcoholic fatty liver disease
Nampt Nicotinamide phosphoribosyltransferase
NASH Non-alcoholic steatohepatitis
NCBI National centre for biotechnology information
NF Nuclear factor
NMN Nicotinamide mononucleotide
OGTT Oral glucose tolerance test
PBEF Pre-B cell colony enhancing factor
PBS Phosphate buffer saline
PBMC Peripheral blood mononuclear cell
PCI Percutaneous coronary intervention
PCOS Polycystic ovarian syndrome
PCR Polymerase chain reaction
PVDF Polyvinylidene difluoride
QUICKI Quantitative insulin sensitivity check index
RA Rheumatoid arthritis
RASF Rheumatoid arthritis synovial fibroblast
RBP Retinol binding protein
RNA Ribonucleic acid
RNAi Ribonucleic acid interference
Rpm Revolutions per minute
RT-PCR Reverse transcription-polymerase chain reaction
SAP Shrimp alkaline Phosphatase
SAT Subcutaneous adipose tissue
SCF Stem cell factor
SD Standard deviation
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SEM Standard error of the mean
sFFV Spleen focus-forming virus
siRNA Small interference ribonucleic acid
SNP Single nucleotide polymorphism
TAE Tris-acetate-EDTA
xxvi
TBST Tris buffer saline tween
TE Tris-EDTA
TEMED N,N,N’,N’-Tetramethylethylenediamine
TNF-α Tumor necrosis factor-alpha
TK Thymidine kinase
UTR Untranslated region
VAT Visceral adipose tissue
WAT White adipose tissue
WFH Weight for height
WHO World health organization






1.1.1 Prevalence of Obesity
Obesity is defined as an excessive accumulation of body fat, which may have
effects on morbidity and mortality. The increasing prevalence of obesity has reached a
global epidemic proportion and according to World Health Organization (WHO),
more than 400 million adults worldwide were obese in 2005, and the incidence of
worldwide adult obesity is expected to increase to more than 700 million by 2015
(Aronne et al., 2009). Following the worldwide increase in adult obesity, the
frequency of childhood obesity is also on the rise, and is considered as one of the most
serious nutritional disorders in the United States (Rocchini, 2002). In 2010, WHO
reported over 42 million obese cases globally in children under the age of five, and
childhood obesity has been shown to be a predictor of adulthood obesity and
adulthood obesity-related illnesses (Dietz, 1998).
Obesity is accompanied by medical complications such as diabetes,
cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), hypertension,
gallbladder disease and cancer (Bray, 2004). Therefore, the global increase in obesity
poses huge social and economic burdens. In fact, recent opinion had even included
state protective services such as the placement of severely obese children in foster
care in order to protect them from the life-threatening consequences (Murtagh and
Ludwig, 2011).
1.1.2 Obesity and insulin resistance
Obesity has been regarded as a risk factor for insulin resistance, which is a
physiological condition where the body shows decreased sensitivity towards the
ability of insulin at lowering plasma glucose level, thus resulting in higher plasma
2glucose level within the body (Chiarelli and Marcovecchio, 2008). In a population-
based study among adolescents in the United States, obese children were found to be
more insulin resistant as measured by homeostasis model assessment-insulin
resistance (HOMA-IR) when compared to lean controls (Lee et al., 2006). The
reduction in obesity parameters like body mass index (BMI) were shown to result in
improved insulin-sensitivity among obese subjects (Sakamoto et al., 2010). Therefore,
obesity seems to play an important role in the pathogenesis of insulin resistance.
1.1.3 Adipose tissues and adipokines
Inflammation was postulated to be a link between adiposity and insulin
resistance (Reyes et al., 2011), and adipose tissues were shown to secrete substances
collectively termed adipokines. Adipokines could either exert pro-inflammatory or
anti-inflammatory properties (Fantuzzi, 2005). The commonly studied adipokines
included adiponectin, resistin and leptin. Adiponectin was found to be negatively
associated with adiposity and insulin resistance (Weyer et al., 2001), whereas resistin
and leptin were shown to have a positive correlation with insulin resistance (Silha et
al., 2003) .The study of the regulation of adipokines may provide an insight on the
development of insulin resistance in obese subjects.
1.1.4 Visfatin
In 2005, visfatin was first reported as a novel adipokine that was
predominantly secreted by visceral adipose tissue. Visfatin was also found to play a
physiological role in lowering plasma glucose level (Fukuhara et al., 2005). However,
the initial report was later retracted by the same group in 2007 (after the initiation of
the present PhD study). They, and others, were unable to repeat their previous
3reported findings of visfatin being able to bind to and activate the insulin receptor
(Fukuhara et al., 2007). In contrary to Fukuhara et al.’s finding that visfatin was
predominantly secreted by visceral adipose tissue, Berndt et al. showed that there was
no difference in visfatin mRNA expression between subcutaneous and visceral
adipose tissue (Berndt et al., 2005). Thus, this casted doubt on whether visfatin is a
true visceral fat specific adipokine. In addition, visfatin was previously identified as
pre-B cell colony enhancing factor (PBEF), which aids in maturation of B cells
(Samal et al., 1994). Visfatin was also known as nicotinamide
phosphoribosyltransferase (Nampt), a rate-determining enzyme involved in the
biosynthesis of nicotinamide adenine dinucleotide (NAD) that is essential for cellular
redox reactions (Revollo et al., 2007a). Therefore, other than being a possible
adipokine secreted by adipocytes, the secretion of visfatin by tissues other than
adipocytes alludes to its other regulatory roles.
The proposed insulin-mimetic properties of visfatin had led to many studies
that aimed to find a correlation between plasma visfatin level and different metabolic
parameters. The subsequent clinical studies revealed elevated plasma visfatin level in
type 2 diabetic (Chen et al., 2006) and obese subjects (Kaminska et al., 2010).
Circulating plasma visfatin was also reported to increase with progressive beta cell
deterioration (Lopez-Bermejo et al., 2006). However, other clinical studies showed
inconsistent results on the association of visfatin with parameters of glucose
metabolism and insulin resistance (Pagano et al., 2006, Marcinkowska et al., 2007). In
addition, variants within the visfatin gene had been studied, and some of the variants
were found to be associated with different metabolic parameters such as glucose and
lipid level (Bottcher et al., 2006, Tokunaga et al., 2008).
4Despite all the previous findings, there are still many questions about visfatin,
including its expression and regulatory mechanisms, and its functional role in obesity
and metabolism. The present study embarked in examination of the expression,
genetics and physiological regulation of visfatin with the hope of unveiling the
possible effects of visfatin on metabolic diseases.
1.2 Present study
The objective of this study was to investigate the expression, genetics and regulation
of visfatin. The study aimed to:
1. Determine the expression and secretion of visfatin isoforms in a variety of
human cell lines and tissue.
2. Explore genetic polymorphisms in visfatin gene of obese children and,
examine the association between the detected genotypes/diplotypes and
metabolic parameters. In addition, the present study will examine the effect of
genotype-environment interaction on metabolic parameters.
3. Determine the correlation between serum visfatin and metabolic parameters in
obese children.
4. Examine if visfatin is regulated by physiological changes in glucose and
insulin level during oral glucose tolerance test (OGTT) and euglycemic-
hyperinsulinemic clamp. In addition, the present study will examine the
association of visfatin genotypes/diplotypes on the changes of glucose, insulin




52.1 Pathogenesis of obesity
Obesity is a chronic disease which occurs when there is an imbalance between
energy consumption and energy expenditure, thus causing an increase in body weight.
The diagnosis of obesity is based on body mass index (BMI), which is calculated as
weight in kilograms divided by height in meters squared (kg/m2), and obesity is
defined as BMI≥30kg/m2 (Aronne et al., 2009). The escalating prevalence of obesity,
in particular, childhood obesity has become a global epidemic, posing social and
economic problems worldwide. The pathogenesis of obesity involves an interplay
between environmental and genetic factors (Raj and Kumar, 2010). The
environmental risk factors for obesity include dietary intake and physical activity.
Increased availability of a variety of affordable high fat dietary food has led to
overconsumption, and together with the lack in physical activity due to the
advancement in modern technology, caused an accumulation of body fat that resulted
in obesity (Hill and Peters, 1998). Genetic predisposition had also been reported to
play a role in the development of obesity. Children with obese parents conferred
higher risk of adulthood obesity than children with non-obese parents (Whitaker et al.,
1997). Genome-wide association studies had identified obesity-susceptibility single
nucleotide polymorphisms (SNPs) and obesity-susceptibility genes such as the fat
mass and obesity-associated (FTO) gene, which were found to be associated with
parameters of obesity such as BMI and weight (Thorleifsson et al., 2009, Scuteri et
al., 2007).
2.1.1 Obesity, insulin resistance and metabolic syndrome/diseases
Obesity is characterized by an infiltration of macrophages on the adipose
tissue, and is defined as a state of low grade chronic inflammation (Weisberg et al.,
62003). The expression of inflammatory genes was up-regulated during obesity-related
insulin resistance, and this suggested that chronic inflammation of the adipose tissue
may aid in the development of insulin resistance in obesity (Xu et al., 2003). In
particular, visceral obesity (also referred to as abdominal or central obesity) was
associated with insulin resistance and increased metabolic risk factors (Nomura et al.,
2010). Homeostasis model assessment-insulin resistance (HOMA-IR) is a method
used to assess insulin resistance, and it is calculated as fasting plasma insulin (mU/L)
× fasting plasma glucose (mmol/L) ÷ 22.5 (Matthews et al., 1985). Obesity-related
insulin resistance was correlated with metabolic syndrome (Hirschler et al., 2010),
which comprises a group of metabolic risk factors such as visceral obesity,
dyslipidemia, hypertension and hyperglycemia that contribute to the development of
metabolic diseases e.g. type 2 diabetes, non-alcoholic fatty liver disease (NAFLD)
and cardiovascular diseases (Grundy et al., 2005).
2.2 Adipose tissue
Adipose tissue was initially reported as an energy storage depot but growing
evidences have shown adipose tissue as an endocrine organ capable of secreting bio-
active proteins known as adipokines that play a role in obesity-related inflammation
(Galic et al., 2010). The two types of adipose tissue are white adipose tissue (WAT)
and brown adipose tissue (BAT). WAT constitutes the major part of adipose tissue
and is responsible for energy storage, whereas BAT participates in energy expenditure
during thermogenesis (Balistreri et al., 2010). In addition, WAT consists mainly of
adipocytes and other cell types such as pre-adipocytes, macrophages, endothelial
cells, fibroblasts and leukocytes, which secrete adipokines that are involved in energy
metabolism and obesity-related inflammation (Wozniak et al., 2009, Trayhurn and
7Beattie, 2001, Clement et al., 2004). WAT is further divided into subcutaneous
adipose tissue (SAT) and visceral adipose tissue (VAT). As compared to SAT, VAT
had a greater capacity in secreting adipokines, and was closely associated with
metabolic parameters (Ibrahim, 2010).  VAT was also shown to correlate with type 2
diabetes (Cruz et al., 2002), and the accumulation of VAT caused an increase in
expression of pro-inflammatory adipokines in the state of type 2 diabetes (Samaras et
al., 2010).
2.2.1 Adipokines
The adipose tissue provides a source of pro-inflammatory and anti-
inflammatory adipokines that play a role in obesity-related inflammation and energy
homeostasis. Serum adipokines were found to be associated with obesity and
metabolic syndrome (Valle et al., 2005), and adipokines were suggested to be the
inflammatory link between obesity and obesity-related insulin resistance. The
adipokines secreted by the adipose tissue included adiponectin, leptin, resistin and
visfatin which will be discussed in the later sections.
2.2.1.1 Adiponectin
Adiponectin is an adipocyte-derived cytokine with insulin-sensitizing effects
and anti-inflammatory effects. Plasma adiponectin was found to be decreased in obese
and type 2 diabetic subjects (Arita et al., 1999, Hotta et al., 2000). Furthermore,
plasma adiponectin was negatively correlated with parameters of glucose and lipid
metabolism, and positively correlated with insulin-sensitivity (Tschritter et al., 2003).
In cases of improved insulin-sensitivity due to use of insulin-sensitizers e.g.
thiazolidinediones, plasma adiponectin level was increased (Yu et al., 2002). The
8infusion of recombinant adiponectin was able to ameliorate insulin-resistance in
obesity-induced diabetic mice (Yamauchi et al., 2001). Adiponectin was also able to
inhibit the lipopolysaccharide (LPS)-induced secretion of pro-inflammatory cytokines
such as IL-6 and TNF-α in adipocytes (Ajuwon and Spurlock, 2005). SNPs along the
adiponectin gene were shown to be associated with insulin resistance (Filippi et al.,
2004). Therefore, adiponectin may offer a possible treatment in enhancing insulin
sensitivity and reducing obesity-related inflammation in obese and diabetic subjects.
2.2.1.2 Leptin
Leptin was cloned from the obesity (ob) gene and was found to regulate
energy homeostasis through the central nervous system. The lack of leptin caused an
increase in body mass, and the administration of recombinant leptin was associated
with decreased adiposity (Winters et al., 2000) and increased insulin-sensitivity
(Nagao et al., 2008). Despite the role of leptin in energy expenditure, plasma leptin
was associated with obesity and increased concentration of soluble TNF-α receptors
(van Dielen et al., 2001). The increased level of plasma leptin in obese subjects
represented a state of leptin resistance, which involved a feedback mechanism in the
regulation of leptin (Friedman and Halaas, 1998).
2.2.1.3 Resistin
Resistin was identified as a pro-inflammatory adipokine, which activated the
secretion of other pro-inflammatory cytokines such as TNF-α and IL-6 (Bokarewa et
al., 2005). Circulating level of resistin was found to be associated with obesity and
insulin resistance (Chanchay et al., 2006). The neutralization of resistin protein in
mice caused an improvement in glucose tolerance and insulin sensitivity, whereas the
9addition of recombinant resistin caused a decrease in glucose uptake in cultures of
3T3L1 adipocytes (Steppan et al., 2001)  However, there had been conflicting studies
on the tissue-specific expression of resistin and its association with obesity and
glucose metabolism (Savage et al., 2001, Lee et al., 2003). Therefore, the
physiological role of resistin still requires further examination.
2.2.1.4 Other adipokines
Besides the well-studied adipokines like adiponectin, leptin and resistin,
adipose tissue was also found to be capable of secreting tumor necrosis factor-alpha
(TNF-α), interleukin-6 (IL-6), retinol binding protein 4 (RBP-4), apelin, chemerin,
omentin and the recently discovered adipokines like visfatin and vaspin. Moreover,
these adipokines were shown to be involved in inflammation and energy metabolism
(Rabe et al., 2008). Thus, the adipokines secreted by the adipose tissue may be
possible therapeutic targets in the treatment of metabolic diseases.
2.3 Visfatin
2.3.1 Sources of visfatin
2.3.1.1 Adipose tissue
Through differential display of paired cDNA samples from human
subcutaneous and visceral adipose tissues, visfatin was first identified as a novel
adipokine that was predominantly expressed and secreted in visceral adipose tissue by
Fukuhara and his colleagues. Plasma visfatin level was found to correlate with
visceral fat area (Fukuhara et al., 2005). Consistent with Fukuhara et al.’s finding, the
expression of visfatin was higher in visceral adipose tissue as compared to
subcutaneous adipose tissue in mice (Kralisch et al., 2005a), and the level of plasma
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visfatin was correlated with increased visceral fat level in adult subjects (Indulekha et
al., 2011). However, some studies had failed to establish a positive relationship
between visfatin and visceral adipose tissue. Kloting et al. reported a similar visfatin
expression between visceral and subcutaneous adipose tissue in mice (Kloting and
Kloting, 2005). Berndt et al. also found no difference in the mRNA expression of
visfatin between visceral and subcutaneous adipose tissue in human adults, and
plasma visfatin was not shown to correlate with visceral fat area (Berndt et al., 2005).
Moreover, there was no difference in subcutaneous or visceral visfatin mRNA
expression between obese and non-obese subjects (Chang et al., 2010).
2.3.1.2 Alternative sources
Apart from adipose tissue, other cells and tissues were found to serve as
alternative sources of visfatin. Since hepatocytes are known to play a role in glucose
metabolism, the level of visfatin in hepatocytes was investigated. Visfatin was
reported to be constitutively secreted from HepG2 cells, and primary rat and human
hepatocytes (Garten et al., 2010). Visfatin was also highly expressed and secreted in
macrophages as compared to adipocytes. This indicated that the macrophages that
infiltrated the adipose tissue during obesity may be the source of secreted visfatin
observed in adipose tissue (Curat et al., 2006).  Furthermore, the placental tissue from
women with gestational diabetes mellitus (GDM), and the circulating blood
monocytes were additional sources of visfatin (Telejko et al., 2009, Laudes et al.,
2010).
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2.3.2 Roles of visfatin
2.3.2.1 Visfatin as insulin-mimetic molecule
Fukuhara et al. first reported visfatin as an adipokine with insulin-mimetic
properties. The treatment with visfatin increased glucose uptake in adipocytes and
myocytes, and decreased glucose release in hepatocytes to a similar extent as that of
insulin. In addition, visfatin was shown to have a physiological role in glucose
homeostasis. The intravenous administration of recombinant visfatin was shown to
cause a decrease in plasma glucose level of normal C57BL/6J mice, and a decrease in
plasma glucose level of insulin resistant KKAY and streptozotocin-treated mice to a
similar extent as that of insulin injection. Moreover, visfatin heterozygous mice were
found to have higher plasma glucose level as compared to controls. Visfatin was also
shown to bind to and activate the insulin receptor (IR) at a site distinct from insulin
(Fukuhara et al., 2005). However, the paper was later retracted in 2007 when the
group was unable to repeat their results on visfatin binding to and activating the IR
(Fukuhara et al., 2007).
Similar to Fukuhara et al.’s finding, the incubation of human osteoblasts with
visfatin significantly increased the incorporation of labelled 2-[3H]-deoxyglucose in a
similar manner as that of insulin. Visfatin was able to induce the tyrosine
phosphorylation of IR and insulin receptor substrate (IRS), whereas the pre-treatment
with IR inhibitor abrogated the visfatin-induced phosphorylation of IR and IRS in the
osteoblasts. The inhibition of IR also inhibited the visfatin-induced glucose uptake in
the osteoblasts, suggesting that visfatin-induced glucose uptake may occur through the
IR signalling pathway (Xie et al., 2007). In addition, a recent report showed a visfatin-
induced glucose uptake in mouse podocyte cell line and murine cortical tubule (MCT)
cells, which was found to be mediated by visfatin-induced up-regulation of glucose
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transporter-1 (GLUT-1). The stimulation of mouse podocyte cell line and MCT cells
with visfatin also caused the induction of tyrosine phosphorylation of IR and insulin
receptor substrate-1 (IRS-1) (Kang et al., 2010b).
However, there were in vitro studies that did not observe a direct insulin-
mimetic effect of visfatin. Although the addition of 10nM insulin was shown to cause
a 3-fold increase in glucose uptake as compared to baseline, a similar dosage of 10nM
visfatin was not able to induce glucose uptake in matured human adipocytes (Wanecq
et al., 2009). Harasim et al. observed an increase in expression of glucose transporter-
4 (GLUT-4) and glucose uptake in muscle tissue during treatment with visfatin but the
increment was lesser as compared to that of insulin. There was also a lack of effect of
visfatin on the phosphorylation of insulin receptor and downstream signalling
molecules involved in insulin signalling pathway (Harasim et al., 2011).
In addition to exerting insulin-mimetic effects, visfatin was able to maintain
glucose homeostasis through regulation of insulin-sensitivity. The over-expression of
visfatin through administration of visfatin plasmid in mice caused a significant
increase in glucose infusion rate during euglycemic-hyperinsulinemic clamp, which
represented an improvement in insulin sensitivity (Sun et al., 2009). The use of RNA
interference (RNAi) down-regulated visfatin expression in Fao rat hepatocytes, and
this led to a decrease in insulin-stimulated glucose uptake (Skop et al., 2010).
Moreover, the incubation of mouse pancreatic β cells with recombinant visfatin also
increased insulin secretion and mRNA expression of key diabetes genes including
insulin gene. (Brown et al., 2010).
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2.3.2.2 Visfatin as a pro-inflammatory cytokine
The level of visfatin was found to be up-regulated in inflammation-related
diseases such as acute pancreatitis, rheumatoid arthritis (RA) and chronic kidney
disease (CKD. Serum visfatin was higher in patients with acute pancreatitis as
compared to control, and a positive correlation was observed between serum visfatin
and IL-8. The level of visfatin was also positively correlated with the severity of acute
pancreatitis (Daniel et al., 2010). In addition, visfatin was postulated to be involved in
the inflammatory process of RA due to increased visfatin expression in the synovial
tissues of RA patients. There was higher level of visfatin in the serum and synovial
fluid of patients with RA, and the increased visfatin level correlated with C-reactive
protein (CRP) level. Rheumatoid arthritis synovial fibroblasts (RASFs) were exposed
to increasing level of visfatin, and this induced a dose-dependent up-regulation of the
levels of IL-6, matrix metalloproteinase (MMP)-1 and MMP-3. The stimulation of
human monocytes with visfatin also caused an increase in the secretion of pro-
inflammatory cytokines such as IL-6 and TNF-α (Brentano et al., 2007).
Serum visfatin was found to be higher in patients with CKD than healthy
controls, and serum visfatin was found to have a positive correlation with levels of
CRP and IL-6 (Bessa et al., 2010). In addition, immuno-staining on carotid plaques of
patients with atherosclerotic disorder revealed the localization of visfatin around
macrophages, and recombinant visfatin was able to stimulate the secretion of TNF-α
and IL-8 from peripheral blood mononuclear cells (PBMCs) (Dahl et al., 2007). Kang
et al. reported that cultured adipocytes subjected to visfatin stimulation were shown to
have significantly higher expression of pro-inflammatory cytokines such as TGFβ1,
PAI-1, MCP-1 and type 1 collagen genes (Kang et al., 2010a).
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The elevated level of visfatin in inflammatory diseases, and the positive
correlation between visfatin and inflammatory cytokines suggested that visfatin may
participate as a pro-inflammatory cytokine during the inflammatory process of the
diseases.
2.3.2.2.1 Interplay between adipokines
As discussed previously in 2.3.2.2, visfatin was found to correlate with
different inflammatory cytokines, and this led to the postulation of a possible interplay
between the different inflammatory adipokines. Adiponectin and visfatin were found
to be differentially regulated in obese women undergoing oral glucose tolerance test
(OGTT). At baseline level, obese subjects were shown to have lower serum
adiponectin and higher serum visfatin level as compared to lean controls. The change
in visfatin during OGTT was found to be positively correlated with change in insulin,
whereas change in adiponectin was negatively correlated with change in insulin level
(Unluturk et al., 2010).  Wang et al. also reported a significant negative correlation
between adiponectin and visfatin in subjects with polycystic ovarian syndrome
(PCOS) (Wang and Yu, 2009).  Obese non-diabetic subjects were divided into 2
groups according to their median value of visfatin. The group with high median value
of visfatin was found to have higher level of resistin as compared to the group with
low median value of visfatin, and the resistin level was found to have a positive
correlation with visfatin level (de Luis et al., 2010). The increased leptin and visfatin
levels were also shown to have a positive association in patients with pre-eclampsia
(Adali et al., 2009). In addition, leptin was able to increase the expression and
secretion of visfatin in both human and murine adipocytes in a dose-dependent
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manner. However, high dose of leptin was shown to inhibit the elevated visfatin level
(Tan et al., 2009).
2.3.2.3 Visfatin as pre-B cell colony enhancing factor (PBEF)
Before the identification of visfatin as an adipokine, visfatin was initially
discovered by Samal et al. as a protein known as pre-B cell colony enhancing factor
(PBEF). PBEF synergizes with stem cell factor (SCF) and IL-7 to aid in the
maturation of B cells. The addition of PBEF in the presence of SCF and IL-7,
promoted the formation of pre-B cell colonies on the agar culture of mouse bone
marrow cells. PBEF was highly expressed in bone marrow, liver and muscle tissue,
and its sequence was found to be in homology with the signal peptidase cleavage site
of cytokine genes (Samal et al., 1994). The important role of visfatin as PBEF was
further proven in visfatin knock-out mice, which died during early embryogenesis
stage (Fukuhara et al., 2005).
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2.3.2.4 Visfatin as nicotinamide phosphoribosyltransferase (Nampt)
Visfatin also possesses an enzymatic role as nicotinamide
phosphoribosyltransferase (Nampt) that is involved in the biosynthesis of
nicotinamide adenine dinucleotide (NAD), which is an important coenzyme in cellular
redox reactions. Nampt is the rate-determining enzyme that converts nicotinamide
into the intermediate, nicotinamide mononucleotide (NMN), which is then later
converted into NAD as illustrated in Figure 2.1. Nampt was also proposed to exist in
two  forms: Intracellular Nampt (iNampt) and extracellular Nampt (eNampt) (Revollo
et al., 2007a).


















2.3.2.4.1 Intracellular Nampt (iNampt)
Intracellular Nampt (iNampt) is mainly expressed within the cells, and it
functions as the biosynthetic enzyme of NAD. The use of ribonucleic acid
interference (RNAi) induced a decrease in the expression of iNampt, which was found
to cause a subsequent decrease in glucose uptake and insulin-sensitivity of rat
hepatocytes. As the decreased expression of iNampt was accompanied by reduced
level of NAD, iNampt was suggested to regulate glucose homeostasis of hepatocytes
through biosynthesis of NAD (Skop et al., 2010). The inhibition of iNampt by
pharmacological inhibitor, FK866 directly caused down-regulation of both NAD and
pro-inflammatory cytokines such as IL-6 and TNF-α in paw cells of mice with
collagen-induced arthritis. This indicated that the enzymatic role of iNampt in the
biosynthesis of NAD may be associated with inflammation (Busso et al., 2008). In
addition, the FK866-mediated inhibition of iNampt was shown to cause cell death and
cell senescence, whereas the over-expression of iNampt was found to have anti-
apoptotic effects and was able to delay cell senescence (Dahl et al., 2010, van der
Veer et al., 2007).
2.3.2.4.2 Extracellular Nampt (eNampt)
Extracellular Nampt (eNampt) refers to the secreted form of Nampt, which
was reported by Fukuhara et al. as an adipokine, visfatin that had insulin-mimetic
properties (Fukuhara et al., 2005). Although eNampt failed to exert direct insulin-
mimetic effects on glucose uptake during in vitro and in vivo experiments, Nampt-
deficient heterozygous mice, which had decreased levels of eNampt and NAD, were
shown to have impaired glucose tolerance and decreased glucose-stimulated insulin
secretion. The reduction in glucose-stimulated insulin secretion was reversed in the
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Nampt-deficient heterozygous mice through addition of the by-product of Nampt,
NMN that could be found in blood circulation due to secretion by circulating eNampt.
Therefore, eNampt had been suggested to regulate glucose homeostasis through the
biosynthesis of NAD (Revollo et al., 2007b). Caton et al. also recently examined the
function of eNampt on islet function during inflammation. eNampt was found to be
decreased in fructose-fed mice, and the decrease in eNampt was associated with
decreased insulin secretion and increased inflammation. The administration of the by-
product of eNampt, NMN was able to reverse the suppressed insulin secretion in both
fructose-fed mice and pro-inflammatory cytokine-induced mouse pancreatic cells. In
addition, the NMN-induced insulin secretion was in parallel with an increase in
expression of Pdx-1 and GLUT-2 genes, which were involved in β cell function. The
study indicated that eNampt may play a protective role against pro-inflammatory
cytokine-induced islet dysfunction through the regulation of the expression of genes
involved in β cell function (Caton et al., 2011).
2.3.3 Structure of visfatin
2.3.3.1 Molecular structure
The visfatin monomer contains 22 β-strands and 15 α-helices, which are
segregated into 3 domains: A, B and C. Visfatin protein exists as a homo-dimer, with
2 monomers arranged head to tail with each other. In relation to the enzymatic
function of visfatin as Nampt, the active site for binding of substrate occurs at the
interface of the homo-dimer structure. The binding of the reaction product, NMN at
the interface of the visfatin dimer is as illustrated in Figure 2.2 (Khan et al., 2006).
The substrate specificity of visfatin was determined by the amino acid residues that
constituted the active site at the interface of the dimer e.g. aspartic acid at position 219
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(Asp219), and mutations of the amino acid residues at the active site or dimer
interface were shown to affect the binding of substrates such as FK866 inhibitor
(Olesen et al., 2010).
Figure 2.2 The complex of NMN at the dimer interface of visfatin. The green C
represents carbon atom of NMN (Khan et al., 2006).
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2.3.3.2 Genetic structure
The human visfatin gene (NC_000007.13) is mapped at 7q22.3 on the long
arm of chromosome 7, which has been linked to insulin resistance (Arya et al., 2002).
It spans at an approximated length of 34.7 kbp and consists of 11 exons and 10
introns. The 5’-untranslated region (UTR), which extends into Exon 1, is divided into
proximal and distal regions which are ~1.4kbp and ~1.6 kbp upstream of the major
transcription initiation site respectively. The proximal region contains a Guanine-
Cytosine (GC)-rich proximal promoter that lacks TATA and CAAT boxes, and the
distal region contains a distal promoter with initiator sequences and several TATA
and CAAT boxes. The 5’-UTR also contains multiple binding sites for transcription
factors such as nuclear factor 1 (NF-1), activator protein (AP-1 and AP-2), specificity
protein-1 (SP-1), glucocorticoid receptor (GR) and other responsive regulatory
elements such as cAMP response element binding protein (CREB) in both the
proximal and distal regions. The coding region of the visfatin gene includes region
encoded by the 11 exons, which occurs from the start codon ATG (+1) on Exon1 to
the stop codon on Exon 11 (excluding the 3’-UTR found on Exon 11) (Ognjanovic et
al., 2001). The full coding region encodes for a 52KDa visfatin protein. The schematic
diagram of the human visfatin gene was illustrated in Figure 2.3.
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Figure 2.3 Genomic structure of visfatin gene. A. Exon/Intron organization of visfatin gene. The purple shaded region represents the coding
region of the visfatin gene and the stated length represents the length of the introns and coding region within the exons. B. The upstream
promoter region of visfatin gene. The +1 position of the visfatin gene is taken as the A nucleotide of the start codon on exon 1 and the upstream
region was denoted as negative number of bases away from +1 position. The different shapes along the upstream promoter region represent the
different transcription factor and response elements. The figure was drawn with reference to NC_000007 human visfatin gene and paper by

























































2.3.4 Genetic polymorphisms in visfatin gene
Single nucleotide polymorphisms (SNPs) are genetic variants which occur due
to alteration in a single nucleotide base along the deoxyribonucleic acid (DNA), and
they have been found to serve as useful biomarkers for different diseases. The study
of the human visfatin gene in different sample populations had led to the identification
of novel genetic SNPs that were found to be associated with different metabolic
parameters. In this section, we will review the common SNPs and haplotypes that
were detected in the upstream promoter, exonic and intronic regions of the visfatin
gene.
2.3.4.1 Visfatin upstream promoter SNPs
2.3.4.1.1 SNP -3186C>T (rs11977021)
Bailey et al. performed genotyping of -3186C>T SNP in a population of
French-Canadian subjects, and -3186C>T was shown to occur at a minor allele
frequency (MAF) of 0.17. Moreover, -3186C>T was significantly associated with
total plasma cholesterol and LDL-cholesterol levels under the additive model of
inheritance (Bailey et al., 2006).
2.3.4.1.2 SNP -1543C>T (also known as -1535C>T) (rs61330082)
The -1543C>T SNP was genotyped in a population of white subjects that
consisted of healthy controls and subjects with either sepsis-associated acute lung
injury (ALI) or sepsis alone. Subjects with ALI were found to have significantly
lower T allele frequency as compared to healthy controls, and a borderline significant
association (p=0.059) was observed between -1543C>T genotypes and ALI. The T
variant of -1543C>T SNP was shown to cause a nearly 2-fold decrease in
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transcriptional activity of luciferase reporter gene assay in human lung microvascular
endothelial cells (HMVEC-L) (Ye et al., 2005). In addition, the T variant of -
1535C>T was shown to cause a decrease in IL-1β-induced visfatin expression in
pulmonary vascular endothelial cells, and this may be due to decreased binding of
visfatin promoter to an IL-1β-induced unknown transcription factor. The group also
postulated that the reduction in IL-1β-induced visfatin expression may cause a
decrease in IL-1β-induced cell permeability, which may confer a lower risk of ALI
(Liu et al., 2009).
Bajwa et al. also performed genotyping for the -1543C>T SNP in their
population of patients with acute respiratory distress syndrome (ARDS) and at-risk
controls. The genotype frequency of -1543C>T did not differ between patients with
ARDS and at-risk controls. However, the T variant of -1543C>T was associated with
decreased risk of developing ARDS in patients with septic shock, and it was also
associated with improved outcomes during course of ARDS (Bajwa et al., 2007).
Tokunaga et al. reported that there was no significant difference in the
genotype and allele frequencies of -1535T>C SNP (also known as -1543C>T)
between their population of type 2 diabetic and non-diabetic Japanese subjects. This
suggested that -1535T>C was not directly associated with type 2 diabetes. However,
the -1535T allele was shown to be associated with lower serum triglyceride and
higher high density lipoprotein (HDL)-cholesterol in the group of non-diabetic
subjects. The group also conducted a reporter gene assay in 3T3L1 adipocytes, and in
contrary to the study by Ye et al. (Ye et al., 2005), they did not observe a difference in
transcriptional activity for the -1535T>C SNP (Tokunaga et al., 2008).
The -1535C>T SNP was found to be associated with reduced risk of coronary
artery disease (CAD) and reduced level of triglyceride in a population of Chinese
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subjects (Yan et al., 2010). Wang et al. investigated the association between -
1535C>T SNP and levels of inflammatory markers in patients with CAD. They found
that the -1535C>T SNP was associated with decreased levels of plasma visfatin, as
well as other inflammatory cytokines such as IL-6, TNF-α and CRP (Wang et al.,
2011b). In a more recent study by the same group, they showed that the T variant of -
1535C>T caused a significant decrease in transcriptional activity of reporter gene
assay in human umbilical vein endothelial cells (HUVECs). The group also examined
the binding affinity of the human visfatin promoter to the nuclear transcription factors
using electrophoretic mobility shift assay. The probe from human visfatin promoter
with -1535T allele was shown to have lower binding affinity to nuclear protein than
that of -1535C allele, and this effect was accentuated in the presence of TNF-α. In
addition, the retarded complex formed by -1535C or -1535T-probe binding to nuclear
protein was inhibited by unlabeled AP-1 specific probe in competition experiment.
This suggested that AP-1 may be the target nuclear effector of the -1535C>T visfatin
promoter probe, and the association between -1535C>T and reduced risk of CAD may
be due to altered binding affinity between the visfatin promoter and AP-1 (Wang et
al., 2011c).
2.3.4.1.3 SNP -1001T>G (rs9770242)
Ye et al. found that the frequency of variant G allele of -1001T>G was
significantly higher in patients with either ALI or sepsis alone as compared to healthy
controls. The genotypes of -1001T>G was associated with ALI and sepsis, and the
carriers of variant G allele were found to have increased risk of ALI as compared to
controls. The group also investigated the effect of variant G allele of -1001T>G on
transcriptional activity of reporter gene assay but no significant difference in
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luciferase activity was observed between G and T allele of -1001T>G SNP (Ye et al.,
2005). The variant G allele of -1001T>G was also found to be associated with
increased risk of ARDS and poor outcomes during course of ARDS (Bajwa et al.,
2007).
The screening of all coding regions and ~1.5kbp upstream promoter region of
the visfatin gene in 23 French-Canadian subjects led to the detection of a total of 11
SNPs including -1001T>G, which was further genotyped in the population. It was
found to be at perfect linkage disequilibrium with another upstream SNP, -423A>G
(rs1319501). These 2 SNPs, -1001T>G and -423A>G, were shown to be associated
with lower fasting plasma insulin and glucose levels (Bailey et al., 2006).
In a recent study by Garcia-Bermudez et al., they found that the -1001T>G
SNP was not associated with risk of developing rheumatoid arthritis (RA), and it was
also not associated with cardiovascular risk factors in patients with RA (Garcia-
Bermudez et al., 2011).
2.3.4.1.4 SNP -948G>T (also known as -948C>A)
Bottcher et al. studied the -948G>T SNP in their population of type 2 diabetic
and healthy controls. They found that -948G>T was not associated with type 2
diabetes. However, under the additive and recessive modes of inheritance, -948G>T
was significantly associated with lower fasting plasma insulin and 2-hour plasma
glucose levels. Subjects with TT genotype of -948G>T were shown to have lower
visfatin/subcutaneous visfatin mRNA expression ratio as compared to subjects with
GG and GT genotypes of -948G>T (Bottcher et al., 2006). In contrary to the study by
Bottcher et al., Zhang et al. showed that -948C>A (also known as -948G>T) was
associated with type 2 diabetes, as well as higher levels of fibrinogen and C-reactive
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protein (Zhang et al., 2006). The -948G>T SNP was also found to be significantly
associated with fasting insulin, total apolipoprotein B (apoB) and LDL apoB levels
under dominant model of inheritance in a French-Canadian population (Bailey et al.,
2006).
The -948G>T SNP was genotyped in groups of healthy lean and obese white
children. There were no significant difference in genotype frequency between the 2
groups, and -948G>T was not associated with parameters of obesity and glucose
metabolism. However, -948G>T was found to have a significant association with
increased diastolic blood pressure in obese children under recessive mode of
inheritance (Korner et al., 2007a). Johansson et al. also examined the -948G>T SNP
in their population of obese adults. They found that -948G>T was not directly
associated with obesity but was associated with higher level of HDL-cholesterol
(Johansson et al., 2008).
2.3.4.1.5 Summary of common upstream SNPs
Table 2 showed a summary of common SNPs in the upstream promoter region
of human visfatin gene, and their associations with metabolic diseases/parameters. In
summary, SNPs detected in the upstream promoter region of visfatin gene had been
shown to be associated with disease susceptibility and metabolic risk factors. These
associations suggested that visfatin may be a possible candidate gene for metabolic
diseases.
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Table 2 Summary of common upstream SNPs in the visfatin gene
-1543C>T/-1535C>T (rs61330082) -1001T>G (rs9770242) -948G>T/-948C>A
Relevant findings References Relevant findings References Relevant findings References
 Frequency of T allele was significantly
lower in patients with ALI as compared
to healthy controls
 T variant resulted in 2-fold decrease in
reporter gene expression





Bailey SD et al.
(2006)
 Associated with decreased risk of ARDS
 Associated with improved outcomes
during course of ARDS
Bajwa EK et al. (2007)










Ye SQ et al.
(2005)
 Not associated with diabetes
 Associated with lower serum triglyceride
and higher HDL-cholesterol level in
non-diabetic subjects
 T variant did not result in difference in
reporter gene expression










Bottcher Y et al.
(2006)
 T variant caused a decrease in IL-1β-
induced visfatin expression in pulmonary
vascular endothelial cells














Zhang Y-Y et al.
(2006)
 Conferred lower risk of CAD
 Associated with lower level of serum
triglyceride level
Yan JJ et al. (2010)
 Associated with lower plasma visfatin in
patients with CAD
 Associated with lower levels of
inflammatory cytokines such as TNF-α,
IL-6 and hs-CRP
Wang LS et al. (2011)















Korner A et al.
(2007)
 T variant caused a decrease in reporter
gene expression
 T variant caused a decrease in promoter
binding affinity to nuclear factor, AP-1
Wang YS et al. (2011)













2.3.4.2 Exonic and intronic SNPs
The visfatin gene was screened for SNPs in 24 DNA samples, and a
synonymous SNP, +903G>A (rs11553095) with MAF of 0.41 was detected in exon 7
of the coding region. The SNP did not result in a change in amino acid (Ser301) of the
visfatin protein, and thus no association studies was performed between the +903G>A
SNP and metabolic parameters (Bottcher et al., 2006). Bailey et al. (2006) also
identified the presence of +21327A>G (rs2302559, also known as rs11553095) in
exon 7 of the visfatin gene after screening for visfatin SNPs in DNA of 23 subjects.
However, the synonymous SNP which resulted in a silent mutation was not genotyped
in the French-Canadian population (Bailey et al., 2006). In addition, +903G>A (also
known as rs2302559) was detected in the visfatin gene in Japanese subjects with and
without type 2 diabetes but as +903G>A was not associated with type 2 diabetes, no
other association studies were performed on the SNP (Tokunaga et al., 2008).
Blakemore et al. conducted genotyping for 8 haplotype-tagging SNPs in their
obese children population, and a rare SNP (rs10487818) of MAF of 0.004 was
detected in intron 4 of the visfatin gene. The intronic SNP (rs10487818) was shown to
be associated with a protective effect against severe obesity as the SNP had a lower
frequency of occurrence in severely obese children as compared to controls
(Blakemore et al., 2009).
2.3.4.3 Haplotypes
In addition to the associations between visfatin SNP and metabolic parameters,
haplotypes derived from the combination of SNPs occurring in the visfatin gene of the
same population were shown to be associated with metabolic parameters.
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Carriers of [G-T-A] haplotype, which was derived from [rs9770242, -948G>T,
rs4730153], were found to have significantly lower fasting plasma insulin and 2-hour
plasma glucose level as compared to non-carriers. The haplotype association was
supportive of the association found between T allele of -948G>T and levels of fasting
insulin and 2-hour plasma glucose. Carriers of [T-G-A] haplotype were also shown to
have higher 2-hour plasma glucose and lower glucose infusion rate (Bottcher et al.,
2006).
Jian et al. reported that -1535C>T was not associated with parameters of lipid
and glucose metabolism but haplotype derived from -1535C>T and 2 other intronic
SNPs was found to be associated with parameters of lipid and glucose metabolism
(Jian et al., 2006).
2.3.5 Visfatin level in metabolic diseases
2.3.5.1 Visfatin and diabetes
Diabetes mellitus is a chronic disease that occurs when the pancreas of the
body produces no (type 1 diabetes mellitus) or insufficient (type 2 diabetes or
gestational diabetes mellitus, GDM) amount of insulin, thus leading to high glucose
level in the blood. Due to the reported insulin-mimetic properties of visfatin, many
clinical studies had aimed to examine the association between visfatin and diabetes.
Plasma visfatin was found to be increased in type 2 diabetic patients as
compared to non-diabetic controls, and was independently associated with type 2
diabetes (Chen et al., 2006). Another study by Esteghamati et al. also found elevated
plasma visfatin in type 2 diabetic patients, and plasma visfatin was significantly
associated with homeostasis model-insulin resistance (HOMA-IR) (Esteghamati et al.,
2011). Serum visfatin was shown to be associated with progressive β cell
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deterioration. Type 1 diabetic patients were shown to have higher serum visfatin as
compared to type 2 diabetic and non-diabetic patients, while type 2 diabetic patients
were shown to have higher serum visfatin than non-diabetic controls. The visfatin
level was negatively correlated with insulin secretion in non-diabetic male subjects,
and positively correlated with hyperglycemia in type 2 diabetic patients. However,
visfatin level in type 1 diabetic patients was not correlated with insulin secretion or
hyperglycemia, suggesting different visfatin responses in different states of diabetes
(Lopez-Bermejo et al., 2006). Dogru et al. also reported that plasma visfatin level was
higher in type 2 diabetic patients than controls, while there was no significant
difference in plasma visfatin level between patients with impaired glucose tolerance
and controls. This suggested that visfatin level increased with worsening of glucose
tolerance (Dogru et al., 2007).
Patients with GDM were found to have higher visfatin level than healthy
pregnant controls, and the visfatin level was correlated with weeks of gestation
(Krzyzanowska et al., 2006a). There was no difference in visfatin level between GDM
and type 2 diabetic patients but GDM and type 2 diabetic patients were shown to have
higher visfatin level than controls (Coskun et al., 2010). Increased visfatin expression
was also observed in placenta of GDM patients, and it was correlated with increased
serum visfatin, which was found to decrease after delivery. This implied that visfatin
production from placenta may play a role in pathogenesis of GDM (Ma et al., 2010).
Despite the various reports on significant associations between visfatin level
and diabetes or parameters of glucose metabolism, other conflicting data had been
reported. Plasma visfatin was found to be lowered in type 1 diabetic patients as
compared to healthy controls, and it was negatively correlated with hyperglycemia
(Toruner et al., 2009). Serum visfatin was significantly higher in type 2 diabetic Asian
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Indians but visfatin level was not shown to be associated with HOMA-IR or other
parameters of glucose metabolism (Sandeep et al., 2007).
Telejko et al. examined the expression and secretion of visfatin in two groups
of GDM patients at different weeks of gestation. Visfatin concentrations did not differ
between GDM patients at 26-33 weeks of gestation and normal glucose tolerance
subjects. For GDM patients at full term of gestation, serum visfatin was significantly
lower than healthy pregnant controls but there was no difference in visfatin mRNA
expression between the two groups. The serum visfatin in GDM patients did not
correlate with any clinical or metabolic parameters, and visfatin expression in
placenta tissues of GDM patients also did not correlate with the level of serum
visfatin (Telejko et al., 2009).
The differing reports indicated that more studies are needed to elucidate the
association between visfatin and insulin resistance.
2.3.5.2 Visfatin and obesity
Fukuhara et al. first discovered visfatin as an adipokine, which was
predominantly secreted by visceral adipose tissues (Fukuhara et al., 2005), and this
led to studies that examine the association between visfatin and obesity. Serum
visfatin of obese women was found to be higher than controls, and it was positively
correlated with glucose within the obese group (Zahorska-Markiewicz et al., 2007).
Comparing between obese and non-obese Asian Indians with type 2 diabetes, the
obese group was shown to have higher serum visfatin, which was significantly
associated with parameters of obesity such as BMI and waist circumference after
adjusting for type 2 diabetes (Sandeep et al., 2007). Obese children were also shown
to have significantly higher serum visfatin than lean controls (Haider et al., 2006a).
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The elevated visfatin level in obese children was found to have a positive correlation
with the level of high-density lipoprotein (HDL) (Jin et al., 2008). In addition, the
increased visfatin level in obese children was found to correlate with visceral adipose
tissue area (Araki et al., 2008).
However, there were reports that showed contrasting data. There was a
decrease in visfatin expression in subcutaneous adipose tissue (SAT) of obese subjects
as compared to normal weight controls, and this was accompanied by a decrease in
plasma visfatin. The plasma visfatin was negatively correlated with BMI in obese
subjects (Pagano et al., 2006). Another study by Ersoy et al. reported no difference in
serum visfatin between healthy females of different BMI, and there was no significant
correlation between serum visfatin and parameters of obesity (Ersoy et al., 2010).
2.3.5.3 Visfatin and non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that
results in accumulation of lipids (namely triglyceride) in hepatocytes, which causes
lipid peroxidation, inflammation and induction of Fas ligand, thus leading to cell
damage or cell death. It is characterized by elevated levels of liver enzymes such as
alanine transaminase (ALT), aspartate transaminase (AST) and gamma-glutaryl
transferase (GGT) (Angulo and Lindor, 2002). NAFLD was also found to be
associated with obesity and insulin resistance. Lee et al. reported an increased level of
liver enzymes in severely obese children with higher waist-hip ratio, and had also
shown that obese children with abnormal glucose tolerance or type 2 diabetes were
found to have higher levels of liver enzymes (Lee et al., 2008). The accumulation of
lipids in NAFLD also led to the study of adipocyte-derived inflammatory adipokines
and their role in the pathogenesis of NAFLD.
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Obese children with NAFLD were found to have significantly higher serum
leptin level and lower serum adiponectin level as compared to obese controls without
NAFLD. There were also significant negative correlations between ultrasonographic
grade of liver steatosis and levels of serum adiponectin and resistin, where advanced
liver steatosis was associated with lower levels of serum adiponectin and resistin as
compared to mild liver steatosis (Lebensztejn et al., 2009). Serum adiponectin to
leptin ratio was significantly lower in patients with NASH as compared to patients
with simple steatosis and controls, and multivariate analysis also showed that serum
adiponectin to leptin ratio was independently associated with non-alcoholic
steatohepatitis (NASH). Thus, serum adiponectin to leptin ratio may be a predictive
indicator of non-alcoholic liver steatosis (Lemoine et al., 2009).
The newly discovered adipocyte-derived inflammatory adipokine, visfatin was
also studied in patients with NAFLD. The mRNA expression of hepatic visfatin in
liver biopsies of patients with NAFLD was reduced as compared to controls, and
immunohistochemistry staining of the hepatic tissue of patient with NAFLD also
revealed diffused cytoplasmic staining of visfatin in the hepatocytes. The reduction in
mRNA expression of hepatic visfatin was accompanied by decreased level of secreted
visfatin in patients with NAFLD as compared to controls. Huh7 hepatocytes and
HEK293 embryonic kidney cells transfected with visfatin were exposed to high
glucose concentrations mimicking the elevated plasma glucose level during diabetes
mellitus, and upon exposure to increasing glucose concentrations, the expression of
visfatin was shown to be significantly decreased through PCR and immunostaining of
the cells. This indicated that the association between NAFLD and insulin resistance
may be attributed by the decreased expression of visfatin in the hepatocytes. The
inhibition of visfatin expression in hepatocytes through small interference-RNA (si-
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RNA) also resulted in apoptosis of the hepatocytes as observed by reduction in
mitochondrial dehydrogenase activity of hepatocytes and increased DNA fragments as
detected by terminal deoxynucleotidyltransferase dUTP nick end labelling (TUNEL)
assay. These findings suggested that visfatin may play a protective role in the
apoptosis of hepatocytes during NAFLD (Dahl et al., 2010). Visfatin level of visceral
adipose tissues was lower in patients with NAFLD as compared to non-NAFLD
subjects. In addition, other studies had reported decreased hepatic visfatin expression
and serum visfatin in patients with NASH and liver cirrhosis as compared to controls
(Jarrar et al., 2008, de Boer et al., 2009).
However, another study by Aller R et al. showed that higher serum visfatin
level was observed in patients with portal inflammation, which is a feature of NAFLD
(Aller et al., 2009). Immuno-staining of liver biopsies in obese NAFLD patients also
revealed a positive correlation between visfatin expression and fibrosis stage (Kukla
et al., 2010). In conclusion, visfatin may play a role in the pathogenesis of NAFLD,
and the level of serum visfatin may be indicative of the degree of liver steatosis.
2.3.5.4 Visfatin and cardiovascular disease
Cardiovascular disease refers to disorders of the heart or blood vessels, and it
includes coronary heart disease (heart attack), cerebrovascular disease (stroke), raised
blood pressure (hypertension), peripheral artery disease, rheumatic heart disease,
congenital heart disease and heart failure. According to WHO, cardiovascular disease
is the world’s leading killer, claiming about 17.1 million lives a year. Obesity has
been regarded as one of the risk factors for cardiovascular disease, and the obesity-
related inflammation was suggested to be the link between obesity and cardiovascular
disease (Wang and Nakayama, 2010). Adipose tissue was shown to be capable of
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secreting adipokines that may serve as inflammatory mediators in the pathogenesis of
cardiovascular disease (Funahashi et al., 1999).
Serum leptin level was found to be significantly higher, and plasma
adiponectin level was found to be significantly lower in patients with ischemic
cerebrovascular disease as compared to controls (Jaleel et al., 2010). Serum
adiponectin level was also lower in patients with coronary heart disease (CHD) than
patients without CHD (Kajikawa et al., 2011). In addition, obese patients with
coronary artery disease (CAD) were found to have lower level of plasma adiponectin
as compared to obese patients without CAD. There was also reduced expression of the
adiponectin receptors, AdipoR1 and AdipoR2, in the peripheral monocytes of patients
with CAD as compared to controls (Kollias et al., 2011). There was decreased
expression of adiponectin in the epicardial adipose tissues of CAD patients, and
adiponectin was able to suppress the secretion of pro-inflammatory cytokines such as
IL-6 and TNF-α and also the apoptosis of stearic acid-stimulated monocytes (Zhou et
al., 2011).
The inflammatory role of visfatin was also studied in cardiovascular disease.
Serum visfatin level was shown to be elevated in patients with CAD as compared to
healthy controls, and the level of serum visfatin was positively correlated with the
level of high sensitivity-C reactive protein (hs-CRP) in CAD patients. This suggested
that visfatin may be involved in the inflammation during the development of CAD
(Kadoglou et al.). Another study by Cheng et al. showed higher visfatin level in the
epicardial and abdominal adipose tissues of CAD patients as compared to controls.
However, abdominal adipose tissues were shown to secrete more visfatin than
epicardial adipose tissues, suggesting that abdominal tissues may contribute to CAD
(Cheng et al., 2008). Patients with metabolic syndrome and carotid plaque had
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significantly higher serum visfatin than patients with metabolic syndrome but with no
carotid plaque. Serum visfatin was also found to correlate positively with carotid
intimal-media thickness (IMT), which was derived from the thickness of the carotid
plaque as a cardiovascular risk factor (Zhong et al., 2008). Carotid plaques were
obtained from patients with or without cerebrovascular disease, and both mRNA and
protein expressions of visfatin were increased in carotid plaques from patients with
cerebrovascular disease. Immunostaining with anti-visfatin antibody revealed positive
staining of macrophages within the lipid-rich core of the carotid plaque. Upon rupture
of the plaque induced percutaneous coronary intervention (PCI) in CAD patients,
plasma visfatin was found to increase and visfatin was expressed on macrophages
within the lipid-rich core of the ruptured plaque. Moreover, oxidized low density-
lipoprotein (ox-LDL) and TNF-α were able to induce expression of visfatin in THP-1
monocytes, and recombinant visfatin was able to increase expression of matrix
metallopeptidase-9 (MMP-9). These indicated that visfatin may play a role in the
pathogenesis of plaque destabilization in cardiovascular disease (Dahl et al., 2007).
Despite various reports suggesting a pathogenic role of visfatin in
cardiovascular disease, in vivo study using mice model of acute myocardial infarction
showed that administration of visfatin reduced the size of myocardial infarct, and the
addition of visfatin also reduced the death of cardio-myocytes, implying that visfatin
may exert cardio-protective effects (Lim et al., 2008).
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2.3.5.5 Visfatin and metabolic syndrome/metabolic diseases
Metabolic syndrome is defined as the presence of at least three of the
abnormalities: obesity, triglycerides, low level of high density lipoprotein (HDL)-
cholesterol, glucose intolerance and significant or severe hypertension (2001).
Visceral adiposity was associated with cardiovascular risk factors such as
hyperlipidemia, hypertension and abnormal glucose tolerance, which are criteria of
metabolic syndrome. Thus, the adipokines secreted by visceral adipocytes had been
postulated to be involved in the development of metabolic syndrome (Matsuzawa,
2006).
Serum adiponectin was found to be lower in patients with metabolic syndrome
than controls. The expression of adiponectin correlated negatively with the expression
of TNF-α, while the expression of leptin correlated positively with TNF-α in the
adipose tissue of patients with metabolic syndrome (Gormez et al., 2011). There were
also studies reporting on the level of serum visfatin in metabolic syndrome. Kolsgaard
et al. found higher plasma visfatin level in obese subjects with metabolic syndrome as
compared to obese subjects without metabolic syndrome (Kolsgaard et al., 2009).
Kim et al. and Filippatos et al. also reported increased plasma visfatin in patients with
metabolic syndrome (Kim et al., 2010, Filippatos et al., 2008). In addition, all these
studies showed that plasma visfatin increased proportionally with the number of
components of metabolic syndrome. Thus, these data suggested that alterations in the
level of visfatin may be indicative of the degree of metabolic syndrome.
Apart from being associated with metabolic syndrome, visfatin was found to
be altered in metabolic diseases such as polycystic ovarian syndrome (PCOS) and
thyroid disorder. Serum visfatin was increased in patients with PCOS, and it
correlated positively with HOMA-IR (Cekmez et al., 2011). Another study reported
38
elevated serum visfatin in PCOS patients as compared to controls and through logistic
regression, plasma visfatin was shown to be a significant determinant of PCOS (Chan
et al., 2007). In patients with hyperthyroidism, plasma visfatin was found to be higher
than in controls and after hormonal normalization treatment, plasma visfatin was
found to be reduced in controls. There was no significant correlation between plasma
visfatin and HOMA-IR in patients with hyperthyroidism (Chu et al., 2008). Caixas et
al. reported elevated plasma visfatin level in patients with hyperthyroidism and
hypothyroidism respectively, and the plasma visfatin level in both groups of patients
was found to be further increased after treatment. There was also no significant
correlation between plasma visfatin and HOMA-IR or inflammatory markers (Caixas
et al., 2009). The differing reports on the level of visfatin and its association with
metabolic parameters showed that further studies are needed to gain a better
understanding on the role of visfatin in metabolic diseases.
2.3.5.6 Visfatin and cancer
Cancer occurs as a result of uncontrolled growth and spreading of abnormal
cells, which may eventually lead to the formation of a tumour. As mentioned in
section 2.3.2.4.1, visfatin was found to prolong cell survival through its enzymatic
role as Nampt and upon inhibition of Nampt, the cells were found to undergo
apoptosis and senescence (Dahl et al., 2010, van der Veer et al., 2007). Thus, due to
the reported anti-apoptotic effect of visfatin, there had been studies investigating on
the relationship between visfatin and cancer.
Visfatin level was found to be higher in patients with colorectal cancer and/or
gastric cancer as compared to controls, and the level of visfatin was significantly
correlated with tumour stage progression (Nakajima et al., 2010, Nakajima et al.,
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2009). There was increased visfatin mRNA expression in human prostate cancer cell
lines and human prostate cancer tissues as detected by RT-PCR and
immunohistochemistry. The addition of visfatin stimulated the proliferation of
prostate cancer cell line and caused a dose-dependent increase in secretion of MMP-2
and MMP-9 that may be involved in the breakdown of extracellular matrix during
prostate cancer metastases (Patel et al., 2010). Wang et al. reported an up-regulation
of visfatin in human prostate cancer tissues, and the knockdown of visfatin through
small hairpin RNA was shown to induce apoptosis of prostate cancer cells. The
knockdown of visfatin in xeno-grafted prostate cancer tumours in mice model caused
slower growth rate and smaller tumour size as compared to controls. The reduction in
level of NAD during inhibition of visfatin may be a regulatory mechanism involved in
controlling the growth of prostate cancer cells (Wang et al., 2011a). The over-
expression of visfatin was found in human ovarian cancer tumour and human
malignant lymphoma, with a significant higher expression in higher tumour grades
(Shackelford et al., 2010, Olesen et al., 2011). The treatment of human breast cancer
cell line, MCF7 with visfatin caused an increased in cell proliferation and expression
of cyclin-dependent kinases (cdks) and cyclin D1, which are regulators of the cell
cycle (Mazaki-Tovi et al., 2010). Other than MCF7, visfatin treatment also resulted in
increased cell proliferation of mouse insulinoma cell line, MIN6, and the
simultaneous administration of visfatin was able to suppress palmitate-induced
apoptosis of MIN6 (Cheng et al., 2011).
FK866 (also known as APO866) is a chemical inhibitor of visfatin, and it had
been shown to trigger cell death in hematologic malignant cells but not in normal
hematopoietic progenitor cells. FK866 also exerted anti-tumour effects in mice model
of human hematologic malignancies. The administration of FK866 was able to cause a
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reduction in tumour growth and prolonged the survival period of the mice, while not
causing any signs of toxicity to the mice (Nahimana et al., 2009). The incubation of
HepG2 cells with FK866 revealed that FK866 did not have an immediate or direct
toxicity effect on the cells, and the carcinoma cell numbers gradually decreased with
longer exposure to the compound. FK866 was shown to cause cell death by apoptosis
as observed in the electron micrographs, and the apoptotic effects of FK866 was
accompanied by a depletion in level of NAD and ATP (Hasmann and Schemainda,
2003).
The expression of visfatin may serve as a marker for cancerous tumours, and
the inhibition of visfatin may offer a potential treatment for cancer.
2.3.6 Response of visfatin to glucose and insulin
2.3.6.1 Oral glucose tolerance test (OGTT)
Oral glucose tolerance test (OGTT) is a clinical technique used to determine
the body’s ability to metabolize glucose. The glucose loading after an overnight fast
had been shown to cause an initial increase in plasma glucose, which was stabilized at
later time-point of OGTT. As expected, the change in glucose level was positively
correlated with the change in insulin during the course of OGTT. Serum visfatin was
shown to decrease progressively during OGTT in both normal weight and obese
subjects. Although obese subjects showed a faster decrease in serum visfatin, there
was no statistically significant difference in the change of serum visfatin between the
normal weight and obese subjects during the course of OGTT. Overall, a negative
correlation was found between fasting plasma glucose and fasting serum visfatin
(Bala et al., 2011a). The decline in visfatin level during OGTT was also observed in
obese children before and after weight reduction but there was no significant
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difference in the change of visfatin level during OGTT even after weight reduction.
Moreover, there was no significant correlation found between the level of glucose,
insulin and visfatin during OGTT (Martos-Moreno et al., 2011).
Friebe et al. carried out OGTT in both obese insulin-sensitive and obese
insulin-resistant children, and found that the decrease in serum visfatin was more
pronounced in obese insulin-resistant children. The visfatin level was negatively
correlated with the insulin-to-glucose ratio at each time-point of OGTT (Friebe et al.,
2011). Another report found that the area under curve (AUC)-visfatin was positively
correlated with AUC-insulin during OGTT, and fasting visfatin level was correlated
with fasting plasma glucose level (Unluturk et al., 2010). Fasting visfatin was also
shown to correlate with fasting insulin, insulin level at 120 minute of OGTT and
glucose level at 120 minute of OGTT in pregnant women with or without GDM
(Lewandowski et al., 2007).
Despite the various reports on the progressive decline of serum visfatin during
OGTT, Hofso et al. had shown a transient increase in serum visfatin at 30 minute
time-point of OGTT in groups of normal-weight and morbidly obese subjects with or
without diabetes. The serum visfatin eventually returned to baseline level at 120
minute time-point of OGTT, and the change in serum visfatin was not significantly
correlated with changes in glucose or insulin level (Hofso et al., 2009). On the
contrary, Li et al. and Marcinkowska et al. were not able to detect any change in
visfatin level during the glucose challenge in subjects with or without diabetes (Li et
al., 2006, Marcinkowska et al., 2007).
The dynamic change in visfatin level during OGTT suggested a possible
responsive mechanism of visfatin towards changes in glucose and insulin level.
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However, further evidence is needed to elucidate the relationship between visfatin,
glucose and insulin.
2.3.7 Regulation of visfatin
2.3.7.1 Glucose and insulin
Due to the alteration of visfatin concentration in hyperglycemic and
hyperinsulinemic subjects, glucose and insulin had been postulated to be involved in
the regulation of visfatin. The exposure of mouse podocyte cell line and MCT cells to
high glucose concentration was found to cause an increase in expression and secretion
of visfatin (Kang et al., 2010b). The increase in expression and secretion of visfatin
was also observed in cultured adipocytes that were treated with high glucose (Kang et
al., 2010a). J774.2 mouse monocytes cell line treated with extracellular insulin was
shown to have an increase in visfatin protein expression, whereas the treatment with
glucose did not have an effect on the visfatin expression (Laudes et al., 2010). In
addition, Bala et al. reported that there was no difference in visfatin concentration in
3T3L1 adipocytes incubated with glucose but a reduction in visfatin concentration
was observed in 3T3L1 adipocytes incubated with high insulin level (Bala et al.,
2011a).
Besides the in vitro studies on the direct effect of glucose and insulin on
visfatin expression in cell lines, there were also in vivo studies that investigated the
effect of insulin on visfatin expression. Healthy subjects who undergone a glucose
clamp showed an increasing plasma glucose level, which was in parallel with an
increasing visfatin level. However, the co-infusion of insulin abolished the glucose-
induced increase in visfatin level (Haider et al., 2006b). Another study also found that
43
the simultaneous administration of insulin was able to suppress the endotoxin-induced
increase in plasma visfatin (Dandona et al., 2010).
2.3.7.2 Hormones
Adipose energy storage and insulin resistance had been shown to be affected
by hormones, thus these indicated that hormonal control may play a part in the
regulation of visfatin. Dexamethasone is a member of the glucocorticoid hormones
with anti-inflammatory properties. 3T3L1 adipocytes treated with dexamethasone
were shown to have an up-regulated mRNA expression of visfatin, whereas treatment
with growth hormone was shown to cause a down-regulation in mRNA expression of
visfatin (Kralisch et al., 2005a). MacLaren et al. also found that dexamethasone was
able to stimulate visfatin mRNA expression in both 3T3L1 pre-adipocytes and
adipocytes. Sex hormones like progesterone and testosterone were shown to cause an
increase in visfatin expression in 3T3L1 pre-adipocytes, while oestrogen was not
found to have an effect on visfatin expression (MacLaren et al., 2007).
2.3.7.3 Inflammatory cytokines and adipokines
As mentioned in section 2.3.2.2, visfatin was shown to be involved in
inflammation, and was correlated with other inflammatory cytokines and adipokines.
This suggested that inflammatory cytokines and adipokines may participate in the
regulation of visfatin. TNF-α was shown to trigger a significant increase in mRNA
expression of visfatin in human visceral adipose tissue (Hector et al., 2007). However,
the human placental BeWo cells showed a dose-dependent increase in the secretion of
extracellular visfatin only after 48 hours of incubation with TNF-α, and this was
accompanied by reduced mRNA and protein expression of intracellular visfatin (Ma
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et al., 2010). Li et al. revealed that mice undergoing a week of TNF-α treatment had a
lower plasma visfatin level, and the mRNA expression of visfatin in the adipose tissue
of these mice was found to be down-regulated (Li et al., 2009). Another pro-
inflammatory cytokine, IL-6, was found to cause a dose-dependent and time-
dependent inhibition on visfatin mRNA expression in 3T3L1 adipocytes (Kralisch et
al., 2005b).
The adipokine, leptin, was able to up-regulate the expression and secretion of
both intracellular and extracellular visfatin in 3T3L1 adipocytes and adipose tissue
explants of human and mice. The knockdown of leptin receptor in 3T3L1 adipocytes
through si-RNA caused a decrease in leptin-induced mRNA expression of visfatin,
and the addition of leptin to adipose tissue explants of leptin-deficient mice increased
the production of visfatin. Moreover, intra-peritoneal injection of leptin into mice also
resulted in an increase in visfatin protein production in the adipose tissues of the mice
(Tan et al., 2009).
2.3.7.4 Metformin and thiazolidinedione
Metformin and thiazolidinedione are anti-diabetic drugs used to improve
insulin-sensitivity in diabetic patients. The increased visfatin level in women with
PCOS was significantly reduced after 3 months of metformin treatment, and this was
accompanied by a decrease in BMI, fasting insulin and HOMA-IR (Ozkaya et al.,
2010). Metformin also resulted in a decrease in fasting glucose level, and an
improvement in β cell function in type 2 diabetic patients but there was no significant
change in plasma visfatin level after treatment (Hsieh et al., 2007).
Mice on high fat diet were shown to be more insulin-resistant as compared to
mice on chow diet, and plasma visfatin level was elevated in the high fat diet-induced
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insulin-resistant mice. Upon treatment with pioglitazone, there was a subsequent
reduction in fasting glucose, fasting insulin and HOMA-IR in the insulin-resistant
mice. The elevated plasma visfatin level and mRNA expression of visfatin in the
visceral adipose tissues of the insulin-resistant mice were also decreased (Lv et al.,
2009). In another study by Choi et al., rosiglitazone reportedly cause a decrease in
insulin and glucose concentrations, and a significant increase in visfatin mRNA
expression in visceral fats of obese diabetic rats (Choi et al., 2005).
Despite an improvement in glucose tolerance, the treatment with metformin or
thiazolidinedione had failed to cause a significant difference in visfatin level in type 2
diabetic patients (Erdem et al., 2008, Kadoglou et al., 2010).
2.3.7.5 Obesity
Visfatin is as an adipokine shown to be predominantly secreted from visceral
adipose tissues, and the associations between visfatin and obesity suggested that
weight loss through dietary control, exercise and surgery may be able to regulate
visfatin level. Obese women without diabetes who undergone a 12-weeks dietary
control program showed a decrease in body weight and BMI but a significant increase
in serum visfatin. The change in serum visfatin was negatively correlated with the
change in lean mass. Moreover, after controlling for the change in body weight, the
change in circulating visfatin was found to have a positive correlation with
quantitative insulin sensitivity check index (QUICKI) and a negative correlation with
HOMA-IR. This suggested that the change in serum visfatin during weight loss may
play a role in glucose homeostasis (Agueda et al., 2010). In a study by Haus et al.,
subjects undergoing 12-weeks of aerobic exercise training showed a decrease in body
weight, visceral adipose tissue (VAT), subcutaneous adipose tissue and plasma
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visfatin as compared to pre-intervention values. The exercise-induced reduction in
visfatin was also found to correlate with change in VAT, changes in glucose and
insulin AUC response curves during OGTT and the improvement of insulin resistance
index (Haus et al., 2009). Plasma visfatin was also found to be reduced in another
group of healthy obese women, whose BMI and body weight were reduced after a 12-
weeks exercise training program (Choi et al., 2007).
Besides dietary and exercise program, weight loss could also be induced by
bariatric surgery. Gastro-plastic surgery was carried out in severely obese subjects,
and this resulted in a reduction of body weight, fasting insulin, fasting glucose and
HOMA-IR. However, plasma visfatin was increased in most of the patients after
surgery. After adjusting for weight loss, the increase in plasma visfatin was found to
correlate with the decrease in HOMA-IR (Krzyzanowska et al., 2006b). Plasma
visfatin was also elevated in obese subjects with or without abnormal glucose
tolerance after intestinal bypass, and the increase in visfatin was negatively correlated
with the reduction in waist circumference (Garcia-Fuentes et al., 2007). Moschen et al
reported a significant decrease in body weight and plasma visfatin level in obese
children after gastric banding, and the liver biopsies of the patients showed a decrease
in histological scores for steatosis. The immuno-histochemistry of liver biopsies
before and after surgery revealed that there was a reduction in hepatic visfatin staining
after gastric banding (Moschen et al., 2009). Another group of obese subjects also
showed a reduction in body weight, BMI and waist circumference after gastric
banding. This was paralleled by a decrease in plasma visfatin level, which had a




Obesity, in particular, childhood obesity is a rising concern among many
developed and developing countries as obesity is a risk factor for insulin resistance
and metabolic diseases. Adipose tissue had been found to secrete adipokines like
adiponectin, leptin and resistin, which were found to be associated with inflammation
and energy metabolism. Visfatin was first discovered as an adipokine with insulin-
mimetic properties, it was shown to be expressed in adipose tissues as well as other
tissues such as brain, heart and liver. Visfatin also served other roles like pre-B cell
colony enhancing factor (PBEF) that aids in maturation of pre-B cell, nicotinamide
phosphoribosyltransferase (Nampt) that is involved in biosynthesis of NAD and pro-
inflammatory cytokine that is involved in inflammation. Polymorphisms within the
visfatin gene were associated with different cardiometabolic parameters. Although
there were debates regarding the visfatin level in different disease states, the
alterations in visfatin concentration and the significant correlations between visfatin
and cardio-metabolic parameters indicated that visfatin may play a role in the
pathogenesis of metabolic diseases. In addition, visfatin level may be a possible
biomarker for different disease states. Visfatin was also shown to be regulated by
hormones, cytokines and components of insulin resistance and obesity.
Therefore, visfatin remains an interesting adipokine for future studies, and the
elucidation of the regulation and role of visfatin may serve as important therapeutic







3.1.1 Primary cells and cell lines
All cell cultures were maintained in tissue culture treated dishes or flasks
containing the essential culture medium, and were incubated at 37oC with 5% CO2.
The cells were subcultured at 80-90% confluency, where the cells were trypsinized
after the removal of culture medium and the washing with 1×Phosphate Buffer Saline
(PBS).
3.1.1.1 Primary human subcutaneous pre-adipocytes
The primary human subcutaneous pre-adipocytes were isolated from the
human breast fat tissue as previously described (Zuk et al., 2001), and were provided
by Dr Kerri Tang (Department of Orthopedics, NUS).
3.1.1.2 Human cord lining epithelial cells (CLECs)
The CLECs were isolated from the cord lining tissues of human umbilical cord
as previously described (Sivalingam et al., 2010), and were a kind gift from Prof.
Phan Toan Thang (Department of Surgery, NUS).
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3.1.1.3 American type culture collection (ATCC) cell lines
Table 3.1 showed the various cell lines that were purchased from American
type culture collection (ATCC) and used in this study.
Table 3.1 ATCC cell lines











HepG2 Liver carcinoma Homo sapiens (human)
Huh7 Liver carcinoma Homo sapiens (human)
Jeg3 Placental choriocarcinoma Homo sapiens (human)
MCF7 Breast adenocarcinoma Homo sapiens (human)
MRC5 Lung fibroblast Homo sapiens (human)
Panc1 Pancreatic carcinoma Homo sapiens (human)
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3.1.1.4 Culture medium
The primary cells and cell lines were cultured in different culture media
supplemented with different nutrients that were essential for their respective growth.
3.1.1.4.1 Culture medium for human subcutaneous pre-adipocytes
The human subcutaneous pre-adipocytes were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) [Sigma-Aldrich, USA] containing 50 % F12
medium, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin [Invitrogen Life
Technologies, USA] and 10ng/ml of recombinant human fibroblast growth factor
(FGF) [ProSpec, USA].
3.1.1.4.2 Culture medium for CLECs
The CLECs were cultured in Medium 171 [Cascade Biologics, Portland]
supplemented with 50µg/ml insulin-like growth factor-1, 50µg/ml platelet-derived
growth factor-BB, 5µg/ml transforming growth factor-β1 and 5µg/ml insulin [R&D
Systems, Minneapolis].
3.1.1.4.3 Culture medium for ATCC cell lines
The cell lines purchased from ATCC were cultured in DMEM supplemented
with 10% FBS and 1% penicillin/streptomycin.
3.1.1.5 Freezing medium
The freezing medium that was used to store unused cells at liquid nitrogen
contained DMEM with 20% FBS, 10% Dimethyl Sulfoxide (DMSO) [Sigma-Aldrich,
USA] and 1% penicillin/streptomycin.
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3.1.1.6 Conditioned culture supernatants
The conditioned culture supernatants were collected after 24 hours of
incubation with cells that had reached about 70% confluency, and used for
measurement of secreted visfatin concentration by Enzyme Linked Immunosorbent
Assay (ELISA). The unused supernatants were stored at -20oC and discarded after a
week.
3.1.2 Primers
The reference gene and messenger Ribonucleic Acid (mRNA) sequences of
visfatin were downloaded from National Center for Biotechnology Information
(NCBI). The primers were designed using an online Primer3 program:
http://frodo.wi.mit.edu/primer3/. The specificity of the designed primers was checked
using Basic Local Alignment Search Tool (BLAST)-Primer BLAST, and the primers
were synthesized by 1st base Private Limited, Singapore.
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3.1.2.1 Reverse transcription-polymerase chain reaction (RT-PCR) primers
Table 3.2 showed the list of primers used for reverse transcription-polymerase
chain reaction (RT-PCR) in this study.























































































The PCR primers were designed based on the reference gene sequence
NC_000007 of human visfatin gene. The primers were designed to cover ~3.5kbp
upstream promoter region including exon 1 and each of the remaining 10 exons
including the exon-intron boundaries respectively as shown in Table 3.3.
Table 3.3 Primers used in PCR










































3.1.2.3 Molecular cloning primers
Table 3.4 showed a list of the primers used for cloning of visfatin isoforms.




































































The sequencing primers were generated based on the expected PCR product
sequence of the upstream region and each of the 11 exons including the respective
exon-intron boundaries of the visfatin gene as mentioned in 3.1.2.2. Each sequencing
primer was designed to cover ~500bp of the PCR product sequence. As the length of
each of the visfatin exons was relatively short, either the PCR forward or reverse
primer was re-used as sequencing primer for the exon and its respective exon-intron
boundary. The list of sequencing primers used in this study was shown in Table 3.5.
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Table 3.5 Primers used in sequencing






















3.1.3 Gene expression construct
3.1.3.1 Lenti-viral vector
The lenti-viral vector backbone, EMW (kind gift from Dr Zhao Jing from Dept
of Medicine Cambridge University) was used for cloning of visfatin isoforms in this
study. The genes of interest (visfatin isoform a and b) were respectively inserted into
the vector using BamHI and XhoI restriction enzyme digests, which removed the
human insulin (hINS) gene from the vector construct. The expression of the insert was
under the control of a constitutive spleen focus-forming virus (sFFV) promoter, and
the EMW vector also expressed reporter enhanced green fluorescent protein (eGFP)
bicistronically linked to the gene of interest via an internal ribosomal entry site
(IRES). The structure of EMW-hINS lenti-viral vector construct was as illustrated in
Figure 3.1.
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NcoI,1466 2177-2218BsrGI, XmaIII, AccI, SphI, NotI,
DrdI, HincII, BsiEI, XbaI, SalI
LTR: Long Terminal Repeat
cPPT: Central Polypurine Tract
sFFV promoter: Spleen focus-forming virus (sFFV) promoter
hINS gene: Human insulin gene
IRES: Internal ribosomal entry site
eGFP: Enhanced green fluorescent protein




3.1.4 Antibodies and kits
Big dye terminator v3.1 cycle sequencing kit [Applied Biosystem, USA]
DC protein assay [Bio-Rad, USA]
Dual-luciferase reporter gene assay system [Promega, USA]
Goat Anti-Mouse Immunoglobulins Horse Radish Peroxidase (HRP)-conjugate
[Sigma-Aldrich, USA]
Human visfatin ELISA kit [Alpco Diagnostics, USA]
Insulin ELISA kit [Mercodia, Sweden]
Mouse Anti-GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) [Ambion, USA]
PureYield Plasmid Maxiprep System [Promega, USA]
PureYield Plasmid Miniprep System [Promega, USA]
QIAquick gel extraction kit [Qiagen, USA]
QIAquick nucleotide removal kit [Qiagen, USA]
Rabbit Anti- C-terminal PBEF (Pre-B cell colony enhancing factor) [Bethyl
Laboratories, USA]
Rabbit Anti-N-terminal PBEF (Pre-B cell colony enhancing factor) [Santa Cruz
Biotechnology, USA]
RNeasy mini kit [Qiagen, USA]





Two hundred and forty-three children with early onset severe obesity were
recruited from the nationwide school health service, a primary healthcare service and
facility which routinely screens schoolchildren. Consecutive patients who met the
inclusion criteria of severe obesity with body weight at least 140% of the ideal weight
for height (WFH) based on local weight for height chart were invited by my co-
supervisor, Prof Lee Yung Seng, to participate in the study. Children with known pre-
existing obesity-related morbidities, those with syndromes or conditions associated
with obesity, and those with family history of inherited metabolic disorders were
excluded. Referral for screening was universal in terms of age, gender and race. More
than 90% of eligible children were enrolled for the study, which spanned over a two-
year period. Standard anthropometric measurements were taken, and blood samples
were collected from these obese children for assays of various metabolic parameters
and DNA extraction.
Thirty-five out of two hundred and forty-three obese children whose weight is
> 140% of ideal WFH and with no impaired glucose tolerance were randomly chosen
for oral glucose tolerance test.
Informed consent was obtained from all subjects and parents. This research
was approved by the National University Hospital Research and Ethics Committee.
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3.1.5.2 Cord Blood samples
Three hundred and four cord blood samples were collected from consecutive
newborns that were recruited for glucose-6-phosphate dehydrogenase (G6PD)
screening program under Department of Paediatrics, NUH. DNA was extracted from
these cord blood samples. This study was approved by the ethics committee of
National University Hospital, Singapore with written consent from the parents of the
subjects.
3.1.5.3 Type 2 diabetic patients
Fourteen type 2 diabetic patients were recruited by my supervisor, Prof Lee
Kok Onn, for the euglycemic-hyperinsulinemic clamp study, and blood samples were
collected. All fourteen type 2 diabetic patients were on divided doses of 1.5g/day of
metformin treatment. The study was approved by the research ethics committee of




3.2.1 Molecular biology techniques
3.2.1.1 RNA extraction
Total Ribonucleic Acid (RNA) was extracted from the cultured cells using
Qiagen RNeasy Mini kit [Qiagen, USA] according to the manufacturer’s instructions.
In brief, the culture medium was aspirated completely followed by cell lysis and on-
column purification to obtain total RNA, which was quantified by Nanodrop ND-
1000 spectrophotometer. The RNA was stored at -80oC when not in use.
3.2.1.2 RT-PCR
Reverse transcription-polymerase chain reaction (RT-PCR) is a technique used
to detect the mRNA expression of genes and in this study, it was used to determine
the mRNA expression of visfatin in various cell lines.
 3.2.1.2.1 Reverse Transcription
Reverse transcription is a process whereby complementary DNA (cDNA) is
produced from RNA in the reverse direction of transcription through the use of
enzyme, reverse transcriptase.
The reaction was carried out using SuperScript III Reverse Transcriptase
[Invitrogen Life Technologies, USA]. 1-5µg of RNA (extracted from cultured cells)
was mixed with 2.5µM of oligo deoxythymine (dT) primer [1st Base, Singapore],
0.5mM of deoxyribonucleotide triphosphate (dNTP) and diethylpyrocarbonate
(DPEC) water in a total volume of 14µl. The mixture was heated at 65oC for 5
minutes and incubated on ice for 1 minute.
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After incubation on ice, 4µl of 5x First-Strand buffer, 0.005M of dithiothreitol
(DTT) and 200units of SuperScript III reverse transcriptase were added to the reaction
mixture to a total volume of 20µl. The reaction mixture was further incubated at 50oC
for an hour and the reaction was terminated at 70oC for 15 minutes.
 3.2.1.2.2 PCR
Polymerase chain reaction allows the amplification of cDNA/DNA strands and
in this study, it was used to amplify genetic sequence of visfatin. The PCR was
performed on a PTC-100 Peltier Thermal Cycler [Bio-Rad, USA] using the GoTaq
Flexi DNA polymerase [Promega, USA].
The PCR mixture consisted of 5µl of 5x Green or colorless GoTaq Flexi
buffer, 1.5mM of Magnesium Chloride (MgCl2), 0.2mM of deoxynucleotide
triphosphate (dNTP), 0.4µM of forward and reverse PCR primers [1st Base,
Singapore] respectively, 1.25units of GoTaq Flexi polymerase, 1-2µl of cDNA/DNA
(product from reverse transcription of RNA of cultured cells) and nuclease-free water
to make up a total volume of 25µl.
The PCR thermal cycling conditions were at 95oC for 3 minutes for initial
denaturation of double-stranded DNA followed by 30-35 cycles of 95oC for 30
seconds, annealing temperature of 50-65oC (~5oC below melting temperature of PCR
primers) for 45 seconds, 72oC for 1-4 minutes and lastly, a final extension/elongation
of the PCR products at 72oC for 10 minutes. The PCR products were stored at -20oC
until they were used for agarose gel electrophoresis and sequencing.
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3.2.1.3 Agarose gel electrophoresis
Agarose gel electrophoresis was employed to separate the cDNA/DNA
(visfatin isoforms) in the PCR products by size. 1% agarose gel was prepared by
dissolving 0.6g of agarose gel powder [Bio-Rad, USA] in 60ml of Tris-Acetate-
EDTA (TAE) buffer [1st Base, Singapore], GelRed nucleic acid stain [Biotium, USA]
was added in 10,000x dilution (6ul in 60ml) to the agarose gel mixture, and the gel
was casted and left to cool. 10µl of PCR products synthesized using GoTaq green
buffer or mixed with 6x blue loading dye [Promega, USA] and 5ul of 1Kb Plus DNA
ladder [Invitrogen Life Technologies, USA] were added into the wells of the 1%
agarose gel. The gel electrophoresis was carried out at 80-110V using PowerPac 300
[Bio-Rad, USA] until the dye front reached the edge of the agarose gel, and the DNA
bands were visualized on a UV-20 transilluminator [Hoefer, USA] and captured by
Kodak 1D imaging program, version 3.6.
3.2.1.4 Enzyme-linked immunosorbent assay (ELISA)
Enzyme-linked immunosorbent assay (ELISA) was used to quantify and
measure the amount of secreted protein in the conditioned culture supernatants as
mentioned in 3.1.1.6 or in serum samples. The commercially available ELISA kit
[Alpco Diagnostics, USA] used in this study was specific for the human full-length
visfatin protein with a sensitivity of 30pg/ml and measures up to 16ng/ml. The mean
intra-assay variation (CV, n=4 samples tested 4 times between 1.48-2.87ng/ml) was
5.63% and the mean inter-assay variation (CV, n=4 samples tested 7 times between




Molecular cloning was used to isolate and obtain multiple copies of DNA
sequence of interest.
The DNA sequence of interest (visfatin isoforms) was synthesized from the
cDNA sample through PCR as described in 3.2.1.2.2 using iProof Taq polymerase
[Bio-Rad, USA]. The DNA (visfatin isoforms) in the PCR product was separated
according to its length by agarose gel electrophoresis as described in 3.2.1.3 and was
extracted from agarose gel using QIAquick gel extraction kit [Qiagen, USA] in
accordance with the manufacturer’s instructions.
The vector construct (EMW-hINS lenti-viral vector as shown in Figure 1.1)
used for cloning and the DNA product (visfatin isoforms) were digested with the same
appropriate restriction enzymes, BamHI and XhoI [Promega, USA] to create the same
sticky ends. The restriction enzyme digest mixture consisted of 2µl of 10xBSA, 2µl of
10X restriction enzyme buffer, 1-5µg of DNA/vector, 5units of restriction enzyme
and nuclease-free water to make up a total volume of 20µl. The mixture was
incubated at 37oC for 2 hours.
After restriction enzyme digestion, the excess nucleotides were removed by
QIAquick nucleotide removal kit [Qiagen, USA] following the manufacturer’s
instructions. The digested vector and DNA insert were ligated overnight at 4oC in a
mixture containing 2µl of 10XT4 DNA ligase buffer, 100-150ng of digested
vector/DNA, 3units of T4 DNA ligase [Promega, USA] and nuclease-free water to
make up a total volume of 20µl.
The ligated product (EMW-visfatin plasmid) was transformed into competent
DH5α E.coli bacterial cells [Invitrogen LifeTechnologies, USA] for propagation by
the heat shock method. 5-10µl of plasmid was added into 100µl of competent DH5α
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E.coli bacterial cells and the mixture was incubated on ice for 30 minutes. The sample
was further incubated at 42oC for 45 seconds and placed on ice for another 2 minutes.
The sample was mixed with 500µl of Luria Broth (LB) medium [Becton Dickinson
Diagnostics, USA], and incubated at 37oC upon shaking for an hour. 100-200µl of the
sample was spread evenly onto a LB agar plate containing the appropriate selection
marker e.g. ampicillin, and the plate was incubated overnight at 37oC.
Colonies were picked and prepared by PureYield plasmid miniprep system
[Promega, USA] in accordance with manufacturer’s instructions. The plasmid
samples containing the correct DNA insert (visfatin isoforms) were identified by
appropriate restriction enzyme digestion and sequencing as described in 3.2.1.11. The
plasmid containing the correct DNA insert was prepared in large quantities using
PureYield plasmid maxiprep system [Promega, USA] following manufacturer’s
instructions.
3.2.1.6 Gene expression
Gene expression is a process whereby genetic information is being used in the
synthesis of a functional gene product e.g. protein. In this study, visfatin isoforms
genes were stably expressed in 293T cells through lenti-viral vector containing
reporter eGFP.
3.2.1.6.1 Stable infection using lenti-viral construct
The lenti-viral transduction of Panc-1a or Panc-1b into 293T cells was
performed by my co-supervisor, Dr Gan Shu Uin. The visfatin isoforms (Panc-1a,
Panc-1b) were cloned from Panc-1 human pancreatic cell line (Table 3.1) and inserted
into lenti-viral vector encoding IRES-linked GFP as mentioned in 3.2.1.5.
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Approximately 5x106 cells were seeded in each 10-cm tissue culture plates 24 h
before transfection.  Calcium phosphate precipitation method was used for packaging
virus encoding the gene of interest (EMW lenti-viral vector-visfatin). 10µg of lenti-
viral vector, 7.5 mg helper plasmid pPax2, and 2.5 mg of MD2G envelope plasmids
(EMW-Panc-1a-GFP, EMW-Panc-1b-GFP) were used for packaging. The transfection
medium was replaced with complete culture medium after 12-14 hours incubation.
The viral supernatant was harvested 24 and 48 hours after complete culture medium
change and was filtered through a 0.45-mm filter. The titer of supernatant on 293T
cells was determined using flow cytometry. Target cells were infected at a multiplicity
of infection (MOI) of 1-5. The transduction efficiency can be visualized and assessed
by the GFP positivity.
3.2.1.7 Protein extraction and quantification
Protein was extracted from cultured cells for Western blot using cell lysis
buffer containing 20mM Tris-HCl (pH 7.5), 150mM Sodium Chloride (NaCl), 1%
Nonidet P-40, 0.5% Sodium deoxycholate, 1mM Ethylenediaminetetraacetic acid
(EDTA), 0.1% Sodium dodecyl sulfate (SDS) and EDTA-free protease inhibitor
cocktail tablet (1 tablet in 10ml of cell lysis buffer) [Roche Diagnostics, Germany].
In brief, the culture medium was aspirated and the cells were washed with
PBS to remove residual culture medium, and 200-500µl of cell lysis buffer was added
to the cells and left to incubate for a minute. The cells were scrapped using a cell
scrapper and the cell lysates obtained were centrifuged at 13,000 rpm for 5 minutes.
All procedures of protein extraction were carried out on ice to minimize protein
degradation. The supernatants were collected as protein samples which were
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quantified by the DC protein assay [Bio-Rad, USA], following manufacturer’s
instructions. The protein samples were aliquoted and stored at -80oC until use.
3.2.1.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was used to separate the proteins in the cell lysates according to
their molecular weight for western blot. The SDS-PAGE gel consisting of a resolving
gel (10% acrylamide mix, 375mM Tris-HCl (pH 8.8), 0.1% SDS, 0.1% ammonium
persulfate (APS), 0.04% N,N,N’,N’-Tetramethylethylenediamine (TEMED)) and a
stacking gel (5% acrylamide mix, 125mM Tris-HCl (pH 6.8), 0.1% SDS, 0.1% APS,
0.1% TEMED) was prepared. The mini Protean 3 cell gel electrophoresis system
[Bio-Rad, USA] was assembled, and 4ml of freshly prepared 10% acrylamide
resolving gel mix was added. Upon polymerization of the resolving gel, 1ml of freshly
prepared 5% acrylamide stacking gel mix was casted on top of the resolving gel, and a
10well x 1.0mm comb was inserted into the stacking gel. The gel was left to
polymerize at room temperature.
The protein samples (50µg) were mixed with 5x bromophenol blue loading
dye (60mM Tris-HCl (pH 6.8), 20% glycerol, 2% SDS, 5% β-mercaptoethanol and
0.01% bromophenol blue) at 4:1 (v/v) and placed in boiling water  for 5 minutes. The
protein samples were then loaded into the wells, and an appropriate standard protein
molecular weight marker e.g. Precision plus protein standards of 10-250kD [Bio-Rad,
USA] was added as reference. The initial gel electrophoresis of the stacking gel was
carried out at 50V then at 120V for the resolving gel in 1X SDS/glycine
electrophoresis buffer (0.025M Tris-HCl (pH7.4), 0.1% SDS and 0.192M glycine) till
the samples reached the bottom of the gel using PowerPac 300 [Bio-Rad, USA].
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3.2.1.9 Western blot
Western blot, also known as protein immunoblot is a technique used to
identify specific protein in the cell lysates through specific binding of antibodies with
the protein of interest (visfatin isoforms). After SDS-PAGE, the proteins on the SDS
polyacrylamide gel were transferred onto polyvinylidene difluoride (PVDF)
membrane [Bio-Rad, USA] through electroblotting. The SDS polyacrylamide gel and
PVDF membrane which was pre-wetted in 100% methanol and equilibrated in
transfer buffer for 10 minutes were assembled into the mini Trans-blot electrophoretic
transfer cell [Bio-Rad, USA]. The electroblotting process was then carried out in
transfer buffer (0.025M Tris-HCl (pH7.4), 0.1%SDS, 0.192M glycine and 20%
methanol) at 50V on ice for an hour.
After electroblotting, the PVDF membrane was washed with 1xTris buffer
saline tween (TBST), which was made up of 10mM Tris-HCl (pH 7.4), 100mM NaCl
and 0.1% Tween 20. The PVDF was then blocked with 5% skim milk TBST at 4oC
overnight on shaking platform at 35rpm. After overnight blocking, the PVDF
membrane was washed twice with 1xTBST for 10 minutes on a shaking platform at
35rpm, and incubated with primary antibody (rabbit anti-C-terminal PBEF/rabbit anti-
N-terminal PBEF) at a suitable dilution (1:1000) in 1% skim milk TBST for 2 hours
at room temperature. Afterwhich, the PVDF membrane was washed thrice with
1xTBST for 10 minutes each upon shaking. The final incubation was done with swine
anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody at a suitable
dilution in 1% skim milk TBST for an hour at room temperature. The PVDF
membrane was washed four times with 1xTBST for 10 minutes each time upon
shaking. The chemiluminescent substrate [Pierce Biotechnology, USA] at 1:1 ratio of
enhancer: peroxide solution was added to the membrane for a minute. The membrane
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was then exposed to a Kodak Biomax photographic film in dark for 1-10 minutes, and
the film was developed and fixed by the Kodak film processing system.
3.2.1.10 DNA extraction
DNA was extracted from human blood for subsequent gene analysis. In this
study, the method for DNA extraction was phenol-chloroform. The whole blood
samples from human subjects were mixed with Tris-EDTA (TE) buffer (10mM Tris-
HCl (pH 8), 10mM EDTA) and centrifuged at 4krpm for 5 minutes. The process was
repeated (2-3 times) to lyse all the red blood cells and pellet the white blood cells. The
white blood cells pellet was resuspended in 5ml of TE buffer containing 0.5% SDS
and 50µg/ml Proteinase K, and the mixture was incubated at 37oC overnight.
An equal volume of buffered phenol was mixed gently with the mixture for
10minutes. The mixture was centrifuged at 4krpm for 5 minutes and the top aqueous
phase of the mixture was transferred into a new tube, the process was repeated twice.
The process was repeated twice again using chloroform: isoamylalcohol (24:1), and
the DNA was collected as the top aqueous layer.
The DNA aqueous layer was mixed gently with 2-3 volumes of 100% ethanol
by inverting the tube for a few times and the sample was centrifuged at 4krpm for 2
minutes. The supernatant was discarded, and the pellet was washed with 70% ethanol.
The sample was then centrifuged at 4krpm for 2 minutes, and the ethanol was
discarded. The DNA pellet was left to dry, and the pellet was resuspended in
appropriate amount of TE buffer. The DNA samples were stored at -20oC.
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3.2.1.11 Direct DNA sequencing
Direct DNA sequencing allows the determination of the precise nucleotide
sequence in a DNA sample, and it was used to detect SNPs along visfatin gene. The
DNA sample was extracted from human blood as described in 3.2.1.8, and the
upstream promoter and coding regions of the visfatin gene were amplified  from the
DNA sample through PCR as described in 3.2.1.2.2. After identifying the length of
the PCR product through agarose gel electrophoresis as described in 3.2.1.3, the PCR
product was purified and incubated in a mixture of 1x Shrimp Alkaline Phosphatase
(SAP) buffer, 5units of Exonuclease (Exo 1) and 0.25 units of SAP [Fermentas, USA]
at 37oC for an hour followed by termination at 95oC for 5 minutes.
The sequencing reaction was carried out using Big Dye Terminator v3.1 cycle
sequencing kit [Applied Biosystem, USA]. In brief, the reaction mixture consisted of
2µl of sequencing mix RR-100, 2µl of 5X sequencing buffer, 0.32µM of sequencing
primer, 1µl of DNA (visfatin PCR product) and distilled water in a total volume of
10µl was placed in the PTC-100 Peltier Thermal Cycler [Bio-Rad, USA]. The cycling
conditions for the sequencing process were 25 cycles of 96oC for 10 seconds, 50oC for
5 seconds, 60oC for 4 minutes followed by a final temperature of 4oC.
The sequencing product was precipitated by adding 26µl of 100% ethanol: 3M
sodium acetate (25:1) to 10µl of sequencing product and placed on ice for 5 minutes.
The sample was centrifuged at 13krpm for 20 minutes and after discarding the
supernatant, the pellet was washed with 50µl of 70% ethanol on centrifugation at
13krpm for 10 minutes. The excess ethanol was removed and the pellet was left to dry
at room temperature. 15µl of Hi-Di formamide [Applied Biosystem, USA] was added
to dissolve the pellet and the sample was transferred into a microamp optical 96-well
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reaction plate, which was placed in the ABI 3100 genetic analyzer [Applied
Biosystem, USA] for genetic analysis of the sequencing product.
3.2.2 Clinical techniques
3.2.2.1 Measurement of standard anthropometric parameters of obese children
The standard anthropometric parameters of the two hundred and forty-three
obese children were measured according to previous study (Lee et al., 2008). Briefly,
height and weight were measured and body mass index (BMI) of the subjects was
calculated; BMI-standard deviation score (BMI-SDS) was calculated using local
population based growth data. The percentage of ideal weight for height (WFH) was
obtained for each subject using our percentage ideal weight for height chart
(Percentage Ideal Weight for height chart, 1993, School Health Service, Ministry of
Health, Singapore), which has been used as an acceptable measure of degree of
childhood adiposity (Mei et al., 2002, Alemzadeh R, 1996). Body fat composition was
assessed by dual energy x-ray absorptiometry (DEXA) bone density scan (Norland
DEXA model XR-36, Fort Atkinson, WI) and by bipedal bioimpedance analysis
(BIA) using the portable body composition analyzer TBF-300GS (Tanita, Tokyo,
Japan).
3.2.2.2 Measurement of metabolic parameters of obese children
Blood samples were obtained from the obese children in the fasted state.
Venous glucose from oral glucose tolerance test (OGTT), which was obtained at 60
and 120 minutes time-points (glucose loading of 1.75g/kg after overnight fasting and
at a maximum amount of 75g within a 5 minute time frame) was measured by
colorimetry. Insulin level was assayed using the microparticle enzyme enhanced
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immunoassay (Axsym, Abbot Laboratories, Illinois, USA), and serum C-peptide level
was measured by chemiluminescence. Fasting visfatin was measured using human
full-length visfatin ELISA (Alpco Diagnostics, USA), and visfatin levels were also
assayed at 60 and 120 minutes time point of the OGTT in a subgroup of thirty-five
subjects from the two hundred and forty-three obese children cohort. Leptin was
measured using the DSL-10-23100 human leptin ELISA (Diagnostic Systems
Laboratories, Webster, TX). Serum total adiponectin (Bioplex, BioRad) and high-
molecular weight (HMW)-adiponectin (Millipore, USA) were measured. Serum
cholesterol (Total-, HDL-, LDL-cholesterol) and triglyceride levels were also assayed
by colorimetry method. Conjugated bilirubin, lactate dehydrogenase, albumin, alanine
transaminase (ALT), aspartate transaminase (AST) and gamma-glutaryl transferase
(GGT) levels were measured using kinetic assays (Vitros 950, Ortho-Clinical
Diagnostics, Rochester, IL). Abnormal liver function test suggestive of non-alcoholic
fatty liver function disease (NAFLD) was defined as elevated liver enzymes including
AST, ALT and/or GGT (Lee et al., 2008). Blood pressure (BP) was measured with an
appropriately large cuff twice, 30 minutes apart, using an automated blood pressure
machine (Dinamap, GE healthcare, UK) and hypertension status was classified by age
(1987). Insulin resistance is calculated using the homeostasis model assessment
(HOMA) (Matthews et al., 1985). Abnormal glucose tolerance is defined in this study
as impaired fasting venous glucose ≥ 6.1mmol/L or impaired glucose tolerance with
venous glucose at 120 minutes of OGTT ≥ 7.8mmol/L according to WHO criteria.
Estimation of physical activities was obtained using a physical activity questionnaire
from the Activity Questionnaire for Adolescents and validated in our local population
(Aaron et al., 1995, Schmidt et al., 1998) . The activity categories ranged from 1-5,
such that category 1 most sedentary/inactive and category 5 is most active physically
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(Lee et al., 2008).  We further classified our subjects to “physically inactive” if they
fall into categories 1 and 2, and “physically active” if they were classified into
categories 3-5.
3.2.2.3 Euglycemic-hyperinsulinemic clamp
The euglycemic-hyperinsulinemic clamp technique measures the amount of
glucose needed to compensate for an increase in insulin level without causing
hypoglycemia, and it is used as a determination of insulin sensitivity.
The euglycemic-hyperinsulinemic clamp performed in this study was carried
out by Dr Mya Thway Tint according to the protocol stated in (Liew et al., 2005).
Unlike the non-diabetic subjects in the study by Liew et al., the subjects in this study
were type 2 diabetic patients. Thus, insulin was infused through a peripheral vein at a
constant infusion rate of 80mU/m2 body surface area per minute throughout 120
minutes of the clamp. The blood glucose level was checked every 5-10minutes, and
the infusion rate of the 20% dextrose was adjusted manually to maintain a constant
blood glucose concentration of 5mmol/L. Blood samples were collected from patients
at baseline; 30, 60 and 120 minutes during the clamp and stored at -80oC.
3.2.2.3.1 Measurement of insulin level during euglycemic-hyperinsulinemic
clamp
Serum insulin level of subjects undergoing euglycemic-hyperinsulinemic
clamp was assayed using the microparticle enzyme enhanced immunoassay (Axsym,
Abbot Laboratories, Illinois, USA) by the National University Hospital (NUH)
service laboratory. Serum insulin level was also measured by a commercially
available insulin ELISA kit [Mercodia, Sweden]. The ELISA kit has a detection limit
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of 1mU/L, a mean intra-assay variation (CV, n=4 samples tested 6 times) of 3.35%
and a mean inter-assay variation (CV, n=4 samples tested 6 times) of 2.975%. The use
of the ELISA kit was in accordance with the manufacturer’s instructions.
3.2.3 Statistical Analysis
The statistical analysis was performed using SPSS version 18 (SPSS: An IBM
Company, Chicago III, USA) unless otherwise stated, and all statistical significance
was set at p<0.05. The descriptive statistics were presented as mean ± SEM for
continuous parameters and n (%) for categorical parameters. All statistical analysis
performed were adjusted for age, gender, ethnicity and BMI-SDS, which may be
significant confounders for the metabolic risks in our population.
3.2.3.1 Spearman’s rank correlation coefficient and partial correlation
Spearman’s rank correlation coefficient is a non-parametric test used to
correlate serum visfatin level with serum insulin/plasma glucose level in non-
parametric samples of obese and type 2 diabetic subjects undergoing OGTT and
euglycemic-hyperinsulinemic clamp respectively. It was also used to correlate fasting
serum visfatin level with other metabolic parameters in the obese children population.
Partial correlation was used for adjustment.
3.2.3.2 Hardy-Weinberg equilibrium
Hardy-Weinberg equilibrium was used to determine if a population is able to
maintain its pool of variability through generations. The Hardy-Weinberg equilibrium
for all visfatin SNPs detected in this study was calculated using an online Hardy-
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Weinberg equilibrium calculator available at http://www.oege.org/software/hwe-mr-
calc.shtml .
3.2.3.3 Chi-square test
Chi-square test is used to determine if there is a significant difference between
expected and observed frequencies among different groups. In this study, chi-square
was used to compare the allele and genotype frequencies between obese children and
cord blood samples. It was also used to determine the association between categorical
metabolic parameters and different genotypic groups/models.
3.2.3.4 Logistic and linear regression
Logistic regression is an approach used to study the relationship between
multiple variables. In logistic regression, the dependent outcome variable must be a
dichotomous categorical parameter. It can also be used to adjust for the interactions
between different independent variables before a relationship is established between
the dependent outcome variable and the tested independent variables. In this study,
logistic regression was used for adjustment between categorical metabolic outcome
and genotypic group/model. Logistic regression was also used to compare each
diplotype (carrier) with the rest of the combined diplotypes (non-carrier) for
association with metabolic parameter after adjusting for possible confounders and
multiple comparisons between diplotype groups.
Linear regression was performed to study the linear relationship across the
different genotypes for each continuous metabolic parameter.
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3.2.3.5 Kruskal-Wallis test
Kruskal-Wallis test is a non-parametric method used to compare the data
between 3 or more independent sample groups, and it was used to determine the
association between continuous metabolic parameters and the different genotypic
groups (-3187G>A/-1537C>T).
3.2.3.6 Mann-Whitney U test
Mann-Whitney U test is used to compare the data of 2 non-parametric
independent samples. In this study, Mann-Whitney U test with post-hoc adjustment
(manual bonferroni) was used for pair-wise comparison of continuous metabolic
parameters between genotypic groups/models.
3.2.3.7 General linear model (GLM)
General linear model (GLM) is a predictive model used to study the
relationship between multiple variables. However, in GLM, the dependent outcome
variable is a continuous variable. Similar to logistic regression, GLM can be used to
adjust for the interactions between the different independent variables before a
relationship is established between the dependent outcome variable and the tested
independent variables. In this study, GLM was used for adjustment between
continuous metabolic outcome and genotypic group/model, and in particular, gamma
with log-link GLM was used as the data were non-parametric. Gamma with log-link
GLM was also used to compare each diplotype (carrier) with the rest of the combined
diplotypes (non-carrier) for association with metabolic parameter after adjusting for






4.1 Expression and secretion of visfatin isoforms in human cell lines
Fukuhara et al. first reported visfatin to be predominantly expressed in visceral
adipose tissue (Fukuhara et al., 2005). However, Berndt et al. had failed to detect a
difference in visfatin expression between subcutaneous and visceral adipose tissues
(Berndt et al., 2005). Visfatin was also later found to be expressed and secreted by
other tissues and cell types. In addition, a shorter visfatin isoform (BC020691) had
been reported but not shown to be expressed.
RT-PCR, western blot and ELISA were carried out to measure the expression
and secretion of visfatin isoforms in different primary and carcinoma cell lines, as
well as human breast fat tissue. Since the aim was to investigate if visfatin was
expressed by other cell types, we decided to use the different cell lines which were
already available in our laboratory.
Specific hypothesis 1: Visfatin isoforms may be expressed and secreted in different
human cell lines and breast fat tissue.
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4.1.1 mRNA expression of visfatin isoforms in human cell lines
The full length visfatin (isoform a) of 1476bp consisting of 11 exons, and its
shorter isoform (isoform b) of 1107bp consisting of 8 exons and part of intron 8 were
illustrated in the schematic diagram in Figure 4.1A.
PCR primers were designed to amplify exon 7 to exon 11 region of visfatin
isoform a and exon 1 to intron 8 region of shorter visfatin isoform b, producing an
amplicon of 464bp (isoform a) and 1085bp (isoform b) respectively. Both visfatin
isoforms a (464bp) and b (1085bp) were extensively expressed in all the different
human cell lines tested, as well as mouse embryonic fibroblast cell line (3T3L1), and
β-actin was included as loading control for the gene expression as shown in Figure
4.1B.
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Figure 4.1 mRNA expression of visfatin isoforms in human cell lines
A.
Visfatin isoform a (Full length: 1476bp)
Visfatin isoform b (Full length: 1107bp)
B.
A. Schematic diagram of visfatin mRNA isoforms. E represents exon and i represents intron.
         represents forward primer and          represents reverse primer used for PCR.
B. RT-PCR results for mRNA expression of visfatin isoforms in mammalian cell lines (1:
1Kb Plus DNA ladder [Invitrogen Life Technologies, USA], 2: 293T, 3:3T3L1, 4: CLEC,
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4.1.2 Protein expression of visfatin isoforms in human cell lines
The full length visfatin (isoform a) protein of 52KDa was detected in all the
human cell lines tested, as well as mouse embryonic fibroblast cell line (3T3L1) using
the C-terminal PBEF antibody [Bethyl Laboratories, USA] as shown in Figure 4.2.
GAPDH was included as loading control for the protein expression.
This study also attempted to determine the protein expression of the shorter
visfatin isoform b of 39KDa in all the human cell lines tested using the N-terminal
PBEF antibody [Santa Cruz Biotechnology, USA]. However, we were only able to
detect the protein expression of full-length visfatin isoform a of 52KDa, which was
previously shown in Figure 4.2.
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Figure 4.2 Protein expression of visfatin isoform a in human cell lines
Western blot result for protein expression of visfatin isoform a in mammalian cell
lines (1: Precision Plus Protein Standards (BioRad, USA), 2: 293T, 3:3T3L1, 4:
CLEC, 5: HepG2, 6: HUH7, 7: Jeg3, 8: MCF7, 9: Panc1).















4.1.3 Over-expression of shorter visfatin isoform b in 293T cells
The shorter visfatin isoform b was stably over-expressed in 293T cells through
stable infection of 293T cells with the EMW lenti-viral vector construct as illustrated
in the schematic diagram in Figure 4.3A. The vector construct consisted of shorter
visfatin isoform b linked with reporter green fluorescent protein (GFP) under the
constitutive spleen focus-forming virus (sFFV) promoter. The efficiency of infection
was observed as expression of GFP (green cells) in the infected 293T cells under the
fluorescent microscope as shown in Figure 4.3B.
RT-PCR analysis in Figure 4.3C showed an increased mRNA expression of
visfatin isoform b in infected 293T cells as compared to uninfected 293T cells, and β-
actin was included as loading control for the gene expression.
Both 52KDa visfatin protein of isoform a and 39KDa visfatin protein of the
shorter isoform b were detected in 293T cells over-expressing the visfatin shorter
isoform b using the N-terminal PBEF antibody [Santa Cruz Biotechnology, USA] as
shown in Figure 4.3D. GAPDH was included as loading control for the protein
expression.
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Visfatin isoform a and b
                           GAPDH
A. Schematic diagram of EMW lenti-viral vector used for infection.
B. Fluorescence microscopy of 293T cells infected with EMW-visfatin isoform b-GFP.
C. RT-PCR results for mRNA expression of visfatin isoform b (1: 1Kb Plus DNA ladder [Invitrogen
Life Technologies, USA], 2: Uninfected 293T cells, 3: 293T cells infected with isoform b).
D. Western blot results for protein expression of visfatin isoform a and b of infected 293T cells (1:
Uninfected 293T cells, 2: 293T cells infected with isoform b).
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4.1.4 Secretion of full-length visfatin protein in human cell lines and breast fat
tissue
All human cell lines and breast fat tissue tested had secreted full-length
visfatin protein (isoform a) detected in their conditioned culture supernatants as
shown in Figure 4.4 with DMEM+FCS as a control.
The human liver carcinoma cell lines, HepG2 (8.03ng/ml) and Huh7
(7.82ng/ml), and human pancreatic carcinoma cell line, Panc1 (7.73ng/ml) showed the
highest amount of secreted visfatin protein in their culture media, whereas the human
subcutaneous breast fat tissue was shown to secrete a low concentration of 1.85ng/ml
of visfatin protein. Due to unavailability of a sufficiently specific antibody for the
shorter visfatin protein (isoform b), the amount of secreted visfatin (isoform b) protein
could not be determined.
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Figure 4.4 showed the average amount of secreted visfatin (isoform a) protein in the
culture media of different human cell lines and breast fat tissue tested after duplicated
measurements. (293T: Human kidney carcinoma, CLEC: Human cord lining epithelial
cells, HBrFats: Human breast fat tissue, HepG2: Human liver carcinoma, Huh7:
Human liver carcinoma, Jeg3: Human placental choriocarcinoma, MCF7: Human




The mRNA of visfatin isoform a and b were extensively expressed in different
human cell lines. The full length visfatin isoform a was also found to be secreted from
different human cell lines and subcutaneous breast fat tissue into the culture media.
Although the expression or secretion of visfatin isoform b protein were not detected in
the human cell lines and tissue tested, visfatin isoform b protein was shown to be
expressed in 293T cells infected with visfatin isoform b. The extensive expression of
visfatin in different human cell lines and subcutaneous breast fat tissue implied that
visfatin may be essential for cellular activities. Therefore, the examination for SNPs
along the visfatin gene may provide more information on the effect of visfatin on
cellular metabolism.
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4.2 Genetic polymorphisms of visfatin gene in obese children
Genetic polymorphisms (also known as single nucleotide polymorphisms,
SNPs) detected in the visfatin gene were found to be associated with parameters of
lipid and glucose metabolism.
The upstream promoter and coding regions of the visfatin gene were screened
for common SNPs in 24 randomly selected obese children. The detected SNPs were
then genotyped in the rest of the cohort of Singaporean obese children. Statistical
analysis was performed to determine the association between detected SNPs and
metabolic parameters of the obese children.
Specific hypothesis 2: There may be common SNPs in the visfatin gene of our obese
children, and the SNPs may be associated with obesity and metabolic parameters.
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4.2.1 Screening of visfatin gene
The 3.5kbp upstream promoter and full coding regions (11 exons) of the
visfatin gene (NC_000007) including exon-intron boundaries were sequenced in a
group of 24 randomly selected obese children. Two upstream SNPs and two exon
SNPs were detected in the promoter and coding regions of the visfatin gene. The
identified SNPs were checked against the SNP database (dbSNP) using BLAST-SNP
flanks, and the four SNPs were found to have been previously submitted to dbSNP.
The SNPs were -3187G>A (rs11977021) and -1537C>T (rs61330082) on the
upstream promoter region, +7849T>C (rs70937088) on exon 2 and +21426G>A
(rs2302559) on exon 7 as illustrated in Figure 4.5. The SNPs were numbered
accordingly to the number of nucleotides away from the Adenine base of the start
codon (ATG), which was regarded as +1 position.
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Figure 4.5 Schematic diagram of SNPs detected in 3.5kbp upstream promoter
and full coding region of the visfatin gene in DNA of obese children
3.5kbp upstream





rs11977021 rs61330082 rs70937088 rs2302559
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4.2.1.1 Upstream promoter region
4.2.1.1.1 SNP -3187G>A (rs11977021)
Direct sequencing revealed a SNP, -3187G>A, at the upstream promoter
region of the visfatin gene in obese children. The -3187G>A SNP in this study had
previously been reported and submitted to the SNP database as rs11977021.
There were 3 genotypes associated with -3187G>A SNP as observed by the
peak in the chromatogram. The 3 genotypes were homozygous wild-type GG
genotype (Figure 4.6A), heterozygous GA genotype (Figure 4.6B) and homozygous
AA genotype (Figure 4.6C).
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Figure 4.6 Chromatogram of upstream -3187G>A SNP in visfatin gene of obese
children
A. Chromatogram of homozygous GG genotype for upstream -3187G>A SNP (1: GenBank
visfatin DNA reference sequence NC_000007, 2: Visfatin DNA sequence of obese children).
B. Chromatogram of heterozygous GA genotype for upstream -3187G>A SNP.











4.2.1.1.2 SNP -1537C>T (rs61330082)
Direct sequencing revealed another SNP, -1537C>T, at the upstream promoter
region of the visfatin gene in obese children. The -1537C>T SNP in this study had
previously been reported and submitted to the SNP database as rs61330082.
There were 3 genotypes associated with -1537C>T SNP as observed by the
peak in the chromatogram. The 3 genotypes were homozygous wild-type CC
genotype (Figure 4.7A), heterozygous CT genotype (Figure 4.7B) and homozygous
TT genotype (Figure 4.7C).
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Figure 4.7 Chromatogram of upstream -1537C>T SNP in visfatin gene of obese
children
A. Chromatogram of homozygous CC genotype for upstream -1537C>T SNP (1: GenBank
visfatin DNA reference sequence NC_000007, 2: Visfatin DNA sequence of obese children).
B. Chromatogram of heterozygous CT genotype for upstream -1537C>T SNP.











4.2.1.2 Coding region and exon-intron boundaries
4.2.1.2.1 SNP +7489T>C (rs70937088)
A SNP +7489T>C (rs70937088) was detected at exon 2 during direct
sequencing of the coding region and exon-intron boundaries of the visfatin gene in
obese children. However, only 2 genotypes of +7489T>C SNP were detected in our
cohort of obese children. They were homozygous wild-type TT genotype (Figure
4.8A) and heterozygous TC genotype (Figure 4.8B) as observed by the peak on the
chromatogram. Homozygous CC genotype was not observed in our sample
population.
The substitution of Thymine base with Cytosine base at +7489 position
resulted in codon sequence AAC instead of AAT. However, both AAC and AAT
coded for the same amino acid residue, Asparagine at position 67 as shown in Figure
4.8C. Therefore, the +7489T>C SNP at exon 2 of the visfatin coding region did not
result in a change in the amino acid composition of the visfatin protein.
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Figure 4.8 Chromatogram of exon 2 +7489T>C SNP in visfatin gene of obese
children
Visfatin sequence:    TTG CAG TAC ATT CTT AAT AAG TAC TTA AAA
+7489T>C SNP:      TTG CAG TAC ATT CTT AAC AAG TAC TTA AAA
A. Chromatogram of homozygous TT genotype for exon 2 +7489T>C SNP (1: GenBank
visfatin DNA reference sequence NC_000007, 2: Visfatin DNA sequence of obese children).
B. Chromatogram of heterozygous TC genotype for exon 2 +7489T>C SNP.










4.2.1.2.2 SNP +21426G>A (rs2302559)
Another SNP, +21426G>A (rs2302559) was detected at exon 7 during direct
sequencing of the coding region and exon-intron boundaries of the visfatin gene in
obese children. Although the nucleotide base at +21426 position of reference visfatin
sequence NC_000007 is Adenine base, the SNP was reported as +21426G>A
(rs2302559) as the frequency of Guanine base at +21426 position in our sample size
of obese children was higher than the frequency of Adenine base as shown later in
Table 4.3. There were 3 genotypes associated with +21426G>A SNP as observed
from the peak of the chromatogram. They were homozygous wild-type GG genotype
(Figure 4.9A), heterozygous GA genotype (Figure 4.9B) and homozygous AA
genotype (Figure 4.9C).
The substitution of Guanine base with Adenine base at +21426 position
resulted in codon sequence TCA instead of TCG. However, both TCG and TCA
coded for the same amino acid residue, Serine at position 301 as shown in Figure
4.9D. Therefore, the +21426G>A SNP at exon 7 of the visfatin coding region did not
result in a change in the amino acid composition of the visfatin protein.
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Figure 4.9 Chromatogram of exon 7 +21426G>A SNP in visfatin gene of obese
children
Visfatin sequence:  AGA CAT TTA ATA GTA TCA AGA AGT ACA CAG
     +21426G>A SNP:  AGA CAT TTA ATA GTA TCG AGA AGT ACA CAG
A. Chromatogram of homozygous GG genotype for exon 7 +21426G>A SNP (1: GenBank
visfatin DNA reference sequence NC_000007, 2: Visfatin DNA sequence of obese children).
B. Chromatogram of heterozygous GA genotype for exon 7 +21426G>A SNP.
C. Chromatogram of homozygous AA genotype for exon 7 +21416G>A SNP.













4.2.2 Genotyping of variants in visfatin gene of obese children and cord blood
samples
4.2.2.1 Clinical characteristics of obese children
Obese children with body weight at least 140% of the ideal weight for height
(WFH) based on local weight for height chart were recruited for this study. Table 4.1
showed the clinical characteristics of the local obese children recruited for this study.
The local obese children were made up of both boys (n=155) and girls (n=88) of
different ethnic groups which consisted mainly of Chinese (n=128), Malay (n=79) and
Indian (n=26). They had an average age of 10.9±0.2 years and their average body
mass index (BMI) and WFH were 32.05±0.37kg/m2 and 171.55±1.48% respectively.
Despite recruiting 243 obese children for this study, we were not able to obtain all
metabolic measurements for all the obese children. Moreover, there were insufficient
DNA and serum sample for some of the obese children. Therefore, this caused a
variation in the sample size (n) for each metabolic parameter.
All statistical analysis performed on data of obese children in this study was
adjusted for age, gender, ethnicity and BMI-standard deviation score (SDS). BMI-
SDS was calculated using local population based growth rate, and was adjusted for
age and gender. It had been suggested as a better reference standard for paediatric
obesity than BMI (Must and Anderson, 2006). In this study, BMI-SDS was used for
adjustment of the severity of obesity in the obese children population.
99
Table 4.1 Clinical characteristics of obese children
Clinical characteristics of obese children
Age (years) 10.9±0.2 (n=236)
Gender (Male/Female) 155/88 (n=243)
Ethnicity (Chinese/Malay/Indian/Others) 128/79/26/10 (n=243)
Birth weight (kg) 3.25±0.04 (n=226)
Body fat by DEXA (%) 47.28±0.46 (n=193)
BMI (kg/m2) 32.05±0.37 (n=236)
BMI-SDS 2.35±0.02 (n=236)
Weight for height (%) 171.55±1.48 (n=236)
Fasting glucose (mmol/L) 4.73±0.10 (n=234)
Fasting insulin (mU/L) 34.35±2.87 (n=226)
HOMA 7.24±0.62 (n=226)
Insulin : Glucose ratio 7.59±0.64 (n=226)
HMW-adiponectin (ng/ml) 2.81±0.18 (n=243)
Leptin (µg/L) 50.08±2.33 (n=230)
Serum visfatin (ng/ml) 4.85±0.28 (n=225)
Total cholesterol (mmol/L) 5.01±0.06 (n=234)
HDL-cholesterol (mmol/L) 1.24±0.02 (n=232)
LDL-cholesterol (mmol/L) 3.17±0.05 (n=232)
Triglyceride (mmol/L) 1.35±0.04 (n=233)
Data were expressed as mean ± SEM.
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4.2.2.2 Genotype and allele frequencies of upstream SNPs
The two upstream promoter SNPs, -3187G>A (rs11977021) and -1537T>C
(rs61330082), were found to be in complete linkage disequilibrium due to their
identical genotype and allele frequencies as shown in Table 4.2. Therefore, in this
study, the two upstream SNPs would be represented as -3187G>A SNP.
The -3187G>A SNP was successfully genotyped in DNA of 241 obese
children. The genotype frequencies were 29.5% GG, 51.0% GA and 19.5% AA, thus
resulting in a minor allele frequency (MAF) of 0.45. The -3187G>A SNP was also
successfully genotyped in DNA samples of 304 cord blood controls, which served as
normal controls and the genotype frequencies were 28.6% GG, 48.4% GA and 23.0%
AA, with MAF of 0.47. However, chi-square analysis did not show significant
difference in genotype and allele frequencies between the obese and cord blood
control groups as shown in Table 4.2. The genotype and allele frequencies of the
upstream SNPs did not differ significantly between the ethnic or gender groups (data
not shown).
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Table 4.2 Genotype and allele frequencies of upstream SNPs in obese children










n (sample size) 241 304
GG genotype 71 (29.5%) 87 (28.6%) NS
GA genotype 123 (51.0%) 147 (48.4%) NS
AA genotype 47 (19.5%) 70 (23.0%) NS
G allele 265 (55.0%) 321 (52.8%) NS
A allele 217 (45.0%) 287 (47.2%) NS
Minor Allele
Frequency (MAF) 0.45 0.47 NS
-1537C>T
n (sample size) 241 304
CC genotype 71 (29.5%) 87 (28.6%) NS
CT genotype 123 (51.0%) 147 (48.4%) NS
TT genotype 47 (19.5%) 70 (23.0%) NS
C allele 265 (55.0%) 321 (52.8%) NS
T allele 217 (45.0%) 287 (47.2%) NS
Minor Allele
Frequency (MAF) 0.45 0.47 NS
    NS denotes non-significant value of p>0.05
102
4.2.2.3 Genotype and allele frequencies of exonic SNPs
The synonymous SNP +7489T>C (rs70937088) at exon 2 was genotyped in
DNA of 240 obese children and 273 cord blood controls as shown in Table 4.3. The
genotype frequencies in obese children were 93.3% TT and 6.7% TC, resulting in
MAF of 0.033, while the genotype frequencies in cord blood controls were 92.7% TT
and 7.3% TC, resulting in MAF of 0.037. However, no homozygous CC genotype
was detected in both obese children and cord blood controls. The genotype and allele
frequencies of SNP +7489 C>T did not differ significantly between the obese children
and cord blood controls.
The synonymous SNP +21426G>A (rs2302559) at exon 7 was genotyped in
DNA of 235 obese children and 281 cord blood controls as shown in Table 4.3. The
genotype frequencies in obese children were 77.4% GG, 20.9% GA and 1.7% AA,
with a MAF of 0.12, while the genotype frequencies in cord blood controls were
75.4% GG, 21.7% GA and 2.9%, with a MAF of 0.14. There was no significant
difference in genotype and allele frequencies between the obese children and cord
blood controls.
In addition, the genotype and allele frequencies of the exonic SNPs did not
differ between the ethnic or gender groups (data not shown).
103











n (sample size) 240 273
TT genotype 224 (93.3%) 253 (92.7%) NS
TC genotype 16 (6.7%) 20 (7.3%) NS
CC genotype 0 0
T allele 464 (96.7%) 526 (96.3%) NS
C allele 16 (3.3%) 20 (3.7%) NS
Minor Allele
Frequency (MAF) 0.033 0.037 NS
+21426G>A
n (sample size) 235 281
GG genotype 182 (77.4%) 212 (75.4%) NS
GA genotype 49 (20.9%) 61 (21.7%) NS
AA genotype 4 (1.7%) 8 (2.9%) NS
G allele 413 (87.9%) 485 (86.3%) NS
A allele 57 (12.1%) 77 (13.7%) NS
Minor Allele
Frequency (MAF) 0.12 0.14 NS
 NS denotes non-significant value of p>0.05
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4.2.2.4 Hardy-Weinberg equilibrium of genotyped SNPs
The Hardy-Weinberg equilibrium for all visfatin SNPs detected in this study
was calculated using an online Hardy-Weinberg equilibrium calculator available at
http://www.oege.org/software/hwe-mr-calc.shtml .
The null hypothesis of the test was that the 4 genotyped SNPs were in
accordance with the Hardy-Weinberg equilibrium. Since 5% significance level for 1
degree of freedom (number of genotypes-number of alleles) is 3.84, chi-square value
less than 3.84 meant that the null hypothesis that the 4 genotyped SNPs were in
accordance with the Hardy-Weinberg equilibrium distribution was not rejected.
Therefore, the 4 genotyped SNPs, -3187G>A, -1537C>T, +7489T>C and
+21426G>A, were in accordance with the Hardy-Weinberg equilibrium distribution
as shown in Table 4.4. This meant that the gene frequencies and genotype ratios of
the 4 genotyped SNPs in a random breeding population remained fairly constant from
generation to generation.
105
Table 4.4 Chi-square values of Hardy-Weinberg equilibrium for SNPs detected









Obese children 0.23 0.23 0.29 0.11
Cord blood
samples 0.27 0.27 0.39 1.89
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4.2.3 Upstream SNP -3187G>A (rs11977021)
4.2.3.1 Association with continuous metabolic parameters
4.2.3.1.1 Genotypes of -3187G>A
The association between upstream genotypes and continuous metabolic
parameters was performed using Mann-Whitney U test.
Table 4.5 showed that there was a statistical significant association between
GG, GA and AA genotypes of -3187G>A and metabolic risk factors. The associations
between genotypes and metabolic parameters except parameters of obesity were
adjusted for age, gender, ethnicity and BMI-SDS using GLM. The associations with
parameters of obesity were only adjusted for age, gender and ethnicity. The AA
genotype was associated with higher BMI-SDS (2.42±0.06 vs. 2.33±0.03) and WFH
(178.12±4.00% vs. 168.95±1.85%) as compared to GA genotype, and the GA
genotype was associated with higher fasting glucose (4.82±0.16mmol/L vs.
4.49±0.07mmol/L) and lower insulin:glucose (6.57±0.45 vs. 9.89±2.02) than GG
genotype. The AA genotype was also associated with higher serum visfatin as
compared to GG genotype (6.17±0.76ng/ml vs. 3.92±0.44ng/ml). The AA
(1.39±0.08mmol/L vs. 1.19±0.07mmol/L) and GA genotypes (1.41±0.06mmol/L vs.
1.19±0.07mmol/L) were also associated with higher triglyceride as compared to GG
genotype.
In addition, the association of genotypes with serum visfatin and triglyceride
level still remained significant even after manual bonferroni adjustment for pair-wise
comparisons between the genotypes.
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Table 4.5 Association between genotypes of -3187G>A and continuous metabolic parameters
Upstream SNP -3187G>A








Birth-weight (kg) 3.16±0.06 3.26±0.05 3.34±0.10 0.171 0.085 0.421
n=69 n=121 n=44
BMI (kg/m2) 31.82±0.72 31.72±0.47 33.37±0.96 0.860 0.173 0.136
n=69 n=121 n=44
BMI-SDS 2.33±0.05 2.33±0.03 2.42±0.06 0.968 0.105 0.042
n=55 n=98 n=38
Body fat by DEXA (%) 47.91±0.71 47.12±0.67 46.74±1.03 0.099 0.551 0.299
n=69 n=121 n=44
Weight for height, WFH (%) 171.39±2.71 168.95±1.85 178.12±4.00 0.491 0.152 0.031
n=66 n=119 n=47
Fasting glucose (mmol/L) 4.49±0.07 4.82±0.16 4.62±0.15 0.047 0.985 0.340
n=62 n=116 n=46
Fasting insulin (mU/l) 43.67±9.19 29.89±1.9 33.74±4.57 0.052 0.228 0.626
n=62 n=116 n=46
HOMA 8.67±1.89 6.48±0.51 7.18±1.02 0.271 0.309 0.755
n=62 n=116 n=46
Insulin : Glucose 9.89±2.02 6.57±0.45 7.28±0.99 0.024 0.198 0.643
n=71 n=123 n=47
HMW-adiponectin  (ng/ml) 2.68±0.28 2.91±0.29 2.80±0.37 0.310 0.518 0.986
n=64 n=120 n=44
Leptin (µg/L) 57.19±5.30 46.64±2.86 48.85±4.97 0.358 0.197 0.606
n=63 n=116 n=44
Serum visfatin (ng/ml) 3.92±0.44 4.73±0.39 6.17±0.76 0.167 0.010* 0.084
n=66 n=120 n=46
Total cholesterol (mmol/L) 4.92±0.12 5.08±0.08 4.97±0.11 0.150 0.625 0.773
n=66 n=118 n=46
HDL-cholesterol (mmol/L) 1.23±0.03 1.24±0.02 1.23±0.04 0.747 0.867 0.939
n=66 n=118 n=46
LDL-cholesterol (mmol/L) 3.16±0.11 3.20±0.07 3.11±0.10 0.467 0.995 0.791
n=66 n=119 n=46
Triglyceride (mmol/L) 1.19±0.07 1.41±0.06 1.39±0.08 0.005* 0.034 0.777
Data were expressed as mean ± SEM. The p-value for all associations except for parameters of obesity was adjusted for age, gender, ethnicity and BMI-SDS. Associations
with parameters of obesity were only adjusted for age, gender and ethnicity. * denoted significant p-value <0.05 if manual bonferroni-adjustment for pair-wise comparisons
was performed. Sample size (n) varied due to inability to obtain all measurements from all obese children.
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4.2.3.1.2 Effect of -3187G>A SNP on visfatin level
As shown previously in Table 4.5, the genotypes of -3187G>A SNP were
shown to be associated with serum visfatin. In particular, there was a significant linear
increase in serum visfatin level from wild-type GG genotype to heterozygous GA
genotype to homozygous AA genotype (r2=0.9745, p=0.007). Figure 4.10 showed
that serum visfatin was increased from 3.92±0.44ng/ml in GG genotype to
4.73±0.39ng/ml in GA genotype and to 6.17±0.76ng/ml in AA genotype.
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Data were expressed as mean ± SEM and a significant linear increase in serum
visfatin was observed across GG to GA to GG genotype of -3187G>A.
r2=0.9745, p=0.007
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4.2.3.1.3 Dominant and recessive model of -3187G>A
To determine the genetic effect of the genotypes of the variant under
physiological condition, the genotypes were combined to study the dominant and
recessive effect of the variant on the metabolic parameters. The dominant model of
minor allele A, in -3187G>A was formed by combining GA and AA genotypes,
whereas the recessive model was formed by combining GG and GA genotypes.
Table 4.6 showed that dominant GA+AA genotype model of -3187G>A was
found to be significantly associated with higher level of triglyceride
(1.40±0.05mmol/L vs. 1.19±0.07mmol/L) than GG genotype. The recessive AA
genotype was associated with higher BMI-SDS (2.42±0.06 vs. 2.33±0.03), higher
serum visfatin (6.17±0.76ng/ml vs. 4.45±0.29ng/ml) and higher weight for height,
WFH (178.1±4.0% vs. 169.8±1.5%) as compared to GG+GA genotype group.
Moreover, after adjusting for age, gender, ethnicity and BMI-SDS, the
dominant GA+AA genotype was associated with lower fasting insulin
(30.98±1.88mU/L vs. 43.67±9.19mU/L) and lower insulin:glucose ratio (6.77±0.43
vs. 9.89±2.02) as compared to GG genotype.
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Table 4.6 Association between dominant/recessive model of -3187G>A and continuous metabolic parameters
Dominant model of upstream -3187G>A Recessive model of upstream -3187G>A
Continuous variable GG GA+AA p-value adjusted p-value GG+GA AA p-value adjusted p-value
n=67 n=157 n=182 n=42
Birth weight (kg) 3.16±0.06 3.28±0.04 0.185 0.100 3.22±0.04 3.34±0.10 0.090 0.171
n=69 n=165 n=190 n=44
BMI (kg/m2) 31.82±0.72 32.16±0.43 0.474 0.479 31.76±0.39 33.37±0.96 0.062 0.120
n=69 n=165 n=190 n=44
BMI-SDS 2.33±0.05 2.35±0.03 0.848 0.506 2.33±0.03 2.42±0.06 0.131 0.049
n=55 n=136 n=153 n=38
Body fat by DEXA (%) 47.91±0.71 47.01±0.56 0.48 0.178 47.40±0.50 46.74±1.03 0.664 0.630
n=69 n=165 n=190 n=44
Weight for height, WFH (%) 171.39±2.71 171.40±1.75 0.821 0.966 169.8±1.5 178.1±4.0 0.022 0.043
n=66 n=166 n=185 n=47
Fasting glucose (mmol/L) 4.49±0.07 4.76±0.12 0.791 0.078 4.70±0.11 4.62±0.15 0.952 0.541
n=62 n=162 n=178 n=46
Fasting insulin (mU/L) 43.67±9.19 30.98±1.88 0.368 0.039 34.69±3.45 33.74±4.57 0.668 0.390
n=62 n=162 n=178 n=46
HOMA 8.67±1.89 6.68±0.47 0.445 0.192 7.24±0.74 7.18±1.02 0.711 0.428
n=62 n=162 n=178 n=46
Insulin : Glucose 9.89±2.02 6.77±0.43 0.294 0.019 7.73±0.77 7.28±0.99 0.67 0.354
n=71 n=170 n=194 n=47
HMW-adiponectin (ng/ml) 2.68±0.28 2.88±0.24 0.657 0.296 2.82±0.21 2.80±0.37 0.707 0.834
n=64 n=164 n=184 n=44
Leptin (µg/L) 57.19±5.30 47.23±2.47 0.172 0.283 50.31±2.64 48.85±4.97 0.828 0.446
n=63 n=160 n=179 n=44
Serum visfatin (ng/ml) 3.92±0.44 5.13±0.35 0.06 0.05 4.45±0.29 6.17±0.76 0.041 0.029
n=66 n=166 n=186 n=46
Total cholesterol (mmol/L) 4.92±0.12 5.05±0.06 0.244 0.168 5.02±0.07 4.97±0.11 0.679 0.984
n=66 n=164 n=184 n=46
HDL-cholesterol (mmol/L) 1.23±0.03 1.24±0.02 0.631 0.799 1.24±0.02 1.23±0.04 0.825 0.950
n=66 n=164 n=184 n=46
LDL-cholesterol (mmol/L) 3.16±0.11 3.18±0.06 0.617 0.527 3.19±0.06 3.11±0.10 0.657 0.894
n=66 n=165 n=185 n=46
Triglyceride (mmol/L) 1.19±0.07 1.40±0.05 0.010 0.003 1.33±0.05 1.39±0.08 0.196 0.668
Data were expressed as mean ± SEM. The p-value for all associations except parameters of obesity was adjusted for age, gender, ethnicity and BMI-SDS. Associations with
parameters of obesity were only adjusted for age, gender and ethnicity. Sample size (n) varied due to inability to obtain all measurements from all obese children.
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4.2.3.2 Association with categorical metabolic parameters
4.2.3.2.1 Genotypes of -3187G>A
The association between upstream genotypes and categorical metabolic
parameters was performed using Chi-square analysis.
Table 4.7 showed that AA genotype of -3187G>A was associated with higher
frequencies of severe systolic blood pressure (25.6% vs. 9.9%) and severe
hypertension (27.9% vs. 10.7%) as compared to GA genotype after adjusting for age,
gender, ethnicity and BMI-SDS.
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Table 4.7 Association between genotypes of -3187G>A and categorical metabolic parameters
Upstream SNP -3187G>A









(29.5%) 0.132 0.744 0.257




(19.1%) 0.681 0.839 0.972









(27.9%) 0.594 0.152 0.019
Data were expressed as frequency (%) and p-value was adjusted for age, gender, ethnicity and BMI-SDS.
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4.2.3.2.2 Dominant and recessive model of -3187G>A
The dominant model of minor allele A, in -3187G>A was formed by
combining GA and AA genotypes, whereas the recessive model was formed by
combining GG and GA genotypes.
Table 4.8 showed that recessive AA genotype model of -3187G>A was
associated with higher risk of developing severe systolic blood pressure (25.6% vs.
11.1%) and severe hypertension (27.9% vs. 11.6%) as compared to the GG+GA
genotype group.
The dominant model of -3187G>A was not significantly associated with
categorical metabolic parameters such as abnormal glucose tolerance, abnormal liver
function test, severe systolic blood pressure or severe hypertension.
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Table 4.8 Association between dominant/recessive model of -3187G>A and categorical metabolic parameters
Dominant model of upstream -3187G>A Recessive model of upstream -3187G>A






















































Data were expressed as frequency (%), and p-value and odds ratio (OR) were adjusted for age, gender, race and BMI-SDS.
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4.2.4 Exon 2 SNP +7489T>C (rs70937088)
4.2.4.1 Association with continuous metabolic parameters
Since no CC genotype of +7489T>C was detected in the cohort of 243 obese
children, there was no recessive or dominant model for +7489T>C SNP.
Table 4.9 showed that TC genotype of +7489T>C was found to be associated
with lower birth-weight as compared to TT genotype (3.03±0.13kg vs. 3.27±0.04kg)
but the association became insignificant after adjusting for age, gender, ethnicity and
BMI-SDS. The TC genotype was not significantly associated with other parameters of
obesity and glucose metabolism.
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Table 4.9 Association between genotypes of +7489T>C and continuous metabolic parameters
Exon 2 SNP +7489T>C
Continuous Variable TT TC p-value adjusted p-value
n=207 n=16
Birth weight (kg) 3.27±0.04 3.03±0.13 0.017 0.147
n=217 n=16
BMI (kg/m2) 32.01±0.38 31.83±1.26 0.872 0.736
n=217 n=16
BMI-SDS 2.35±0.02 2.28±0.09 0.585 0.905
n=178 n=14
Body fat by DEXA (%) 47.51±0.47 44.29±1.74 0.085 0.137
n=217 n=16
Weight for height, WFH (%) 171.45±1.54 169.31±5.54 0.506 0.716
n=215 n=16
Fasting glucose (mmol/L) 4.70±0.10 5.14±0.65 0.18 0.290
n=207 n=16
Fasting insulin (mU/L) 34.09±2.99 28.47±3.79 0.998 0.450
n=207 n=16
HOMA 7.14±0.64 6.45±1.07 0.705 0.661
n=207 n=16
Insulin : Glucose 7.58±0.67 6.11±0.93 0.705 0.411
n=224 n=16
HMW-adiponectin (ng/ml) 2.76±0.16 3.54±1.63 0.359 0.071
n=211 n=16
Leptin (µg/L) 50.19±2.40 45.37±10.08 0.239 0.828
n=208 n=14
Serum visfatin (ng/ml) 4.96±0.30 3.35±0.69 0.284 0.068
n=216 n=16
Total cholesterol (mmol/L) 5.00±0.06 5.17±0.18 0.223 0.219
n=214 n=16
HDL-cholesterol (mmol/L) 1.23±0.02 1.28±0.07 0.596 0.813
n=214 n=16
LDL-cholesterol (mmol/L) 3.16±0.05 3.30±0.17 0.289 0.158
n=215 n=16
Triglyceride (mmol/L) 1.36±0.05 1.33±0.14 0.988 0.788
Data were expressed as mean ± SEM. The p-value for all associations except for parameters of obesity was adjusted for age, gender, ethnicity and
BMI-SDS. Associations with parameters of obesity were only adjusted for age, gender and ethnicity.  Sample size (n) varied due to inability to obtain
all measurements from all obese children.
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4.2.4.2 Association with categorical metabolic parameters
Table 4.10 showed that there was no significant association between the
genotype groups of +7489T>C and the categorical parameters. The TT and TC
genotype of +7489T>C were not associated with frequencies of abnormal glucose
tolerance, abnormal liver function test, severe systolic blood pressure or severe
hypertension.
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Table 4.10 Association between genotypes of +7489T>C and categorical
metabolic parameters
Exon 2 SNP +7489T>C
































Data were expressed as frequency (%), and p-value and odds ratio (OR) were
adjusted for age, gender, ethnicity and BMI-SDS.
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4.2.5 Exon 7 SNP +21426G>A (rs2302559)
4.2.5.1 Association with continuous metabolic parameters
As the sample size for the AA genotype detected in the cohort of obese
children was too small (n=4), GA and AA genotypes of SNP +21426G>A were
combined together to form the dominant model of the minor allele, A.
Table 4.11 showed that dominant GA+AA genotype model of +21426G>A
was associated with lower fasting serum visfatin (3.83±0.56ng/ml vs.
5.13±0.34ng/ml), lower fasting plasma glucose (4.37±0.08mmol/L vs.
4.77±0.12mmol/L) and higher insulin:glucose ratio (8.92±1.16 vs. 7.27±0.78) as
compared to GG genotype.
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Table 4.11 Association between dominant model of +21426G>A and continuous metabolic parameters
Dominant model of exon 7 +21426G>A
Continuous Variable GG GA+AA p-value adjusted p-value
n=166 n=52
Birth weight (kg) 3.25±0.04 3.23±0.08 0.745 0.511
n=176 n=52
BMI (kg/m2) 32.14±0.44 32.04±0.69 0.952 0.634
n=176 n=52
BMI-SDS 2.34±0.03 2.39±0.06 0.828 0.969
n=141 n=45
Body fat by DEXA (%) 47.16±0.54 48.33±0.89 0.454 0.458
n=176 n=52
Weight for height, WFH (%) 171.55±1.79 172.45±2.80 0.403 0.779
n=175 n=51
Fasting glucose (mmol/L) 4.77±0.12 4.37±0.08 0.032 0.033
n=169 n=49
Fasting insulin (mU/L) 33.70±3.64 37.04±4.13 0.107 0.154
n=169 n=49
HOMA 7.28±0.80 6.98±0.69 0.198 0.636
n=169 n=49
Insulin : Glucose 7.27±0.78 8.92±1.16 0.045 0.033
n=182 n=53
 HMW-adiponectin (ng/ml) 2.80±0.23 2.91±0.31 0.274 0.809
n=171 n=51
Leptin (µg/L) 48.95±2.62 57.29±5.51 0.148 0.839
n=167 n=50
Serum visfatin (ng/ml) 5.13±0.34 3.83±0.56 0.015 0.017
n=173 n=53
Total cholesterol (mmol/L) 5.03±0.06 4.86±0.14 0.094 0.090
n=171 n=53
HDL-cholesterol (mmol/L) 1.24±0.02 1.21±0.04 0.403 0.895
n=171 n=53
LDL-cholesterol (mmol/L) 3.18±0.06 3.07±0.11 0.167 0.061
n=172 n=53
Triglyceride (mmol/L) 1.34±0.04 1.36±0.11 0.852 0.970
Data were expressed as mean ± SEM. The p-value for all associations except for parameters of obesity was adjusted for age, gender, ethnicity and
BMI-SDS. Associations with parameters of obesity were only adjusted for age, gender and ethnicity. Sample size (n) varied due to inability to obtain
all measurements from all obese children.
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4.2.5.2 Association with categorical metabolic parameters
Table 4.12 showed that the dominant GA+AA genotype model of
+21426G>A was not significantly associated with frequencies of abnormal glucose
tolerance, abnormal liver function test, severe systolic blood pressure or severe
hypertension.
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Table 4.12 Association between dominant model of +21426G>A and categorical
metabolic parameters
Dominant model of exon 7 +21426G>A
































Data were expressed as frequency (%), and p-value and odds ratio (OR) were
adjusted for age, gender, ethnicity and BMI-SDS.
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4.2.6 Genotype-environment interaction
4.2.6.1 Effect of upstream genotype-environment interaction
Table 4.13 showed that there was a difference in the association between
dominant/recessive model of the identified SNPs and metabolic parameters in obese
children with different physical activity level.
Under the dominant model of upstream -3187G>A SNP, subjects who were
less physically active and had GG genotype were shown to have significantly higher
percentage of body fat as measured by bioimpedance analysis (BIA) (56.3±2.6% vs.
46.3±1.3%) and higher leptin level (98.8±12.1µg/L vs. 52.2±5.7µg/L) as compared to
GA+AA genotypes, but this effect was ameliorated in the group of subjects who were
more physically active.  On the other hand, subjects who were more physically active
and had GG genotype were shown to have significantly lower levels of serum visfatin
(3.0±0.5ng/ml vs. 4.9±0.4ng/ml) and triglyceride (1.08±0.07U/L vs. 1.41±0.07U/L) as
compared to GA+AA genotypes.
Under the recessive model of upstream -3187G>A SNP, subjects who were
more physically active and had GG+GA genotypes were shown to have significantly
lower serum visfatin level (3.9±0.4ng/ml vs. 6.4±1.0ng/ml), as well as lower
incidences of severe systolic blood pressure (7.7% vs. 24.1%) and hypertension (7.7%
vs. 27.6%) as compared to AA genotype. However, the protective effect of the
GG+GA genotypes was not conferred to the subjects who were less physically active.
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Table 4.13 Effect of interaction between genotypes of -3187G>A and physical activity level on metabolic parameters
Dominant model -3187 G>A Recessive model -3187 G>A
Variable Less physically active More physically active Variable Less physically active More physically active
GG GA+AA GG GA+AA GG+GA AA GG+GA AA
n=17 n=30 n=33 n=88 n=47 n=9 n=93 n=27
Body fat by
BIA (%) 56.3±2.6** 46.3±1.3 44.1±1. 45.2±1.0
Serum visfatin
(ng/ml) 4.6±0.7 6.5±2.1 3.9±0.4* 6.4±1.0
n=19 n=41 n=35 n=98
Triglycerides











n=17 n=39 n=29 n=91
Serum visfatin











n=18 n=40 n=33 n=98
Leptin (µg/L) 98.8±12.1** 52.2±5.7 39.3±4.1 44.8±3.2
Data were expressed as mean ± SEM or frequency (%). The p-value for all associations except for parameters of obesity was adjusted for age,
gender, race and BMI-SDS. Association with parameters of obesity was only adjusted for age, gender and ethnicity. *denotes p-value<0.05 and
** denotes p-value<0.01. Sample size (n) varied due to inability to obtain all measurements from all obese children.
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4.2.6.2 Effect of exon genotype-environment interaction
The interaction between genotypes of exon 2 +7489T>C and physical activity
level did not have any significant effect on the metabolic parameters in obese children
(data not shown).
The interaction between dominant genotype model of exon 7 +21426G>A and
physical activity level also did not have any significant effect on the metabolic




Diplotypes were obtained by combining genotypes of upstream -3187G>A,
+7489T>C at exon 2 and +21426G>A at exon 7.
The diplotypes that were present in the cohort of obese children was
represented in Table 4.14. The diplotype frequencies were 17.3% GG/TT/GG, 7.4%
GG/TT/GA, 1.7% GG/TT/AA, 3.0% GG/TC/GG, 34.6% GA/TT/GG, 13.4%
GA/TT/GA, 3.9% GA/TC/GG, 18.2% AA/TT/GG and 0.4% AA/TT/GA.
Due to the low frequency (0.4%) of D9 diplotype (AA/TT/GA), it was
excluded for analysis in our data.
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Table 4.14 Diplotype (comprising of upstream -3187G>A, +7489T>C at exon2,
+21426G>A at exon7) frequencies of obese children
Number Diplotype Count Frequency (%)
D1 GG/TT/GG 40 17.3
D2 GG/TT/GA 17 7.4
D3 GG/TT/AA 4 1.7
D4 GG/TC/GG 7 3.0
D5 GA/TT/GG 80 34.6
D6 GA/TT/GA 31 13.4
D7 GA/TC/GG 9 3.9
D8 AA/TT/GG 42 18.2
D9 AA/TT/GA 1 0.4
Data were expressed as frequency (%).
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4.2.7.2 Association with continuous metabolic parameters
The association between the 8 diplotypes with frequency > 1% and continuous
metabolic parameters was analyzed by gamma log-link GLM, which compared each
diplotype (carrier) with the rest of the combined 7 diplotypes (non-carrier) for the
metabolic parameter after adjusting for age, gender, ethnicity and BMI-SDS. The
significant associations between visfatin diplotypes and continuous metabolic
parameters were shown in Table 4.15.
The wild-type GG/TT/GG (17.3%) diplotype (comprising of all three major
alleles) was associated with lower levels of fasting C-peptide, triglyceride, gamma-
glutaryl transferase (GGT) and aspartate transaminase (AST).
The GG/TT/GA (7.4%) diplotype was associated with lower fasting plasma
glucose and lower plasma glucose at 120 minutes time-point of OGTT. It was also
associated with higher insulin at 60 minutes time-point of OGTT, higher fasting C-
peptide, higher insulin:glucose ratio, as well as higher levels of liver enzymes
including GGT, ALT and AST.
The GA/TC/GG (3.9%) was associated with lower serum visfatin, lower
insulin at 60 minutes time-point of OGTT and lower insulin:glucose ratio. It was also
associated with higher levels of high molecular weight (HMW)-adiponectin, higher
fasting plasma glucose and higher HMW:total adiponectin ratio.
The AA/TT/GG (18.2%) was associated with higher serum visfatin and higher
plasma glucose at 120 minutes time-point of OGTT.
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Table 4.15 Association between visfatin diplotypes and continuous metabolic parameters
GG/TT/GG GG/TT/GA GA/TC/GG AA/TT/GG
Variable Carrier Non-carrier Variable Carrier Non-carrier Variable Carrier Non-carrier Variable Carrier Non-carrier
n=29 n=182 n=17 n=214 n=9 n=224 n=42 n=176Fasting C-








n=35 n=193 n=17 n=205 n=8 n=196Triglyceride
(mmol/L)*** 1.12±0.09 1.39±0.05
Insulin at 60min






n=35 n=186 n=9 n=216
AST (U/L)* 35.0±2.2 43.7±2.2 n=17 n=186 Insulin:glucose* 5.48±1.18 7.70±0.66Insulin at 60min
OGTT (mU/L)* 304.5±59.6 207.7±13.3
n=34 n=186 n=9 n=215
GGT (U/L)*** 30.5±2.5 39.2±2.1 n=17 n=196
Serum visfatin
(ng/ml)* 2.91±0.58 4.93±0.30Fasting C-







n=17 n=206 n=9 n=233
ALT (U/L)* 76.76±19.89 56.54±3.17
HMW:total
adiponectin *** 0.22±0.10 0.12±0.01
n=17 n=206
AST (U/L)* 49.53±11.12 41.61±1.79
n=17 n=205
GGT (U/L)*** 54.2±14.2 36.4±1.5
Each diplotype (carrier) was compared with the rest of the combined diplotypes (non-carrier) for association with metabolic parameter using gamma log-link GLM.
Data were expressed as mean ± SEM, and all associations shown were significant after adjusting for age, gender, ethnicity and BMI-SDS. Sample size (n) varied
due to inability to obtain all measurements from all obese children. *denotes p-value<0.05, **denotes p-value<0.01 and ***denotes p-value<0.005.
132
4.2.7.3 Association with categorical metabolic parameters
The association between the 8 diplotypes with frequency > 1% and categorical
metabolic parameters was analyzed by logistic regression, which compared each
diplotype (carrier) with the rest of the combined 7 diplotypes (non-carrier) for the
metabolic parameter after adjusting for age, gender, ethnicity and BMI-SDS. Table
4.16 showed significant associations between visfatin diplotypes and categorical
metabolic parameters.
The GA/TT/GG diplotype was associated with lower risk of developing severe
systolic blood pressure and severe hypertension, whereas AA/TT/GG diplotype was
associated with higher risk of developing severe systolic blood pressure and severe
hypertension.
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Each diplotype (carrier) was compared with the rest of the combined diplotypes (non-carrier) for association with metabolic parameter using logistic




Two upstream SNPs, -3187G>A (rs61330082) and -1537C>T (rs11977021) at
perfect linkage disequilibrium, were detected in the upstream promoter region of the
visfatin gene in obese children. Another two SNPs +7489T>C (rs70937088) and
+21426G>A (rs2302559) were also detected in the coding region of the visfatin gene
in obese children at exon 2 and exon 7 respectively. The genotypes of the detected
SNPs were found to be significantly associated with parameters of obesity and
glucose metabolism such as triglyceride, birth weight, fasting glucose and fasting
insulin. The genotypes were also significantly associated with severe systolic blood
pressure and severe hypertension. The interaction between the genotypes and
environmental factor such as physical activity level was shown to have an effect on
the metabolic parameters. Moreover, the diplotypes of the upstream, exon 2 and exon
7 SNPs were shown to be significantly associated with metabolic parameters.
These data suggested that the visfatin may exert a genetic effect on metabolic
risk factors, thus we hypothesized that serum visfatin may also be associated with
metabolic parameters. Therefore, we proposed to measure the fasting serum visfatin
level of the obese children, and determine if serum visfatin is correlated with
metabolic parameters.
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4.3 Serum visfatin of obese children
Serum visfatin was found to be elevated in obese subjects and patients with
metabolic diseases such as type 2 diabetes and non-alcoholic fatty acid liver disease
(NAFLD). In addition, serum visfatin was found to correlate with different metabolic
parameters.
Fasting serum visfatin was measured in the cohort of Singaporean obese
children using the full-length visfatin ELISA kit [Alpco Diagnostics, USA]. The
correlation between fasting serum visfatin and metabolic parameters in the obese
children was determined by Spearman’s correlation and partial correlation analysis.
Specific hypothesis 3: Fasting serum visfatin in the cohort of obese children may
correlate with some of the metabolic parameters.
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4.3.1 Correlation of serum visfatin with metabolic parameters
Fasting visfatin was measured in the available fasting serum samples of 225
local obese children which included 146 boys and 79 girls (Chinese: 118, Malay: 75,
Indian: 23, others: 9), with age of 10.9±0.2 years, WFH of 172.1±1.5% and BMI-SDS
of 2.35±0.02. Serum visfatin level in these obese children was measured using the
full-length human visfatin ELISA (Alpco Diagnostics, USA). The sample size of each
variable may differ due to inability to achieve all measurements for all subjects. The
correlations between serum visfatin and metabolic parameters were listed in Table
4.17.
Fasting serum visfatin was found to correlate with anthropometric parameters
such as BMI (r=0.155), BMI-SDS (r=0.138), percentage body fat by dual energy X-
ray absorptiometry (DEXA) (r=0.174), WFH (r=0.211) and metabolic parameters
such as plasma glucose level at 60 minutes of OGTT (r=0.153) and triglyceride level
(r=0.153). Significant positive correlation was also reported between visfatin and liver
enzymes such as ALT (r=0.154), AST (r=0.231), GGT (r=0.223), as well as
conjugated bilirubin (r=0.293) and lactate dehydrogenase (0.211). These variables
except triglycerides remained significantly correlated with serum visfatin after
adjusting for age, gender, ethnicity and BMI-SDS. However, visfatin was not
significantly correlated total cholesterol level, fasting glucose level, fasting insulin
level, insulin:glucose, HOMA or other adipokines including HMW-adiponectin and
leptin.
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      Table 4.17 Spearman’s correlation and partial correlation between serum visfatin and metabolic parameters
Bivariate correlation Partial correlationVariable
r p-value adjusted r adjusted p-value
Birth weight (kg) -0.019 0.781 0.005 0.946
BMI (kg/m2) 0.155 0.022 0.269 <0.001
BMI SDS 0.138 0.042 0.194 0.004
Body fat by DEXA (%) 0.174 0.021 0.261 0.001
Weight for height, WFH (%) 0.211 0.002 0.317 <0.001
Fasting glucose (mmol/L) 0.064 0.352 0.075 0.278
Glucose at 60minutes of OGTT(mmol/L) 0.153 0.031 0.172 0.017
Fasting insulin (mU/L) -0.053 0.448 -0.084 0.232
Insulin:Glucose -0.056 0.422 -0.090 0.205
HOMA -0.037 0.596 -0.072 0.306
Alanine transaminase, ALT (U/L) 0.154 0.026 0.224 0.001
Aspartate transaminase, AST (U/L) 0.231 0.001 0.298 <0.001
Conjugated bilirubin (U/L) 0.293 <0.001 0.212 0.003
Gamma-glutaryl transferase , GGT (U/L) 0.223 0.001 0.202 0.004
Lactate dehydrogenase (U/L) 0.211 0.002 0.248 <0.001
HMW-adiponectin (ng/ml) -0.067 0.321 -0.040 0.557
Leptin (µg/L) 0.038 0.578 0.025 0.720
Total cholesterol (mmol/L) 0.051 0.458 0.034 0.629
HDL-cholesterol (mmol/L) -0.091 0.183 -0.020 0.773
LDL-cholesterol (mmol/L) -0.005 0.944 -0.025 0.721
Triglyceride (mmol/L) 0.153 0.024 0.106 0.127
Correlations with all variables except parameters of obesity were adjusted for age, gender, ethnicity and BMI-SDS using partial correlation.
Correlations with parameters of obesity were only adjusted for age, gender and ethnicity.
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4.3.2 Serum visfatin in obese children with abnormal glucose tolerance
Obese children were classified as having abnormal glucose tolerance if they
have impaired fasting plasma glucose ≥ 6.1mmol/L or impaired glucose tolerance
where plasma glucose at 120 minutes of OGTT was ≥ 7.8mmol/L.
Obese children with abnormal glucose tolerance had elevated level of fasting
serum visfatin as compared to obese children with normal glucose tolerance
(6.58±0.84ng/ml vs. 4.47±0.29ng/ml, p=0.039) as shown in Figure 4.11. The
difference in serum visfatin between obese children with normal or abnormal glucose
tolerance remained significant (p=0.015) after adjusting for age, gender, ethnicity and
BMI-SDS.
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Figure 4.11 Serum visfatin in obese children with normal or abnormal glucose
tolerance
Data are expressed as mean ± SEM and * denotes significant p-value<0.05 as
compared to the normal group. The p-value remained significant after adjustment for
age, gender, ethnicity and BMI-SDS.
*
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4.3.3 Serum visfatin in obese children with abnormal liver function test, NAFLD
Obese children were classified as having abnormal liver function test, which is
also defined as NAFLD if they have elevated liver enzymes such as ALT and AST.
Obese children with abnormal liver function test, NAFLD had elevated level
of fasting serum visfatin as compared to obese children with normal liver function test
(6.02±0.62ng/ml vs. 4.28±0.33ng/ml, p=0.002) as shown in Figure 4.12. The
difference in serum visfatin between obese children with normal or abnormal liver
function test remained significant (p=0.016) after adjusting for age, gender, ethnicity
and BMI-SDS.
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Figure 4.12 Serum visfatin in obese children with normal or abnormal liver
function test, NAFLD
Data are expressed as mean ± SEM and * denotes significant p-value<0.05 as
compared to the normal group. The p-value remained significant after adjustment for




In parallel to the significant associations between genotypes of visfatin SNPs
and metabolic parameters, fasting serum visfatin of obese children was also found to
be significantly correlated with metabolic parameters such as BMI, glucose at 60mins
of OGTT and liver enzyme levels. Serum visfatin was elevated in obese children with
metabolic disorders such as abnormal glucose tolerance and NAFLD as compared to
other obese children. These data suggested that serum visfatin may have an effect on
metabolic parameters, and it may be involved in pathogenesis of metabolic diseases
such as abnormal glucose tolerance and NAFLD.
Therefore, we proposed that serum visfatin may be responsive to changes in
metabolic parameters such as glucose and insulin levels during OGTT and
hyperinsulinemic clamp.
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4.4 Change in serum visfatin during glucose metabolism
Serum visfatin was found to be regulated by glucose and insulin, and visfatin
level was found to be altered after oral glucose tolerance test. In addition, genotypes
and haplotypes of visfatin SNPs were found to be associated with parameters with
glucose metabolism.
Therefore, oral glucose tolerance test and euglycemic-hyperinsulinemic clamp
were performed in obese children and type 2 diabetic patients respectively to examine
if a physiological change in glucose or insulin level will result in a change in serum
visfatin. The association between genotypes/diplotypes of identified SNPs and
parameters of glucose metabolism was also investigated in the obese children using
statistical analysis.
Specific hypothesis 4: Serum visfatin may respond to changes in glucose and insulin
levels during OGTT and hyperinsulinemic clamp.
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4.4.1 Serum visfatin of obese children during oral glucose tolerance test (OGTT)
Oral glucose tolerance test (OGTT) was performed in subgroup of 35 obese
children with normal glucose tolerance. In brief, the subjects were given an oral
glucose loading after an overnight fast, and blood samples were collected at 0, 60 and
120 minute time intervals and used for measurement of visfatin. These subjects
consisted of 28 boys and 7 girls (Chinese: 23 and Malay: 12), with age of 10.5±0.4
years, WFH of 163.8±2.6% and BMI-SDS of 2.24±0.05.
Figure 4.13A showed that serum visfatin in 35 obese children decreased
significantly from a fasting level of 4.82±0.45ng/ml to 3.6±0.46ng/ml at 60 minutes
and to 2.66±0.39ng/ml at 120 minutes after glucose loading. The plasma glucose level
of obese children increased significantly from 4.32±0.06mmol/L to 6.88±0.28mmol/L
at 60 minutes and decreased back to 5.95±0.18mmol/L at 120 minutes after OGTT as
shown in Figure 4.13B. There was a significant increase in the serum insulin level of
the obese children from 31.81±3.65mU/L to 206.3±26.3mU/L at 60 minutes after
glucose loading and the insulin level continued to remain high at 208.5±27.6mU/L
120 minutes after OGTT as shown in Figure 4.13C. The levels of serum visfatin,
plasma glucose and serum insulin during the 2-hour OGTT were shown in Figure
4.13D.
Serum insulin level correlated significantly with serum visfatin level at all
time-points of the 2-hour OGTT (r= -0.275, p=0.005), whereas the plasma glucose
level did not correlate significantly with serum visfatin level (r=-0.167, p=0.089) as
shown in Figure 4.13E and Figure 4.13F scatter-plot respectively.
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Figure 4.13 Dynamic changes in visfatin in obese children undergoing OGTT
A. Serum visfatin of obese children during OGTT.
B. Plasma glucose of obese children during OGTT. Data were expressed as mean ± SEM and








Figure 4.13 Dynamic changes in visfatin in obese children undergoing OGTT
C. Serum insulin of obese children during OGTT.
D. Serum visfatin, plasma glucose and serum insulin of obese children during OGTT. Data
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E. Scatter-plot for correlation between serum visfatin and serum insulin at all time-points of
OGTT.
F. Scatter-plot for correlation between serum visfatin and plasma glucose at all time-points of
OGTT. Correlation was analyzed using non-parametric Spearman’s correlation test.
E.
F.
R= -0.275, p= 0.005
R= -0.167, p= 0.089
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4.4.1.1 Influence of visfatin polymorphisms on OGTT excursion
The different visfatin genotypes were shown to be associated with glucose and
visfatin excursions during OGTT as shown in Table 4.18.
The recessive AA genotype model of -3187G>A was associated with a greater
increase in venous glucose level during 60 minutes (3.76±0.39mmol/L vs.
2.20±0.30mmol/L) and 120 minutes (2.38±0.41mmol/L vs. 1.40±0.16mmol/L) of
OGTT as compared to the GG+GA genotype.
The dominant GA+AA genotype model of +21426G>A was also significantly
associated with an increase in serum visfatin during 2nd hour (0.19±0.46ng/ml vs. -
1.41±0.56ng/ml) of OGTT as compared to the GG genotype but the p-value became
insignificant after adjusting for age, gender, ethnicity and BMI-SDS.
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Table 4.18 Association between genotypes and changes in glucose/visfatin level
during OGTT in obese children
Recessive model of upstream-3187>A
Variable GG+GA AA p-value adjusted p-value
n=27 n=8
Change in glucose during
60min of OGTT
(mmol/L)
2.20±0.30 3.76±0.39 0.006 0.004
Change in glucose during
120min of OGTT
(mmol/L)
1.40±0.16 2.38±0.41 0.023 0.004
Dominant model of exon 7 +21426G>A
Variable GG GA+AA p-value adjusted p-value
n=24 n=10
Change in visfatin
during 2nd hour of
OGTT (ng/ml)
-1.41±0.56 0.19±0.46 0.017 0.186
Data were expressed as mean ± SEM and p-value was adjusted for age, gender,
ethnicity and BMI-SDS. Sample sizes (n) varied due to inability to obtain all
measurements from all 35 obese children undergoing OGTT.
150
4.4.1.2 Influence of visfatin diplotypes on OGTT excursion
Diplotypes were obtained by combining genotypes of upstream -3187G>A,
+7489T>C at exon 2 and +21426G>A at exon 7 as mentioned earlier in 4.2.7.1.
The diplotypes that were present in the group of 35 obese children undergoing
OGTT was represented in Table 4.19. The diplotype frequencies were 8.8%
GG/TT/GG, 8.8% GG/TT/GA, 29.4% GA/TT/GG, 20.4% GA/TT/GA, 11.8%
GA/TC/GG and 20.6% AA/TT/GG. The previously reported diplotypes including D3,
D4 and D9 in 4.2.7.1 were absent in the subgroup of 35 obese children undergoing
OGTT.
The different visfatin diplotypes were shown to be associated with the changes
in glucose and visfatin during OGTT as represented in Table 4.20. The wild-type
GG/TT/GG (8.8%) diplotype was associated with an increase in serum visfatin during
60 minutes of OGTT and greater decrease in serum visfatin during 2nd hour of OGTT
but with a lesser increase in plasma glucose during 120 minutes of OGTT. On the
other hand, the GG/TT/GA (8.8%) was associated with greater decrease in serum
visfatin and a lesser increase in plasma glucose during 60 minutes of OGTT, as well
as with an increase in serum visfatin and plasma glucose during 2nd hour of OGTT.
The AA/TT/GG (20.6%) was associated with greater increase in plasma glucose
during 60 minutes and 120 minutes of OGTT, and also greater decrease in plasma
glucose during 2nd hour of OGTT.
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Table 4.19 Diplotypes (comprising of upstream -3187G>A, +7489T>C at exon 2
and +21426G>A at exon 7) frequencies of obese children undergoing OGTT
Number Diplotype Count Frequency (%)
D1 GG/TT/GG 3 8.8
D2 GG/TT/GA 3 8.8
D5 GA/TT/GG 10 29.4
D6 GA/TT/GA 7 20.4
D7 GA/TC/GG 4 11.8
D8 AA/TT/GG 7 20.6
Data were expressed as frequency (%).
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during 2nd hour of
OGTT (mmol/L)*
0.13±0.12 -1.03±0.20
Each diplotype (carrier) was compared with the rest of the combined diplotypes (non-carrier) for association with metabolic parameter using gamma log-link
GLM. Data were expressed as mean ± SEM and all associations shown were significant after adjusting for age, gender, ethnicity and BMI-SDS. Sample size
(n) varied due to inability to obtain all measurements from all obese children. *denotes p-value<0.05, **denotes p-value<0.01 and ***denotes p-
value<0.005.
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4.4.2 Serum visfatin of type 2 diabetic patients during euglycemic-
hyperinsulinemic clamp
Figure 4.14A showed the serum visfatin level of 14 adult patients with type 2
diabetes. The group of patients included 9 males and 5 females (Chinese: 8 and
Indian: 6) with mean age of 53.6±2.1 years treated with metformin during
euglycemic-hyperinsulinemic clamp. In brief, the subjects were given a constant
insulin infusion to render them hyperinsulinemic, and different amounts of glucose
were co-infused into the subjects to maintain a constant euglycemic blood glucose
concentration. Venous blood samples were collected at 0, 30, 60 and 120 minute time
intervals and used for measurement of serum visfatin level.
Serum visfatin decreased significantly from fasting level of 2.7±0.3ng/ml to
1.41±0.19ng/ml at 30 minutes to 1.44±0.22ng/ml at 60 minutes and remained low at
1.4±0.2ng/ml at 120minutes of the clamp. There was an increase in serum insulin
level from fasting level of 10.31±1.62mU/L to 193.75 ±14.12mU/L at 30 minutes to
219.78±21.92mU/L at 60 minutes then to 221.74±20.28mU/L at 120 minutes of the
clamp as shown in Figure 4.14B. The levels of serum visfatin and serum insulin
during the 2-hour euglycemic-hyperinsulinemic clamp were shown in Figure 4.14C.
Serum insulin level was significantly correlated with serum visfatin level at all time-
points of the 2-hour euglycemic-hyperinsulinemic clamp (r= -0.334, p=0.012) as
shown in Figure 4.14D scatter-plot.
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Figure 4.14 Dynamic changes in visfatin in type 2 diabetic patients undergoing
euglycemic-hyperinsulinemic clamp
A. Serum visfatin of type 2 diabetic patients during euglycemic-hyperinsulinemic clamp.
B. Serum insulin of type 2 diabetic patients during euglycemic-hyperinsulinemic clamp. Data
were expressed as mean ± SEM and * denotes significant p-value<0.05 as compared to
baseline level.
 *  * *
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0.00 1.00 2.00 3.00 4.00 5.00












C. Serum visfatin and serum insulin of type 2 diabetic patients during euglycemic-
hyperinsulinemic clamp.
D. Scatter-plot for correlation between serum visfatin and serum insulin at all time-points of
euglycemic-hyperinsulinemic clamp. Correlation was analyzed using non-parametric
Spearman’s correlation test.





Serum visfatin was shown to decrease in response to increasing glucose and
glucose-induced insulin levels during OGTT of obese children. Serum visfatin level
had a significant negative correlation with serum insulin level, whereas serum insulin
was not significantly correlated with plasma glucose level during OGTT. In addition,
the genotypes and diplotypes of the detected SNPs as mentioned in section 4.2.1 were
associated with changes in glucose and visfatin levels during OGTT.
Serum visfatin was also shown to decrease in response to increasing insulin
level during euglycemic-hyperinsulinemic clamp of type 2 diabetic patients.
Furthermore, serum visfatin was negatively correlated with serum insulin level during
hyperinsulinemic clamp.
These data showed that serum visfatin was responsive to changes in glucose






5.1 Expression and secretion of visfatin in human cell lines and breast fat tissue
The mRNA and protein expression of visfatin isoforms in different cell lines
were determined by RT-PCR and western blot respectively. In addition, the secreted
visfatin protein was measured with a commercially available ELISA (Section 4.1).
In this study, visfatin (isoform a, NM_005746) was expressed and secreted in
human primary cell lines such as CLEC and human breast fat tissue, as well as
carcinoma cell lines such as 293T, HepG2, Huh7, MCF7 and Panc1 (Figure 4.1B,
4.2A and 4.4). The present study also demonstrated for the first time that a shorter
visfatin isoform b (BC020691) was expressed in the different cell lines tested (Figure
4.1B). The protein expression of visfatin isoform b was not detected in the cell lines
through western blot, and this may be due to low level of protein expression. The
secretion of visfatin isoform b protein may also have been difficult to measure due to
the lack of a sufficiently specific antibody for visfatin isoform b. However, when
visfatin isoform b was over-expressed in 293T cells using lenti-viral vector, the
visfatin isoform b protein was detected using western blot (Figure 4.3).
Visfatin was first reported by Fukuhara et al. as a novel adipokine
predominantly secreted by visceral adipose tissues (Fukuhara et al., 2005). The
findings in this study revealed that visfatin isoforms were also extensively expressed
and secreted in different cell lines, as well as human subcutaneous breast fat tissue
(This has been confirmed by several other recent studies which were published after
our experiments and plans for this thesis had started). This widespread expression
implied that visfatin may have a wider role other than its proposed function as an
adipokine. The extensive expression of visfatin in different cell lines may also be
indicative of its other cellular role in its earlier names as pre-B cell colony enhancing
factor (PBEF) and nicotinamide phosphoribosyltransferase (Nampt) (Samal et al.,
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1994, Revollo et al., 2007a). Similar to the findings in the present study, a recent
report by Friebe et al. showed that visfatin was expressed in human tissues including
brain, heart, pancreas and spleen (Friebe et al., 2011). The presence of a shorter
visfatin isoform may indicate a different role of visfatin through its isoform, and the
high level of secreted visfatin observed in human carcinoma cell lines may even
support suggestions that visfatin could play a role in pathogenesis of cancer (Olesen et
al., 2011, Wang et al., 2011a).
This study attempted to determine the functional role of visfatin isoforms
through over-expression of visfatin isoforms using lenti-viral vector, as over-
expression of visfatin was previously shown to affect insulin-sensitivity and cell
senescence (Sun et al., 2009, van der Veer et al., 2007). However, we were unable to
stably infect several targeted cell lines including primary human adipocytes, CLEC
and COS7 (These cell lines were selected because they had lower visfatin expression,
section 4.1) after repeated attempts. This may be attributed to several factors such as
transfection efficiency and suitability of cell lines for transfection. The efforts were
discontinued after a few months of repeated attempts.
5.2 Genetic polymorphisms in the visfatin gene and its associations with
metabolic parameters in Singaporean obese children
Direct DNA sequencing was carried out to screen for genetic polymorphisms
in 3.5kbp upstream promoter and full coding regions of the visfatin gene in 24
randomly selected obese children. The identified SNPs were further genotyped in
another 219 obese children using direct DNA sequencing method. The association
between metabolic parameters and genotypic groups of the SNPs was determined by
non-parametric Mann-Whitney U test. The dominant or recessive effect of the SNPs
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on the metabolic parameters was further determined by the association of dominant or
recessive genotype model with metabolic parameters using Mann-Whitney U test. The
dominant model was formed by combining homozygotes for variant with
heterozygotes of the wild-type allele (AA+GA) vs. homozygotes for the wild-type
allele (GG).  The recessive model was formed by combining homozygotes for wild-
type allele with heterozygotes for wild-type allele (GG+GA) vs. homozygotes for
variant (AA) (Lewis, 2002).
5.2.1 Upstream -3187G>A and -1537C>T SNPs
Two upstream SNPs, -3187G>A (rs11977021) and -1537C>T (rs61330082),
were detected in the promoter region of the visfatin gene in 241 obese children and
304 cord blood samples (Table 4.2). These two upstream SNPs were found to be in
perfect linkage disequilibrium due to their identical allele and genotype frequencies.
The minor allele frequency (MAF) of the upstream SNPs in obese children and cord
blood samples were 0.45 and 0.47 respectively. The high MAF indicated that -
3187G>A and -1537C>T were common SNPs, which occur frequently in the
promoter region of visfatin gene. There was no difference in allele and genotype
frequencies between obese children and cord blood samples, suggesting that the two
upstream SNPs were not directly associated with obesity (Table 4.2). The -3187G>A
SNP was used as a representative of the two upstream SNPs at linkage disequilibrium.
The AA genotype of -3187G>A was associated with higher weight for height
(WFH), higher serum visfatin and higher triglyceride, which are all indices of high
metabolic risk (Table 4.5). The AA genotype was also associated with higher risk of
developing severe systolic blood pressure and severe hypertension (Table 4.7).
Interestingly, a significant linear increase in serum visfatin level was observed across
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GG to GA to AA genotype, which suggested an additive effect of the variant A allele
of -3187G>A on serum visfatin level (Figure 4.10). The dominant GA+AA genotype
model of -3187G>A was associated with higher triglyceride, while the recessive AA
genotype was associated with higher serum visfatin, WFH and higher frequencies of
severe systolic blood pressure and severe hypertension. The associations between the
genotype model and metabolic parameters further revealed the dominant or recessive
effect of SNPs on different metabolic parameters (Table 4.6 and 4.8).
Although -1537C>T (rs61330082) and -3187G>A (rs11977021) had been
reported in previous genetic studies (Ye et al., 2005, Tokunaga et al., 2008, Yan et al.,
2010, Wang et al., 2011b, Bailey et al., 2006), the present study is the first to show
that -1537C>T was in perfect linkage disequilibrium with -3187G>A (rs11977021).
This suggested that there may be a possible additive effect between these two SNPs
through gene-gene interaction. The -3187G>A (rs11977021) SNP was previously
shown to be significantly associated with total plasma cholesterol and low density
lipoprotein (LDL)-cholesterol level in French Canadian subjects (Bailey et al., 2006).
Tokunaga et al. and Yan et al. also demonstrated that -1535C>T (rs61330082) was
significantly associated with cardio-protective effects including lower serum
triglyceride and higher HDL-cholesterol level (Tokunaga et al., 2008, Yan et al.,
2010). These findings differed from the current data, which showed that the upstream
SNPs, -3187G>A (rs11977021) and -1537C>T (rs61330082), were associated with
higher risk factors including higher triglyceride, higher WFH and higher serum
visfatin. Moreover, there was no significant association between the upstream SNPs
and HDL-cholesterol level. Therefore, this suggested that the upstream SNPs may
exert different effects on metabolic parameters in different sample populations.
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Bailey et al. reported that common visfatin promoter polymorphisms such as -
1001T>G (rs9770242) and -948G>A were associated with fasting insulin and glucose
level (Bailey et al., 2006). In addition, -948G>T was associated with increased high-
density lipoprotein (HDL)-cholesterol in obese subjects (Johansson et al., 2008).
However, these common promoter SNPs, -1001T>G (rs9770242) and -948G>A, were
not detected in the visfatin gene of the obese children cohort through direct
genotyping, and this may also be due to different sample population.
5.2.2 Exon2 +7489T>C SNP
The +7489T>C SNP (rs70937088) was detected in exon 2 of the visfatin gene
in 240 obese children and 273 cord blood samples. The allele and genotype
frequencies of the SNP did not differ between the obese children and cord blood
samples, indicating that the SNP was not directly associated with obesity. The CC
homozygotes for the variant allele were not detected in this study, and this may be due
to the low MAF (0.033 in obese children) and small sample size (Table 4.3).
Although +7489T>C occurred in the coding region (Exon 2) of the visfatin gene, it
was shown to be a synonymous SNP that did not result in a change of amino acid in
the protein sequence (Figure 4.8C).
The +7489T>C (rs70937088) was previously submitted to dbSNP but no
association studies between +7489T>C and metabolic parameters had been reported.
The present study also failed to establish a significant association between +7489T>C
and metabolic parameters, which suggested that the synonymous +7489T>C SNP
may not have an effect on metabolic parameters (Table 4.9 and 4.10).
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5.2.3 Exon7 +21426G>A SNP
The +21426G>A SNP (rs2302559) was detected in exon 7 of the visfatin gene
in 235 obese children and 281 cord blood samples. The allele and genotype
frequencies of the SNP did not differ between the obese children and cord blood
samples, indicating that the SNP was not directly associated with obesity (Table 4.2).
The +21426G>A occurred in the coding region (Exon 7) of the visfatin gene, and was
shown to be a synonymous SNP that did not result in a change of amino acid in the
protein sequence (Figure 4.9D). Due to the small sample size of AA homozygotes for
variant allele (n=4), the GA heterozygotes and AA homozygotes were combined to
examine the dominant effect of the variant A allele on metabolic parameters.
The dominant GA+AA genotype model of +21426G>A was associated with
lower fasting glucose and visfatin levels but higher insulin:glucose (Table 4.11 and
4.12). The +21426G>A SNP in the visfatin gene may have caused the direct decrease
in serum visfatin level, and the altered visfatin level may have affected glucose
metabolism in the subjects. The +21426G>A SNP had also been previously detected
in the visfatin gene of other populations but no association studies had been conducted
between +21426G>A and metabolic parameters due to +21426G>A being a
synonymous SNP, which resulted in silent mutation (Bailey et al., 2006, Tokunaga et
al., 2008, Bottcher et al., 2006). However, this study showed that synonymous
+21426G>A SNP was associated with metabolic parameters, and this further
supported the hypothesis that synonymous SNPs may have an effect on metabolic
diseases (Sauna and Kimchi-Sarfaty, 2011).
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5.3 Interaction between genotypes of visfatin SNPs and physical activity level in
obese children
Gene-environment interactions have been proposed to play a role in the
pathogenesis of complex metabolic diseases (Albers, 1997, Schwartz, 2006). Thus, in
this study, the effect of the interaction between genotype model of the SNPs and
environmental factor (physical activity level) on metabolic parameters was
investigated. The obese children cohort was stratified into less physically active and
more physically active groups according to their physical activity level as assessed by
the physical activity questionnaire (Section 3.2.2.2) (Aaron et al., 1995, Schmidt et
al., 1998). The association between the genotype model and metabolic parameters
under each physical activity level group (more physically active or less physically
active) was further determined by statistical analysis.
The data from this study demonstrated that there was a significant association
between visfatin variant genotypes and metabolic risk factors, and that this association
was affected by physical activity level of obese children. For instance, obese children
with GG genotype of -3187G>A was previously shown to be associated with lower
triglyceride level (Table 4.5 and 4.6). In the present analysis, more physically active
obese children with GG genotype were found to have lower triglyceride level as
compared to more physically active subjects with dominant GA+AA genotype, while
there was no difference in triglyceride level in less physically active obese children
with the different genotypes (Table 4.13). This demonstrated gene-behaviour
interaction in the obese children cohort by showing the importance of physical
activity in modifying the association between the genotypes and adverse
cardiometabolic parameters.
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Haus et al. reported that physical activity in the form of exercise was able to
cause a decrease in plasma visfatin that was associated with improvement in glucose
tolerance (Haus et al., 2009). Similar to study by Haus et al., the findings in this study
showed that more physically active obese children with GG+GA genotype had lower
serum visfatin as compared to other more physically active obese children with
recessive AA genotype. However, there was no difference in serum visfatin level
between the different genotypes of less physically active obese children (Table 4.13).
Therefore, while it may be impossible to change the genetic makeup of an individual,
the effect of the genetic variant (SNP) may be significantly modified through
adjustment of environmental factor. Since genotypes of visfatin SNPs were associated
with metabolic parameters (Section 4.2), the effect of interaction between variant
genotypes and physical activity on the metabolic parameters (Table 4.13) could be
used to design a suitable physical activity scheme to improve the genetic effect of
visfatin SNPs.
5.4 Association between diplotypes of visfatin SNPs and metabolic parameters
Haplotypes are generated by the combination of alleles (variant allele of SNP)
at different loci of the chromosome. Since genetic information is encoded in a gene
region, SNPs within the same region of the gene may have a combined effect towards
the decoding of genetic information. Thus, haplotype studies may be useful in the
context of examining association between candidate gene and complex traits (Clark,
2004). However, in this study, the combined effect of identified visfatin SNPs was
determined by diplotypes instead of haplotypes. Heng et al. suggested that the use of
diplotype approach would overcome the errors generated during haplotype estimation
and apportioning the effect of each constituent haplotype within a diplotype for
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heterozygous subjects (Heng et al., 2004). The two upstream SNPs and two exon
SNPs detected in the obese children were combined into eight possible diplotypes
with frequency > 1% (-3187G>A was used to represent upstream SNPs/+7489T>C in
exon 2/+21426G>A in exon 7) as shown in Table 4.14. The association between
diplotype and metabolic parameters was analyzed using gamma log-link general
linear model (GLM).
The visfatin diplotypes (-3187G>A/+7489T>C/+21426G>A) were shown to
be significantly associated with parameters of glucose and lipid metabolism, levels of
liver enzymes and adipokines, as well as severe systolic blood pressure and severe
hypertension (Table 4.15 and 4.16). The effect of individual SNP was still apparent
when analyzed as diplotypes. For example, GG genotype of -3187G>A was
associated with lower serum triglyceride as shown in Table 4.5, and the GG/TT/GG
diplotype was also associated with lower serum triglyceride. However, the various
SNPs in the diplotypes did not exert a synergistic effect on cardiometabolic risk. For
example, GG genotype of -3187G>A and +21426G>A was associated with lower
serum visfatin and higher fasting glucose respectively (Table 4.5 and 4.11) but the
diplotype GG/TT/GG did not show an association with serum visfatin or fasting
glucose level.
Although there had been no previous reports on association between visfatin
diplotypes and metabolic parameters, some studies found that visfatin haplotypes
were associated with blood pressure and parameters of lipid and glucose metabolism
(Korner et al., 2007a, Bottcher et al., 2006, Jian et al., 2006). This implied that the
SNPs at different positions of visfatin gene may interact and influence each other to
exert an effect on metabolic parameters.
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5.5 Correlation between fasting visfatin and metabolic parameters
Fasting serum visfatin in obese children was measured using the specific full-
length visfatin ELISA kit from Alpco Diagnostics, USA (Korner et al., 2007b,
Retnakaran et al., 2008).
In this study (Section 4.3.1), the results demonstrated that fasting serum
visfatin in obese children was significantly correlated with parameters of lipid,
glucose and liver metabolism (Table 4.17). Fasting visfatin was correlated with BMI
and percentage body fat, which supported the role of visfatin as an adipokine that is
affected by obesity (Davutoglu et al., 2009, Friebe et al., 2011). Fasting visfatin was
also correlated with glucose level at 60 minutes of oral glucose tolerance test (OGTT),
suggesting that visfatin may be involved in glucose metabolism during OGTT. The
positive correlations between serum visfatin and liver enzymes such as alanine
transaminase (ALT), aspartate transferase (AST) and gamma-glutaryl transferase
(GGT) suggested that visfatin may exert an effect on the level of liver enzymes, or
conversely, the elevated liver enzymes observed in non-alcoholic fatty liver disease
(NAFLD) may be a contributing factor towards the increased serum visfatin in obese
children with NAFLD (Figure 4.12). Catalan et al. also reported that increased
visfatin level in obese subjects was positively correlated with abnormally elevated
liver enzymes such as ALT, AST and GGT (Catalan et al., 2011).
Visfatin level was shown to correlate positively with HDL-cholesterol levels
and negatively with LDL-cholesterol level in a group of Taiwanese female subjects
(Chen et al., 2007). However, there was no significant correlation of serum visfatin
with cholesterol level, fasting glucose level, fasting insulin level, insulin: glucose
ratio, HOMA or other adipokines including HMW-adiponectin and leptin in the
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cohort of Singaporean obese children, and this may be due to the difference in sample
population.
5.6 Elevated serum visfatin in obese children with metabolic diseases
5.6.1 Elevated serum visfatin in obese children with abnormal glucose tolerance
The obese children population was subdivided and classified as having
abnormal glucose tolerance if they have impaired fasting plasma glucose≥ 6.1mmol/L
or impaired glucose tolerance where their plasma glucose at 120 minutes of OGTT
was ≥ 7.8mmol/L. Mann-Whitney U test was used to compare the difference in serum
visfatin between obese subjects with or without abnormal glucose tolerance (Section
4.3.2).
The data in the present study showed that serum visfatin was significantly
elevated in obese children with abnormal glucose tolerance as compared to other
obese children (Figure 4.11). Similar to the findings in this study, Chen et al. and
Lopez-Bermejo et al. also reported increased visfatin in diabetic subjects (Chen et al.,
2006, Lopez-Bermejo et al., 2006). However, Toruner et al. found that visfatin level
was decreased in their group of diabetic subjects (Toruner et al., 2009). Korner et al.
and Retnakaran et al. had attributed these reported differences to the sensitivity of the
ELISA kits used in measuring visfatin level (Korner et al., 2007b, Retnakaran et al.,
2008). It should be highlighted that this study had employed the use of the more
specific and sensitive ELISA kit from Alpco Diagnostic, while most of the other
studies had used the visfatin ELISA kit from Phoenix Pharmaceutical in the
measurement of secreted visfatin level.
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5.6.2 Elevated serum visfatin in obese children with NAFLD
The obese children population was subdivided and classified as having
NAFLD, which is defined by abnormally elevated levels of liver enzymes including
ALT and AST. Mann-Whitney U test was used to compare the difference in serum
visfatin between obese subjects with or without NAFLD (Section 4.3.3).
In the present study, serum visfatin was significantly elevated in obese
children with NAFLD as compared to other obese children (Figure 4.12).
Romanowska et al. also reported elevated visfatin level in children with NAFLD
(Romanowska and Lebensztejn, 2010), while de Boer et al. found decreased visfatin
level in patients with NAFLD (de Boer et al., 2009). As mentioned in section 5.6.1,
the differences in level of visfatin in various studies may be attributed to the
sensitivity of the visfatin ELISA kits (Korner et al., 2007b, Retnakaran et al., 2008).
Taking together the results of elevated serum visfatin in obese children with
abnormal glucose tolerance and NAFLD (Section 4.3.2 and 4.3.3), an elevated
visfatin level may be involved in the pathogenesis of metabolic diseases.
5.7 Change in visfatin level during glucose metabolism
5.7.1 Decreased visfatin level during OGTT
OGTT was conducted in a subgroup of 35 subjects within the 243 obese
children population. In brief, the subjects were given oral glucose loading after an
overnight fast, and blood samples were collected at 0, 60 and 120 minute time
intervals. The blood samples were used for measurement of serum visfatin level
(Section 4.4.1).
This study demonstrated that glucose loading after an overnight fasting in
obese children caused a significant gradual decrease in serum visfatin (Figure 4.13D).
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A significant negative correlation was observed between serum visfatin and serum
insulin (Figure 4.13E) but no significant correlation was observed between serum
visfatin and plasma glucose (Figure 4.13F). This suggested that visfatin may be
responsive to changes in glucose and insulin level during glucose metabolism. Similar
to the findings in this study, Friebe et al. also reported a decrease in serum visfatin in
obese children undergoing OGTT, and the dynamic change in serum visfatin was
negatively correlated with insulin-to-glucose ratio (Friebe et al., 2011).
5.7.1.1 Association between genotypes of visfatin SNPs and glucose metabolism
during OGTT
The association between genotype model of the identified visfatin SNPs (-
3187G>A/-1537C>T, +7489T>C and +21426G>A) and levels of visfatin, glucose and
insulin during OGTT in obese children was investigated using Mann-Whitney U test
(Section 4.4.1.1).
The data in the current study showed that the recessive AA genotype model of
-3187G>A was associated with a greater increase in plasma glucose during 60 min
and 120min of OGTT, while the dominant GA+AA genotype model of +21426G>A
was also associated with an increase in serum visfatin during 2nd hour of OGTT
(Table 4.18). These suggested that the genotypes of visfatin SNPs -3187G>A and
+21426G>A may have resulted in phenotypes with altered responsiveness towards
visfatin and glucose, thus affecting the metabolism of glucose and visfatin. Previous
studies also showed significant associations between visfatin SNPs and parameters of
glucose metabolism. Bottcher et al. reported that -948G>T was significantly
associated with fasting insulin and 2-hour plasma glucose in non-diabetic Caucasian
subjects undergoing OGTT. The -948T allele was associated with lower fasting
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insulin and 2-hour plasma glucose level (Bottcher et al., 2006). Bailey et al. also
found that G allele in -1001T>G (rs9770242) and -423A>G (rs1319501), was
associated with lower fasting insulin and glucose levels (Bailey et al., 2006).
5.7.1.2 Association between diplotypes of visfatin SNPs and glucose metabolism
during OGTT
The association between diplotypes of identified visfatin SNPs (-
3187G>A/+7489T>C/+21426G>A) and levels of visfatin, glucose and insulin during
OGTT in obese children was also examined using GLM (Section 4.4.1.2).
The results in this study demonstrated that the diplotypes derived from the 3
identified SNPs (-3187G>A/+7489T>C/+21426G>A) were associated with changes
in visfatin and glucose metabolism during OGTT (Table 4.20). The associations
between the diplotypes of combined visfatin SNPs and glucose metabolism during
OGTT further supported our previous finding as mentioned in section 5.7.1.1 that
visfatin SNPs may have a genetic effect on glucose metabolism.
Despite the lack of association studies between visfatin diplotypes and
parameters of glucose metabolism, there had been previous reports that found
significant associations between visfatin haplotypes and glucose metabolism. Bottcher
et al. found that [G-T-A] haplotype derived from (-1001T>G (rs9770242), -948G>T,
c.744-87G>A (rs4730153)) was associated with lower fasting plasma insulin and 2-
hour plasma glucose level. Carriers of [T-G-A] haplotype were also found to have
higher 2-hour plasma glucose and lower glucose infusion rate (Bottcher et al., 2006).
Jian et al. also showed that [C-A-T] haplotype derived from [-1535C>T,
rs2058539A>C, rs10953502C>T] was significantly associated with 2-hour plasma
glucose during OGTT (Jian et al., 2006).
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5.7.2 Decreased visfatin level during euglycemic-hyperinsulinemic clamp
Euglycemic-hyperinsulinemic clamp was conducted in a group of 14 type 2
diabetic patients. In brief, the subjects were given a constant insulin infusion to render
them hyperinsulinemic, and different amounts of glucose were co-infused into the
subjects to maintain a constant euglycemic blood glucose concentration. Venous
blood samples were collected at 0, 30, 60 and 120 minute time intervals and used for
measurement of serum visfatin level (Section 4.4.2).
The results in this study showed that type 2 diabetic patients who had a
clamped euglycemic glucose level, had a significant decrease in serum visfatin that
was negatively correlated with serum insulin (Figure 4.14 C and 4.14 D).
Therefore, taking together the results of OGTT (Section 5.7.1) and
hyperinsulinemic clamp, visfatin level was shown to be negatively correlated with
insulin level but not glucose level. In addition, the negative correlation between
visfatin and insulin may indicate that insulin may be a regulator of visfatin. Similar to
the current findings, Bala et al. reported that high insulin concentration was able to
suppress visfatin secretion in 3T3L1 adipocytes, whereas glucose did not have an
effect on visfatin level (Bala et al., 2011b).
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5.8 Conclusion
In conclusion, the data in this study has contributed towards the understanding
of the expression, genetics and regulation of visfatin. The results in the present study
demonstrated for the first time that a shorter visfatin isoform b (BC020691), together
with the full-length visfatin isoform a (NM_005746), were expressed in all the cell
lines and human breast fat tissue that we had tested. The extensive expression of
visfatin isoforms in different cell types may suggest visfatin as a possible regulator of
cellular activities. In addition, the detection of shorter visfatin isoform b may indicate
a different role of visfatin.
SNPs identified in the visfatin gene of obese children were significantly
associated with measures of obesity, cardiometabolic risk factors and components of
metabolic syndrome. This suggested that visfatin may be a candidate gene for study of
metabolic diseases. In addition, the results in this study demonstrated that SNPs may
be related to metabolic parameters through a complex network of gene-gene
(diplotypes) and gene-behaviour (gene-physical activity level) interactions. The
visfatin SNPs were observed to have a direct effect on visfatin level, thus the SNPs
may have exerted an effect on metabolic parameters through regulation of serum
visfatin level.
Serum visfatin level was altered in obese children with metabolic disorders,
suggesting that visfatin may have a role in the pathogenesis of metabolic diseases. In
addition, serum visfatin level may be a possible biomarker for metabolic diseases.
Fasting serum visfatin was found to be positively correlated with parameters of
obesity, as well as components of glucose metabolism and levels of liver enzymes.
The correlations between visfatin and liver enzymes support a pathogenic relationship
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between this adipokine and NAFLD, and might be the mediating link between
visceral fat, insulin resistance and hepatic fat deposition.
The dynamic relationship between visfatin, insulin and glucose during oral
glucose challenge and euglycemic-hyperinsulinemic clamp provided evidence that
visfatin may be involved in the acute regulation of blood glucose level. Moreover, the
negative correlation between visfatin and insulin indicated that insulin may be a
regulator of visfatin.
Despite the significant associations between visfatin and metabolic
parameters, the present study does not provide information on the exact regulatory
mechanism of visfatin. We hope this study will renew interest in visfatin and generate
impetuous for further research.
5.9 Limitations
1. The level of shorter visfatin isoform b was not measured in the cell lines or
serum samples.
2. Since only 24 randomly-selected obese children were sequenced for variant
detection, it may be possible that a rare variant may be present but not detected
in the population.
3. The sample size of 243 obese children may be too small for a genetic-
association study. This is because rare variants of low frequency may not be
detected within the small sample population, and the small sample size may
affect statistical power during analysis.
4. Although the results demonstrated significant associations between identified
SNPs and metabolic parameters, the exact functional role of the SNPs remains
unknown.
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5. The lack of a lean control sample group did not allow us to investigate the
effect of obesity on metabolic parameters more completely.
6. OGTT and hyperinsulinemic clamp were carried out in obese children and
type 2 diabetic patients respectively. Thus, there was no direct comparison of
visfatin response between the 2 methods.
5.10 Future work
With the suggested future work stated below and the data from this study and
other previous studies, we hope to gain a better understanding of the function and
regulation of visfatin.
1. Visfatin (full length visfatin isoform a) was reported to exert insulin-mimetic
effects, and the study of the function of visfatin isoform b in cellular glucose
uptake will enable us to determine if visfatin isoform b had a similar or
different role in glucose regulation.
2. The screening for SNPs could be performed on other intronic and upstream
regions of the visfatin gene in a larger sample size. This may allow the
detection of rare variants that may exert an effect on metabolic parameters.
3. To further elucidate the genetic effect of visfatin upstream SNPs on metabolic
parameters, the functional role of visfatin upstream promoter SNPs could be
assessed by the rate of transcriptional activity of reporter gene assay.
4. The inclusion of a lean control sample group will allow us to investigate if the
association between the SNPs and metabolic parameters is affected by obesity.
5. Both OGTT and euglycemic-hyperinsulinemic clamp could be carried out on
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